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Abstract 
The aims of this study were to investigate (i) the levels of 
catecholamines, indoleamines, substance P and thyrotrophin-
releasing hormone (TRH) in the post-mortem spinal cord of 
subjects who had died with Parkinson's disease and to compare 
them with those of control subjects (ii) adrenergic and serotonergic 
receptors in the post-mortem Parkinsonian and control spinal 
cord and (iii) the effects of subject age and sex and the interval 
between death and post-mortem (PM!) on the levels of 
neurotransmitters and neuropeptides and on receptor binding in 
post-mortem tissue. 
To perform these investigations (i) a sensitive 
radioimmunoassay which is specific for substance P and has low 
cross-reactivity with other similar peptides and (ii) a common 
extraction medium for the concomitant extraction of 
catecholamines, indoleamines, substance P and TRH from eNS 
tissue were developed. 
The main findings were: 
There were significant correlations between the levels of 
5HT, TRH and O<2-adrenoceptor binding and both subject age and 
the PMI. 
In Parkinson's disease compared with control subjects: 
(i) the levels of noradrenaline were significantly reduced 
in the thoracic ventral region of the spinal cord, 
(ii) dopamine levels were higher in the thoracic ventral and 
dorsal spinal cord, 
(iii) in the lumbar spinal cord 5HT levels were 
significantly reduced in the dorsal horn with an increase in the 
ratio of 5HIAA!5HT, 
(iv) noradrenaline levels were reduced in both dorsal and 
ventral horns of the lumbar spinal cord and 
(v) there were no differences between the levels of substance 
P and TRH in any spinal cord region. 
There were no measurable 5HTIA or 5HT2 binding sites in 
the human spinal cord under the conditions used. However, 
specific tX2-adrenoceptor binding was defined in terms of binding 
affinity and number of receptors in the spinal cord. 
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1. Throughout the text "et. al." should read "et al.". 
2. Page 18: ChAT is an abbreviation of choline acetyl transferase. 
3. Page 128: DDD is an abbreviation of deionised double distilled 
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Chapter 1 General Introduction 
1 
Introduction 
It is now well established, on the basis of animal studies, that 
a number of neuropeptides co-exist with the classical 
neurotransmitters in neurones in various regions of the CNS 
(Hokfelt et.al.,1980; Chan-Palay and Palay, 1984). Reviewed here 
in the General Introduction is the evidence for co-existence of the 
neuropeptides substance P and thyrotrophin-releasing hormone 
(TRH) with 5-hydroxytryptamine (5HT, also known as serotonin) 
in the spinal cord of several species. Much of the evidence comes 
from studies involving stereotaxic or chemical lesions of spinal 
serotonergic pathways. As these experiments are obviously not 
possible to perform on humans evidence for co-depletion of 
neurotransmitters and peptides is difficult to attain. However, 
specific neurotransmitter systems are known to degenerate in 
certain pathological conditions and one approach is to use such 
conditions to study the concomitant effects on neuropeptide levels. 
In this study the neurological disorder, Parkinson's disease, in 
which spinal cord 5HT levels are depleted and which may 
represent degeneration of spinal cord serotonergic pathways, is 
used to investigate whether 5HT depletion is paralleled by 
depletion of substance P and TRH in the human spinal cord. 
Parkinson's disease is generally regarded as a condition 
associated with wide spread loss of dopamine and degeneration of 
dopaminergic systems in the brain (Ehringer and 
Hornykiewicz,1960; Javoy-Agid et. al.,1982). However, recent 
evidence indicates there is also extensive loss of 5HT and 
noradrenaline in the post-mortem spinal cord from Parkinsonian 
patients (Scatton et.aI.,1986). In this study the levels of the 
catecholamines, noradrenaline, adrenaline and dopamine, and 
of 5HT and their metabolites and of the neuropeptides substance P 
and TRH are determined in the human spinal cord. Comparisons 
are made between levels in the spinal cord from patients having 
died with Parkinson's disease and from control subjects to further 
investigate the reported diminution of 5HT and noradrenaline 
and to determine whether changes in 5HT levels are paralleled by 
changes in neuropeptide levels. 
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In addition, serotonergic and noradrenergic receptor 
binding is investigated in the spinal cord from Parkinsonian 
patients and the results are considered in the light of the changes 
seen in noradrenaline and 5HT levels. 
There is evidence from animal studies that the 
catecholamines, indoleamines and neuropeptides have roles in the 
sensory and motor functions of the spinal cord (reviewed below). 
Moreover, it appears that there may be a great deal of interaction 
between these neurochemicals in the modulation of these 
functions. In addition therefore, consideration is given to the roles 
of catecholamines, indoleamines, substance P and TRH in the 
sensory and motor functions of the spinal cord and the relevance of 
these transmitters and peptides to the symptoms of Parkinson's 
disease. References to amines and peptides measured by 
immunogenic techniques should for accuracy include the term 
immunoreactivity, e.g. substance P-immunoreactivity or more 
precisely substance P-like immunoreactivity, as it is this that is 
actually measured. However, for fluency of reading this term has 
been omitted unless it provides additional information or aids the 
clarity of the sentence. 
Background 
The Spinal Cord 
The spinal cord begins from the caudal end of the brain stem 
and comprises four main segments on descending the vertebral 
column, namely the cervical, thoracic, lumbar and sacral cord. 
On cross-section the cord can be seen to be divided into two regions, 
the gray and white matter. The more darkly coloured gray matter 
forms an 'H' shape and is surrounded by white matter. The latter 
is comprised primarily of myelinated ascending and descending 
tracts. The gray matter is made up of three areas, the dorsal 
(posterior), intermediate and ventral (anterior) regions (Fig.I.I). 
The dorsal horn appears laminated and these areas are termed 
lamina I (the marginal zone), lamina II (the substantia 
gelatinosa), and laminae III, IV and V (Fig. I. I). In the thoracic 
segment of the cord there is an extension of the intermediate region 
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DO\: HORN 
INTERMEDIOLATERAL REGION 
Fig. 1 a,.. Cross-section of the mid-thoracic cord. 
The laminae of the gray matter are shown on the left and the 
general remons on the right. -
Fig. 1.£' Simplified representation of afferent and descending 
projections to the dorsal hom of the spinal cord involved in pain 
processing. P AG = periaqueductal gray; NRM = nucleus raphe 
magnus; DRG = dorsal root ganglion; DH = dorsal hom; VH = 
ventral horn. Roman numerals designate the laminar 
arrangement of the dorsal horn. (illustration taken from J essell, 
1982.) 
called the sympathetic lateral horn, intermediate horn or 
intermediolateral cell column (IML). Within each of these 
regions are several groups of cell nuclei which are associated with 
particular functions. 
Spinal cord function 
The dorsal horn is primarily concerned with conveyance of 
sensory information. High threshold mechanical, thermal and 
noxious stimuli are mediated via sensory neurones with cell 
bodies located within the dorsal root ganglia (Fig.1.2). Nearly all 
of the sensory neurones responding to intense cutaneous 
stimulation pass into laminae I and II of the dorsal horn in all 
spinal segments. N eurones conveying information from sensory 
endings responding to light pressure terminate in the deeper 
layers of the dorsal horn (Brown, 1981). It has been recently shown 
that there is somatotopic organization of afferent nerve fibres from 
the limbs in the dorsal horn (Molander and Grant, 1986). 
The ventral horn contains the nuclei of the motoneurones. 
Motoneurones serving the musculature of the limbs are found in 
the lateral regions of cervical and lumbar ventral horn. 
Motoneurones serving the muscles of the trunk are located in the 
medial region of the ventral horn in all segments of the cord 
(Fitzgerald, 1985). The simple reflex arc illustrated in Fig.1.3 
enables a rapid reflex motor response to sensory input from 
muscles independent of supraspinal control. 
The IML of the thoracic cord is the main site of origin of 
preganglionic sympathetic neurones which innervate the viscera 
(Strack et.al.,1988) and will not be discussed in detail. 
It has been considered for some time that activity in sensory 
and motor afferent fibres in the spinal cord are influenced by 
descending pathways from the brain (Eccles,1964; Schmidt,1973). 
There i ~ ~ also evidence that spinal nocioceptive and motor reflexes 
, 
are modulated by supra-spinal activity (Fields and Basbaum,1978; 
McCall and Aghajanian, 1979) for example inhibition of synaptic 
transmission from nocioceptors to neurones in the dorsal horn 
may be responsible for the analgesic effects of brainstem 
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-- Spindle in 
flexor muscle 
t 
To flexors To extensors 
Fig. 1.3 Neurones involved in spinal reflex. This diagram 
shows the neurones involved in a reflex action occuring at the 
level of the spinal" cord. The interneurone (IN) is inhibitory and 
the afferent input results in activation of flexor muscles and 
simultaneous inhibition of extensor muscles. 
5- Hydroxytryptophan 
Tryptamine 5-Hydroxytryptamine 
Fig. 1.4 Biosynthesis of 5-hydroxytryptamine. 
stimulation (Carstens et.al.,1980; Fields and Basbaum,1978). The 
possible origins and transmitters of the supraspinal tracts 
involved in modulation of spinal motor control and sensory 
function are discussed below. 
Neurotransmitters of the spinal cord 1: 5HT, substance P 
and TRH 
5-hydroxytryptamine: synthesis 
The biosynthetic pathway of 5HT is illustrated in Fig.lA. 
5HT is synthesized from the essential amino acid tryptophan via 
the intermediary 5-hydroxytryptophan, the process occurring in 
the neurones in which 5HT is found. Conversion from tryptophan 
to 5-hydroxytryptophan is catalysed by the enzyme tryptophan 
hydroxylase and is the rate limiting step in the synthesis of 5HT. 
The rate of 5HT synthesis depends on the availability of tryptophan 
(see Bowman and Rand,1984; Green and Grahame-Smith,1976). 
After synaptic release a proportion of 5HT is transported back into 
the pre-synaptic terminal by re-uptake mechanisms. 5HT is 
metabolised by mono-amine oxidase (MAO) to 5-
hydroxyindoleacetic acid (5HIAA) and this may occur both in the 
synaptic cleft and in the neuronal cytoplasm (Wolf et.al.,1985). 
Recent evidence indicates that type A MAO (see later page 24) is 
primarily or exclusively responsible for nerve terminal 5HT 
metabolism (Fagervall and Ross,1986; Azzaro et.al.,1988). 
5HT: distribution 
Using immunohistochemical techniques, a serotonergic 
innervation has been visualized in the dorsal and ventral horns of 
all segments of the spinal cord and also in the thoracic IML region 
in close apposition to sympathetic preganglionic neurones in the 
rat (Hokfelt et.al.,1978; Johansson et.al., 1981; Bowker et.al.,1982; 
Appel et al.,1987). Similarly, serotonergic innervation of the 
ventral and dorsal spinal cord of the cat (Holets et.al.,1987) and the 
ventral hom of the primate (Bowker, 1986) has been demonstrated. 
In general 5HT immunoreactive fibres are present throughout the 
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spinal gray matter but are especially dense in laminae I and II of 
the dorsal horn, laminae VIII and IX of the ventral horn (Fig. 1. 1) 
and in the IML. The regions in which the 5HT immunoreactive 
terminals are most dense are laminae I and II, the IML and the 
ventral motor regions (Bowker et.a1.,1983). 
In addition, the levels of 5HT have been determined by 
HPLC in the ventral and dorsal horns and in the IML of the spinal 
cord in the rat (Gilbert et.al 1982; Marsden et al,1982; Lighton 
et.al.,1984; Basbaum et.a1.,1987) the human (Bennett et.al., 1986; 
Scatton et.a1., 1986), and the rabbit (Zivon et.al.,1975; Fone 
et.al.,1987b). In these studies there is general agreement that 
levels of 5HT are 1.1-2 fold greater in the ventral than in the dorsal 
horn and that the neurotransmitter is present in all segments of the 
spinal cord. In a detailed interlaminae and intersegmental study 
of 5HT levels in the rat spinal cord Basbaum and co-workers 
(1987) report that 5HT levels increase caudally from cervical to 
lumbar cord and that 5HT levels were highest in the region of the 
motoneurones (laminae IX). The next highest levels were found 
in laminae X followed by the IML and dorsal horn. 
5HT: brainstem projections to the spinal cord 
In 1965 Dahlstrom and Fuxe (1965) described a serotonergic 
projection from the medullary raphe nuclei (the raphe magnus, 
raphe pallidus and raphe obscurus) to the spinal cord. Serotonergic 
innervation from these nuclei has since been shown to project to the 
thoracic IML, and the ventral and dorsal horns of all spinal cord 
segments (Kuypers and Maisky, 1975; Amendt et.a1.,1979; 
Basbaum and Fields,1979) and electrical stimulation of the raphe 
cells mimics the effects of direct application of 5HT to the spinal 
cord neurones (White and Neuman, 1980). Serotonergic 
projections from the raphe nuclei and the nucleus 
gigantocellularis (NG) in the adjacent reticular formation to the 
spinal cord have been demonstrated in the rat, (Bowker et.a1.,1983; 
Loewy and McKellar, 1981; Loewy, 1981; Huisman et.a1.,1984; 
Millhorn et.a1.,1987), the monkey (Kneisley et.a1.,1978) and the 
possum (Martin et.a1.,1981) in studies using retrograde transport 
with immunocytochemical and immunohistochemical 
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techniques. In the cat, raphe projections to the spinal cord have 
been described (Martin et.al.,1978; Holstege and Kuypers,1982) as 
has 5HT immunoreactivity (lR) in cell bodies of neurones of the 
ventrolateral medulla which have been shown to have direct 
contact with spinal sympathetic areas (Ciriello et.al.,1988) . 
Furthermore, Bowker and co-workers (1987) determined that more 
than 85% of the descending raphe neurones from the raphe pallidus 
and raphe obscurus and 75% of raphe neurones from the raphe 
magnus contain 5HT. The evidence indicates that the greatest 
part of the descending raphe magnus innervation is to the dorsal 
hom whilst that of the pallidus and obscurus is to the IML and 
ventral hom (Basbaum et al.,1978; Holstege and Kuypers, 1982; 
Martin et.al.,1978). In addition there is evidence of a serotonergic 
innervation to the lumbar spinal cord of the cat arising from the 
locus coeruleus of the pons which contains mainly noradrenergic 
cells (Leger et.al,1979; Wiklund et.al.,1981; Lai and Barnes, 
1985). 
Substance P 
Substance P was detected as a peptide with vasodilator 
properties present in the brain as earlier as 1931 (von Euler and 
Gaddum, 1931) but its chemical composition was not identified 
until much later (Chang and Leeman,1970). The undecapeptide 
structure of substance P is illustrated in chapter 2 (Fig.2.2). Small 
biologically active peptides are generally believed to be 
synthesized from larger precursors and analysis of DNA 
sequencing has demonstrated the presence of substance P 
precursors (0<.- and B-preprotachykinin) in bovine brain and in 
human carcinoid tumour from which the substance P structure is 
cleaved (Nawa et.al.,1983; Harmar et al.,1986). Inactivation of 
substance P appears to be due to degradation by membrane bound 
peptidases rather than re-uptake though substance P metabolites 
may have biological activity of their own (Iversen et.al.,1976; 
Arzumanyan et.al.,1985; Chapter 2, page 61). A wide and 
heterogeneous distribution of substance P within the CNS has been 
described from radioimmunoassay and immunocytochemical 
studies (Cuello and Kanzawa,1978; Hokfelt et.al.,1976; Strabanek 
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and Powell,1977) and its role as a neurotransmitter or more 
probably as a neuromodulator has been established by satisfaction 
of the necessary basic criteria (Pernow,1983 for review; Otsuka 
and Konishi,1983; Frenk et.a1.,1988a,b). 
An early study of the distribution of substance P in the rat 
spinal cord reported an extremely dense network of substance P 
containing fibres and cell bodies in the substantia gelatinosa and 
a less dense distribution in the ventral horn (Hokfelt et.a1.,1975). 
Subsequent studies have confirmed that substance P is located in 
the ventral and dorsal horns in all cord segments and in the IML 
but its dense distribution within the dorsal roots and the dorsal 
hom of the spinal cord in particular indicate a role in mediation of 
sensory information. Immunohistochemical and 
radioimmunological studies have described the presence of 
substance P in the spinal cord and dorsal root ganglia of rat 
(Chan-Palay and Palay,1977; Cuello and Kanzawa,1978; 
Ljungdahl et.a1.,1978), cat (Hokfelt et.al,.1975b; Takahashi and 
Otsuka, 1975), pig (Holzer et.al.,1981), monkey (DiFiglia et 
a1.,1982; Lanerolle and La Motte,1982), and humans (Cuello,1976; 
Anand et.al.,1983; Przewlocki et.al.,1983; Bennett et.al.,1986). 
The brainstem origins of the substance P terminals in the spinal 
cord have been demonstrated to be the raphe nuclei and nuclei of 
the adjacent re1ricular formation (Bowker et.a1.,1983; Gilbert 
et.al.,1981; Menetry and Basbaum,1987). As such, there is a great 
deal of overlap of the descending pathways containing substance P 
and 5HT and the evidence for co-existence of substance P with 5HT 
is discussed below. 
TRH 
Original interest in TRH was due to its role as a 
hypothalamic releasing factor and this lead to its chemical 
characterization (Boler et.al., 1969). TRH is a small peptide of 
only 3 amino-acids (pyroGlu-His-ProNH2). There is evidence 
that it is derived from a much larger peptide, prepro-TRH, which is 
processed to 5 molecules of TRH via an intermediary sequence, 
pro-TRH (Lechan et.al.,1986; Wu and Jackson, 1988). TRH is 
rapidly degraded by metabolism at both terminals by neuronal 
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peptidases (Prasad and Peterkofski, 1976; Griffiths et.al.,1980). A 
wide distribution of TRH throughout the eNS has been described 
(Brownstein et.al.,1974; Winokur and Utiger, 1974) and 
experimental evidence supports the principle that TRH has a 
neuromodulator or neurotransmitter role in the CNS (Brown,1981; 
Reichlin,1986 for reviews). 
TRH has been located in the ventral and dorsal horns and 
in the IML region of the spinal cord using immunocytochemistry 
and immunofluorescence (Hokfelt et.al.,1975; Gilbert et.al.,1981; 
Johansson et.al.,1981; Harkness and Brownfield, 1985). Radio-
immunoassay studies indicate that levels of TRH are greater in 
the ventral than in the dorsal horn in the rat (Marsden et.a1.,1982; 
Lighton et.al.,1984), rabbit (Fone et.al.,1987b), monkey (Lechan 
et.al., 1984), and human (Yates et.al.,1983; Mitsuma et.al.,1984; 
Bennett et.al.,1986). The brainstem origins of spinal cord TRH 
include the medullary raphe nuclei, and the nuclei of the 
re.tricular formation (Johansson et.al.,1981; Bowker et.al.,1983) 
and the evidence for co-existence of TRH with 5HT in the 
descending raphe neurones is discussed below. 
Substance P and TRH: Brainstem origin of the neuropeptides and 
evidence of co-existence with 5HT 
Co-existence of neuropeptides with classical 
neurotransmitters within the eNS is now well established (Hokfelt 
et. a1.,1980; Chan-Palay and Palay,1984). There is evidence that 
the neuropeptides substance P and TRH co-exist with 5HT in the 
descending raphe (bulbospinal) pathway. This evidence comes 
from localization of TRH and substance P within the raphe cell 
bodies, within descending serotonergic fibres and in nerve 
terminals. This evidence is reviewed here. 
o Cell bodies containing substance P were located in the 
ventral medulla with a similar distribution to that of 5HT cell 
bodies (Ljungdahl et.al,.1978). Subsequently, the distribution of 
substance P in the serotonergic raphe nuclei and in the nucleus 
gigantocellularis and the nucleus interfasicularis hypoglossi 
(NIH) of the r etricular formation has been confirmed 
(Johansson et.a1.,1981; Bowker et.a1.,1983; Chan-Palay, 1979; 
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Menetry and Basbaum,1987). Substance P and 5HT were also 
demonstrated to have a similar distribution in nerve terminals in 
the spinal cord (Hokfelt et.al.,1978; Johansson et.al.,1981; Gilbert 
et.al.,1981; Gilbert et.al.,1982). Substance P containing fibres 
from the medullary cell bodies were demonstrated to project to the 
spinal cord (Bowker et.al.,1983; Gilbert et.al.,1981; Menetry and 
Basbaum,1987) and substance P and 5HT were shown to have an 
overlapping distribution in spinal cord nerve fibres (Johansson 
et.al.,1981; Gilbert et al.,1982). Destruction of the serotonergic 
fibres resulted in loss of substance P at the level of the spinal cord 
and it was proposed that approximately 40-50% of the serotonergic 
projections to the ventral horn and IML also contain substance P 
though the extent of the supraspinal origin of dorsal horn substance 
P is much lower (Johansson et.al.,1981; Gilbert et.al., 1982; 
Marsden et.al.,1982; Bowker et.al.,1983). 
Similarly, TRH has been located in the raphe nuclei of the 
medulla and of the nuclei of the· retricular formation (Johansson 
et.al.,1981; Bowker et.al.,1983) and in nerve terminals in the 
ventral and dorsal horns and the IML of the spinal cord in a 
similar distribution to that of 5HT and substance P (Johansson 
et.al.,1981; Gilbert et.al.,1982; Lechan et.al.,1984). 
The results of neurochemical and electrothermal lesions of 
the raphe nuclei, the NIH, the NG and the spinal pathways indicate 
that TRH containing fibres project from these nuclei to the ventral 
and dorsal horns of the spinal cord and the IML and that the 
proportion of TRH projections to the IML and ventral horns which 
are also serotonergic may be as much as 90% (Marsden et.al.,1982; 
Gilbert et.al.,1981; Gilbert et.al.,1982; Helke et.al., 1986; Appel 
et.al.,1987). 
There has been a search for evidence that substance P, 5HT 
and TRH measured in cell nuclei, fibres and terminals are 
located within the same cells. By combining immunofluorescence 
histochemistry and elution/restaining techniques with serial 
sections Johansson and co-workers (1981) were able to demonstrate 
the co-existence of 5HT, TRH and substance P within cells of the 
medulla and retricular formation. In addition, using the 
technique of simultaneous double labeling, TRH and 5HT or TRH 
10 
and substance P have been co-localized in the fibres and terminals 
of the spinal cord (Bowker et.al.,1986; Appel et.al.,1987). 
Furthermore, recently 5HT, TRH and substance P have been 
visualized concomitantly in descending bulbospinal neurones 
using a triple labelling method (Staines et.al.,1987). 
In summary, there is evidence that in the rat 80-90% of the 
projections from the raphe nuclei to the spinal cord are 
serotonergic and some of these fibres also contain substance P 
andi or TRH. There are also descending serotonergic and 
peptidergic pathways from the adjacent re.tricular formation. 
The origins and distribution of the serotonergic and peptidergic 
fibres of the spinal cord are not identical but overlap so that various 
proportions of these pathways contain 5HT alone or with one or both 
of the neuropeptides substance P and TRH (Johansson et.al.,1981; 
Bowker et.al.,1983; Helke et.al.,1986). 
Co-storage of 5HT, substance P and TRH 
Further to the investigation into co-existence of TRH and 
substance P with 5HT, there have been some studies into the 
intraneuronal storage and release of these neurochemicals. 
Substance P and 5HT have been located in the same dense core 
vesicles in nerve terminals of the raphe nuclei and dorsal spinal 
cord using serial sections. No more than 20% of serotonin 
containing nerve terminals were also positive for substance P 
(Pelletier et.al.,1981). Depletion of spinal cord 5HT, by compounds 
known to cause neuronal depletion of 5HT by interfering with its 
storage, is accompanied by depletion of substance P and TRH 
which is less marked and of a different time course (Gilbert 
et.al.,1981). As proposed by the authors these results do not 
conclusively indicate a direct action of the drugs on vesicles co-
storing 5HT with substance P and lor TRH but may reflect a 
secondary effect on peptide release due to depletion of 5HT stores. 
Furthermore, that 5HT releasing agents p-chloroamphetamine 
(peA) and fenfluramine have different effects on 5HT and TRH 
release and also affect TRH release in brain areas where 5HT and 
TRH are not known to co-exist indicates that it is likely that there 
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is no co-storage of 5HT and TRH (Marsden et.al., 1982). In 
addition, using gradient centrifugation of isolated synaptic 
vesicles and synaptosomes a distribution of substance P and 5HT 
has been demonstrated which may indicate that at least one 
population of 5HT containing vesicles does not contain substance 
P (Fried et.al.,1984). It therefore appears that in the main at least, 
co-existent 5HT, substance P and TRH are stored separately. 
Further experimental data supports this concept as both low 
frequency stimulation and peA in low doses are capable of 
releasing [3H] 5HT from loaded slices of ventral and dorsal 
spinal cord without substantial release of substance P (Bartfai 
et.al.,1986). However, although substance P and 5HT storage and 
release mechanisms may be separate there is evidence of 
interaction between them. Rats were treated with pharmacological 
agents which block 5HT uptake at nerve terminals and which are 
known to result in a reduction in the firing rate of serotonergic 
neurones. As a result tissue levels of 5HT fell by 10-20% in the 
hypothalamus, cortex and ventral spinal cord. Tissue levels of 
substance P were unchanged in the brain areas where the peptide is 
not co-existent with 5HT but were significantly increased in the 
dorsal and ventral horn spinal cord, thus indicating that 
substance P builds up either because of reduced 5HT axonal firing 
or through a receptor mediated effect brought about by the alteration 
in 5HT release (Bartfai et.al.,1986 for review). Substance P (and 
other neuromodulators) may be stored in large dense core vesicles 
which appear to secrete their neurochemical contents at non-
specialized areas of the membrane whereas classical transmitters 
have been visualized in small synaptic vesicles. This indicates 
that exocytosis involving large vesicles may serve to deliver 
neuropeptide modulators into a wider area and on to appropriate 
receptors than release into a specialized synaptic cleft would allow 
(Zhu et.al., 1986) 
Evidence for functional significance of co-existence of 5HT, substance 
P and TRH 
There is strong evidence for physiological interaction 
between 5HT, substance P and TRH in the spinal cord and for the 
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importance of interaction between these neurochemicals in spinal 
cord function. TRH appears to enhance the stretch reflex through 
interaction with a site closely associated with the 5HT receptor 
(Barbeau and Bedard, 1981): Additionally, substance P causes a 
concentration dependent inhibition of TRH receptor binding in the 
spinal cord, especially in the ventral horn and possibly through a 
discrete population of low affinity substance P receptors (Sharif 
and Burt, 1983). Furthermore, co-depletion of 5HT and TRH in 
spinal neurones by neurotoxins is accompanied by a 30-40% 
increase in the number of TRH binding sites which is apparently 
dependent not on TRH modification but on the loss of serotonergic 
neurones (Sharif et.al., 1983). Also, 5HT can increase the K+-
stimulated release of substance P from nerve terminals in the 
ventral spinal cord and that this may be effected via 5HT2 
receptors (Bartfai et.al.,1986 for review). These effects appear to be 
mediated through post-synaptic receptors. Other evidence 
implicates interaction of 5HT, substance P and TRH at pre-
synaptic receptors. 'Substance P has been shown to antagonise 
inhibition of 5HT release caused by high 5HT concentration in the 
lumbar ventral spinal cord (Mitchell and Fleetwood-Walker,1981) 
and long-term intrathecal administration of TRH analogues 
elevate levels of 5HT in the ventral spinal cord (Fone et.al.,1988a) 
These effects are possibly mediated through interaction with pre-
synaptic 5HT autoreceptors. In summary, these reports indicate 
that 5HT, substance P and TRH interact physiologically in the 
spinal cord at the level of both pre- and post-synaptic receptors and 
that substance P and TRH both tend to enhance 5HT transmission 
though by different mechanisms. 
Substance P and TRH also demonstrate interactions 
independent of 5HT. Substance P antagonists can cause necrotic 
damage to the gray matter of the spinal cord when administered 
intrathecally (Post and Paulsson,1985; Freedman et.al.,1986). It 
has been observed that repeated treatment with TRH before and 
after administration of the substance P antagonist prevents the 
inducement of necrosis (Post and Paulsson,1985; Freedman 
et.al.,1986). Rokfelt and co-workers (1986) suggest that the 
protective effect of TRR in the descending bulbospinal pathways is 
mediated by blockade of the substance Preceptor, thereby 
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preventing interaction between the receptor and the substance P 
antagonist. 
The evidence indicates that the concept of an autoreceptor 
includes regulation of transmitter release not only by the 
transmitter itself but also by release of co-existent peptides. 
Substance P and TRH may therefore act as modulators of the 
effects of 5HT by acting both pre- and post-synaptically, thereby 
incorporating a greater degree of flexibility into regulation of eNS 
functions mediated by 5HT. Separate, but interactive storage and 
release mechanisms for 5HT, substance P and TRH gives rise to 
the possibility of differential release of these neurochemicals by 
different patterns of physiological stimulus. It has been proposed 
that the functional significance of co-existence of substance P and 
TRH with 5HT may be to 'push through' an important message 
travelling in a small system by concomitant release of multiple 
transmitters and the authors provide a hypothetical model for such 
a mechanism (Hokfelt et.al.,1984a). Co-existent peptides may also 
be i m p o r t a n ~ ' l n n regulating the sensitivity of receptors to 5HT and 
thereby providing a flexible regulation of the effect of stimulation 
of the serotonergic system. It has been proposed that co-existing 
, t' "I 
pep tides -change the characteristics of the receptors for' " 
monoaminergic transmitters at the post-synaptic level without at 
the same time inducing compensatory responses at the pre-
,; (;- .. I, . 
synaptic level (Fuxe et.al.,1983). Reviewed here is the evidence 
that (i) the interaction between 5HT and the co-existent peptides 
substance P and TRH in the ventral horn is important in motor 
control and possibly supra-spinal modulation of spinal cord motor 
function and (ii) 5HT, substance P and TRH may play interactive 
roles in nociception. 
The role of 5HT, substance P and TRH in spinal cord motor control 
5HT 
Early histofluorescence studies indicated projections from 
the brainstem raphe nuclei to the motonuclei of the ventral horn of 
the spinal cord (Dahlstrom and Fuxe, 1965). It has since been 
confirmed using retrograde labeling that the more caudal nuclei, 
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the raphe pallidus and raphe obscurus and nuclei of the adjacent 
. r€iricular formation including the NIH and NG project directly 
onto the motoneuronal cell groups in the spinal cord and that the 
bulbospinal projections from the raphe nuclei terminate in the 
ventral hom, closely apposed to the nuclei of motoneurones (Hayes 
and Rustioni,1981; Huisman et.al.,1980; Huisman et.al.,1984; 
Martin et.al.,1981). Immunohistochemical studies have revealed 
5HT in synaptic boutons apposing motoneurones (Atsumi 
et.al,.1985; Takeuchi et.al.,1983). In addition, by combining 
anterograde transport of leucine from the brain stem nuclei and 
retrograde transport of horse-radish peroxidase (HRP) from the 
hind leg muscles direct contacts between descending neurones 
and lumbar motoneurones have been demonstrated (Holstege and 
Kuypers,1987a). These findings have been confirmed recently 
using a different method, anterograde transport of wheat germ 
agglutin in combination with a chromagen which can be 
visualized by electron microscopy (Hoi stege, 1987). Physiological 
evidence also indicates an interaction between 5HT and spinal 
cord motor function as 5HT increases the excitability of 
motoneurones when applied systemically or by bath application to 
isolated tissues (McCall and Aghajanian, 1979; White and 
Neuman,1980; White, 1985). Similarly electrical stimulation of 
the raphe nuclei also produced facilitation of motoneurone 
excitability which can be blocked by 5HT antagonists (Cardona 
and Rudomin,1983). Recently, it was demonstrated that stimulus 
induced plateau potentials in spinal motoneurones were abolished 
after transection of the spinal cord and then re-appeared after 
injection of a 5HT releasing agent (Hounsgaard et.al.,1988). In 
general the evidence supports the principle that activation of the 
bulbospinal pathway and release of 5HT facilitates the excitability 
of the motoneurones (McCall and Aghajanian, 1979). The results 
of injecting fluorescence markers into different levels of the 
spinal cord and then investigating the brainstem nuclei to which 
they are transported indicate that projections from the raphe nuclei 
have collaterals which terminate diffusely at different levels of the 
spinal cord (Huisman et.al.,1984). A diffuse system, as the 
authors suggest, may subserve generalized motor functions such 
as the overall responsiveness of motoneurones. This may be 
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mediated via supra-spinal modulation of muscle afferent fibres in 
the spinal cord (Eccles,1964; Schmidt, 1973). There is evidence that 
a post-synaptic 5HT2 receptor is implicated in mediation of motor 
behaviours including head twitches, fore-paw treading and wet-
dog shakes (Leysen, 1989; Fone, 1989a). In summary, the spinal 
cord serotonergic system appears to be involved in motor function 
both at the level of spinal cord reflexes and supra-spinal 
modulation of reflexes. 
Substance P and TRH 
There has now been amassed a catalogue of data supporting 
the proposal that substance P and TRH have similar effects on the 
motoneurones as 5HT itself. Firstly, substance P and TRH are 
found in the ventral horn and IML in the vicinity of motoneurones 
(Johansson et.al.,1981; Hokfelt et.al.,1975b: Appel et.al.,1987). 
Substance P-immunoreactivity in synaptic boutons has been 
observed in close apposition to motoneurones in the ventral spinal 
cord of the rat (Barber et.al.,1979; Vacca et.al.,1982) and in the 
monkey and human spinal cord (Lanerolle and La Motte,1982). 
Also, TRH has also been observed in synaptic boutons (Johansson 
et.a1.,1980). In the rat autoradiographic studies have demonstrated 
anterograde transport of [3H] leucine from the raphe nuclei to 
terminals of spinal motoneurones which morphologically 
resemble terminals which contain 5HT and / or substance P or 
TRH (Holstege and Kuypers,1987a). In a recent study 5HT, TRH 
and substance P containing axonal boutons and varicosities were 
observed in close contact and forming synaptic contact with 
dendrites of motoneurones in the motor nucleus of the spinal cord 
(Ulfhake et.a1.,1987). Secondly, substance P and TRH have a 
similar excitatory effect on motoneurones as observed for 5HT 
(Barasi and Roberts, 1974; Myslinski and Anderson, 1978; Clarke 
and Stirk,1983; Oka & Fukuda,1984; Nicoll,1978; Clarke 
et.a1.,1985). _ Substance P directly depolarizes the spinal 
motoneurones of newborn rats (Konishi and Otsuka 1974a' Suzue , , 
et. a1.,1981) and certain motor behaviour in the rat (rearing) has 
been attributed to specific amino-termil}a). fragments of the 
substance P structure (Hall e t . a l . , 1 9 8 7 ) : ~ ) S i m i l a r l y , , TRH 
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administered intra the cally or systemically produces clearly 
defined motor behaviours such as wet-dog shakes and fore-paw 
licking (Wei et.al.,1975).· Furthermore, like 5HT, 
iontophoretically applied substance P and TRH enhance both 
glutamate and aspartate induced excitation of spinal cord 
motoneurones (White and Neuman, 1983; White,1985). The effect 
of substance P on motoneurones may be mediated predominantly 
by the direct action on the motoneurone rather than via synaptic 
transmission (Konishi and Otsuka,1974a,b; Nicoll,1978). The 
above evidence indicates that substance P and TRH have direct 
effects on motoneurones. However other evidence also indicates 
that interactions between serotonergic and peptidergic systems are 
important in motor function. TRH activation of the stretch reflex 
may be mediated through 5HT receptors (Barbeau and Bedard, 
1981). Additionally, the sensitivity of motoneurones to 5HT 
increases after destruction of pre-synaptic bulbospinal neurones 
(denervation supersensitivity). It has been demonstrated that this 
supersensitivity is dependent not on the absence of 5HT but 
possibly on the loss of substance P and/or TRH in the destroyed 
terminals (Tremblay et.al.,1985). It therefore appears that 
substance P and TRH are involved in spinal cord motor function 
from their location in the eNS and from their direct and indirect 
motor effects. 
There is also evidence from clinical studies that TRH may 
be important in motor co-ordination in humans. TRH was 
demonstrated to have beneficial effects on the motor deficiencies 
which are symptoms of amyotrophic lateral sclerosis (ALS) (Engel 
et.al.,1983). ALS is a neurological condition which affects 
motoneurones. There is no known cause or cure for ALS and the 
condition progresses relentlessly resulting in the death of the 
at' 
suffel;. after 1-5 years (Engel et.al.,1983). Intravenous. 
administration of TRH in high doses to ALS sufferers was 
originally demonstrated to improve symptoms of muscle 
weakness and spasticity which are related to motoneurone 
function (Engel et.al.,1983). Since then a number of clinical 
studies have been carried out but the benefits ofTRH in ALS 
therapy have not been consistently proven. The ability ofTRH 
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therapy to prevent the progression of ALS and its value in acute 
motor improvement is still controversial (Caroscio et.al.,1986; 
Brooke et.al.,1986; Imoto et.al.,1984; Brooks et.al.,1987; Mitsumoto 
et.al.,1986). 
A trophic function ofTRH may be important to its effects on 
motoneurones. Cell cultures of ventral horn neurones treated with 
TRH are more numerous, more healthy appearing neurones and 
have thicker bundles of long processes compared with controls 
(Schmidt-Achert et.al.,1984). The authors proposed these effects 
were a result of a trophic effect of TRH on lower motoneurones. In 
addition, the TRH analogue CG 3509 (orotyl-L-histidyl-L-Pro-
NH2) significantly increases rat ventral horn ChAT activity 
indicating a trophic-like function on mature motoneurones (Fone 
et.al.,1988a). 
The role of 5HT, substance P and TRH in spinal cord sensory function 
5HT 
Many studies have indicated that the bulbospinal pathway is 
also involved in sensory processing and have implicated the 
serotonergic system descending from the raphe nuclei to the dorsal 
horn in analgesia (Hentall and Fields,1979; Basbaum and Glazer, 
1979; Basbaum,1981; Yaksh and Wilson,1979). It has been 
established that activation of the raphe nuclei is involved in the 
analgesia produced by narcotics or electrical stimulation of the 
mid-brain (Basbaum and Fields,1984). Furthermore, analgesia is 
produced by stimulation of the raphe (Oliveras et.al,.1975; 
Oliveras et.al.,1979) and can be inhibited by lesions or 
anaesthesia of the ventral medulla (Duggan and Morton, 1983; 
Lovick,1985; Sandkuhler and Gebhart, 1984). In addition, 
depletion of the descending serotonergic neurones reduces the 
nociceptive threshold of spinal nociceptive neurones (Proudfit and 
Yaksh,1980). Stimulation of the raphe nuclei in the rat modulates 
spinal nociceptive reflexes as illustrated by stimulation-induced 
inhibition of the heat-evoked tail-flick (Hentall and Fields,1988) 
and other withdrawal responses (Hentall et.al.,1987; Sandkuhler 
and Gebhart, 1984). There is evidence that this effect is mediated 
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through release of SHT. Intrathecal application of SHT inhibits the 
excitatory effects of noxious stimuli on neurones in the superficial 
layers of the dorsal horn (Jordon et.al.,1978) and inhibits reflex 
withdrawal responses elicited by noxious stimuli (Berge 
et.al.,198S). Furthermore, axon terminals that take up [3H] 5HT 
and are assumed to originate from the brainstem synapse with 
dendrites in the dorsal horn (Ruda and Gobel, 1980). The receptors 
through which the antinociceptive effects of SHT are mediated in 
the dorsal spinal cord are reported to be the SHTI receptor with 
different effects being mediated through SHTI subtypes (EI-
Yassir,1988). However, further studies are required to either 
confirm or refute this proposal. In the human the SHT2 receptor 
has been implicated in SHT induced spinal analgesia (Sandrino 
et.al., 1986). This effect however may be partly or wholly supra-
spinally mediated. In summary, the evidence indicates that the 
5HT is involved in the analgesia both at a spinal and supra-spinal 
level. 
Substance P and TRH 
Substance P itself may also be a transmitter in afferent pain 
pathways and evidence for this comes from many lines of 
investigation: (i) substance P and substance P receptors are 
present in the dorsal horn and dorsal root ganglia of the spinal 
cord in high concentrations (Chan-Palay and Palay,1977; Cuello 
and Kanzawa,1978; Ljungdahl et.al.,1978; Quirion et.al.,1983) (ii) 
substance P is released from rat spinal cord with stimulation that 
activates nociceptive neurones (Jessell et.al,.1979), (iii) 
iontophoretically applied substance P activates nociceptive 
neurones in the dorsal hom of the spinal cord (Henry,1976; Randic 
and Miletic,1977) (iv) depletion of substance P from the dorsal hom 
is accompanied by attenuation of pain sensation (Hayes and 
Tyers,1980) and (v) substance P elicits behavioural responses 
thought to be expressions of perceived pain (Piercey et.al,.1981). 
However, in a series of experiments Frenk, Bossut, Mayer and co-
workers (Frenk et.al.,1988a: Frenk et.al.,1988b; Bossut 
et.al.,1988) provided evidence that a number of responses assumed 
to be related to nociception were not necessarily so, indicating that 
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the role of substance P as a neurotransmitter in nociceptive 
afferents has not been validated and that it is more likely that 
substance P acts as a neuromodulator in the perception of pain. 
A model which is in accordance with the evidence is of a 
modulatory role for substance P in spinal cord nociception which 
can modify bulbospinal regulation of spinal reflexes. Other 
evidence supports this interaction. The in vivo release of 5HT in 
the spinal cord can be evoked by exogenous substance P (Tsai 
.,1984). Additionally, using the tail pinch as a noxious 
stimulation 5HT release in the spinal cord was demonstrated in 
vivo and this release was inhibited by administering a substance 
P antagonist (Tsai ,1984). Furthermore, substance P attenuates the 
inhibitory effects of a 5HT agonist on the tail flick test (Eide and 
Hole,1988). 
The inhibitory effects of the raphe neurones may be 
mediated by release of 5HT via post-synaptic receptors at which 
substance P modifies the effects of 5HT and bulbospinal control of 
spinal nociceptive reflexes. It is also possible that TRH in the 
dorsal hom also plays a part in modulation of bulbospinal input. 
TRH has been located in the dorsal horn of the spinal cord in a 
number of species (Marsden et.al.,1982; Fone et.al.,1987b; Lechan 
et.al.,1984; Bennett et.al.,1986). Furthermore, there is evidence of 
a TRH system in the dorsal hom which is separate from the 
descending bulbospinal pathway (Harkness and Brownfield, 1986) 
which may be part of a sensory afferent pathway though TRH has 
not been localized in the dorsal root ganglia. 
Neurotransmitters of the spinal cord 2: Catecholamines 
Noradrenaline 
Dahlstrom and Fuxe (1964) first demonstrated that the 
neurones of the locus coeruleus in the pons are noradrenergic. 
Later, noradrenergic projections from the locus coeruleus to the 
spinal cord were demonstrated using retrograde transport of HRP 
(Kuypers and Maisky,1975; Mason and Fibiger,1979; Basbaum 
and Fields,1979). In the rat the retrogradely labelled cells were 
confirmed to be noradrenergic by immunocytochemical staining 
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techniques combined with HRP histochemistry (Westlund 
et.al.,1983). The results indicated that the nuclei of the pons 
including the locus coeruleus (A6 cell group), the subcoeruleus and 
lateral and Koller-Fuse nuclei (A 7) and the superior olivary 
nucleus (A5) were the sole source of descending nor adrenergic 
innervation. Quantitative analyses demonstrated that 86% of the 
spinal noradrenergic neurones project from the locus coeruleus 
and the sub-coeruleus in the rat (Westlund et.al.,1983). The locus 
coeruleus was confirmed as the major source of spinal cord 
noradrenaline in histochemical and biochemical studies 
(Commissiong et.al.,1978a; Karoum et.al.,1980; Nygren and 
Olson,1976). More recently, the pontine source of descending 
noradrenergic innervation in the cat has been located as the more 
caudal locus coeruleus pars ex and the sub-coeruleus rather than the 
locus coeruleus proper (Nakazato,1987). 
Noradrenergic terminals in the spinal cord are observed 
throughout the spinal gray matter and are most heavily 
concentrated in the superficial layers of the dorsal horn (laminae 
I, II and Ill), in the ventral horn, in the IML and around the central 
canal (Anden,1965; Carlsson,1964; Lackner,1980; 
Westlund, 1983). Reported levels of noradrenaline in the ventral 
and dorsal horn of the rat spinal cord detected by radio-enzymatic, 
gas chromatography- ~ a s s s spectrometric (GC-MS) or HPLC 
h . . ccmS\s.\et\ r I tec nlques are III 8 n ~ e e m e I I t t (Commissiong et.a .,1978a; 
Mouchet et.al.,1982; Basbaum et.al,.1987) and are similar to those 
in the cat (Fleetwood-Walker and Coote,1981). 
Dopamine 
Dopamine levels in the spinal cord are at least ten fold lower than 
those of noradrenaline (Commissiong and Neff,1979; Mouchet 
et.al.,1982; Basbaum et.al,.1987) and in the past it was thought that 
dopamine in the spinal cord was present solely as a precursor of 
noradrenaline (Anden et.al.,1966). However, an independent 
transmitter role for dopaminergic innervation of the cord is being 
established on the basis of evidence from spinal lesions, 
retrograde axonal tracing and immunohistochemistry of 
dopamine synthesizing enzymes (Commissiong et.al.,1978a,b; 
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Commissiong and Neff,1979; Bjorklund and Skagerberg,1979; 
Magnusson,1973; Skagerberg and Lindvall, 1985). The sole 
source of spinal cord dopaminergic innervation is the 
diencephalic All catecholamine cell group (Bjorklund and 
Skagerberg, 1979; Hokfelt et.al.,1979; Skagerberg and Lindvall, 
1985; Skagerberg et.al.,1988; Takada et.al.,1988). This cell group, 
first defined by Dahlstrom and Fuxe (1964) is located in the dorsal 
and posterior hypothalamus, the caudal thalamus and the 
mesencephalic periaqueductal gray. This diencephalo-spinal 
dopaminergic system projects mainly to the dorsal horn, the IML 
and the central gray matter at all spinal segments (Bjorklund and 
Skagerberg,1979; Hokfelt et.al.,1979; Skagerberg et.al,1982; 
Skagerberg et.al.,1988). Using GC-MS, HPLC or enzymatic 
methods dopamine has been measured in the dorsal and ventral 
horns in all spinal segments and in the thoracic IML 
(Commissiong et.al.,1978; Commissiong and Neff,1979, Mouchet 
et.al.,1982; Basbaum et.al,.1987). The distribution of dopamine 
reported is in agreement in general with the studies of 
dopaminergic innervation although dopamine terminals in the 
ventral horn are reported to be sparse or negligible (see Basbaum 
et.al.,1987). Dopamine levels are highest in the dorsal horn, IML 
and around the central canal and ventral horn levels of dopamine 
are approximately one third of dorsal horn levels (Commissiong 
et.al.,1978; Commissiong and Neff,1979, Mouchet et.al.,1982; 
Basbaum et.al.,1987). 
Adrenaline 
The distribution of adrenaline in the spinal cord is less well 
documented and adrenergic fibres are concentrated almost 
exclusively in the thoracic (Coote et.al.,1981; Ross et.al.,1984; 
Kohno et.al.,1988) and to a lesser extent in the sacral (Hokfelt 
et.al.,1984b) intermediolateral region. The spinal adrenergic 
innervation originates solely from the ventrolateral medulla 
(Hokfelt et.al.,1974; Hokfelt et.al.,1984b). 
There is also growing evidence for catecholaminergic 
neurones which are not supra-spinal in origin but intrinsic to the 
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spinal cord in both lower vertebrates (Parent and Northcutt, 1982; 
Wolters et.al.,1984) and in the rat (Mariani et.al,.1986). 
eNS synthesis and metabolism of catecholamines 
Independent noradrenergic, dopaminergic and adrenergic 
systems are possible due to specific enzymes within the common 
pathway for synthesis of the catecholamines. In addition a 
description of this pathway will facilitate understanding of the 
mechanism of action of the drug L-dopa which is administered in 
the treatment of Parkinson's disease and which is discussed later 
(pp.29). Furthermore, the enzyme systems responsible for 
catabolism of the catecholamines may playa part in the cause of 
Parkinson's disease. For these reasons the catecholamine 
synthetic and catabolic pathways are outlined here. 
The main pathway in the synthesis of catecholamines in the 
eNS is illustrated in Fig.1.5. Catecholamine synthesis starts with 
two essential amino acids phenylalanine and tyrosine, and 
tyrosine can be synthesized from phenylalanine by the enzyme 
phenylalanine hydroxylase. The enzyme tyrosine hydroxylase 
catalyses the conversion of tyrosine to dopa and this step is 
important in regulation of catecholamine synthesis. Tyrosine 
hydroxylase is produced in the cell body of the adrenergic 
neurones and its rate of synthesis is dependent on the level of 
neuronal activity and the rate of release of catecholamines. When 
the rate of catecholamine release is high tyrosine hydroxylase 
synthesis is enhanced. Furthermore, the conversion of tyrosine to 
dopa is relatively slow so that this process is the rate limiting step 
in the pathway. Tyrosine hydroxylase activity is inhibited by 
noradrenaline through competition for the cofactor 
tetrahydrobiopterin which is essential for the conversion 
(Kaufman and Fisher,1974). Tyrosine hydroxylase is affected by 
neuronal depolarisation (Alousi and Weiner,1966; Roth 
et.al.,1966) and during in situ nerve stimulation tyrosine 
hydroxylase appears to maintain the stores of noradrenaline 
(Weiner et.al,1978). Once formed, dopa is rapidly converted to 
dopamine by dopa decarboxylase which requires pyridoxal 
phosphate as a co-enzyme. Dopa decarboxylase acts only on the L-
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Fig 1.5 The main pathway in the synthesis of 
catecholamines. 
isomer of dopa and this isomer is used in the treatment of 
Parkinson's disease in the form of Levadopa (L-dopa). In the 
dopaminergic system described above the synthetic pathway stops 
at the formation of dopamine as these neurones lack the enzyme, 
dopa B-hydroxylase, necessary for the formation of 
noradrenaline. Similarly, in noradrenergic systems conversion 
of noradrenaline to adrenaline is prevented by the absence of the 
necessary enzyme (phenylethanolamine-N -methyl transferase). 
Catecholamines are catabolised by two main enzyme 
systems. Two enzymes catecholamine-O-methyl transferase and 
mono-amine oxidase act concomitantly. Catechol-O-methyl 
transferase (COMT) acts on dopamine, noradrenaline and 
adrenaline and the 3-methoxy products of its actions inhibit the re-
uptake of the catecholamines. The main products of metabolism of 
noradrenaline and adrenaline are 3-methoxy-4-hydroxyphenyl-
ethyleneglycol (MHPG) and 3,4-dihydroxyphenyl-ethyleneglycol 
(DHPG) and those of dopamine are 3,4-dihyroxyphenylacetic acid 
(DOPAC) and homovanyllic acid (HVA). Monoamine oxidase 
(MAO) is the major enzyme responsible for degradation of amines 
and exists in two forms, MAO A and MAO B. The MAO enzymes 
catalyse oxidation of the catecholamines to the deaminated state. 
The difference between these two enzymes is their specificity for 
different substrates, their inhibitor specificity, their distribution 
and immunological characteristics (Denney et.al.,1982, 1983 for 
review). However, in vivo, the effects of released catecholamines 
are tenninated to a large extent by their rapid up-take into pre- and 
post-synaptic terminals and the exact physiological function of the 
MAOs has not been determined. Roles proposed for MAO include 
regulation of pre-synaptic neurotransmitter levels (Von Korff,1979 
for review). 
The role of the catecholamines in spinal cord motor function 
It has been proposed that the noradrenergic innervation of 
the ventral spinal cord originating in the locus coeruleus is 
involved in regulation of spinal motor activity (Grillner,1975). 
The terminals of noradrenergic spinal pathways are found in the 
ventral hom in the areas where motoneurones are concentrated 
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and have been observed to be in close contact with motoneurones 
(Anden,1965; Lackner,1980; Westlund et.al.,1983; Holstege and 
Kuypers,1987). In addition, electrical stimulation of the locus 
coeruleus facilitates activity of the spinal motoneurones (Fung 
and Bames,1981). This effect is mediated at least partly by the 
large noradrenergic component of the locus coeruleus as 
facilitation of lumbar flexor and extensor monosynaptic reflexes 
produced by stimulation of this nucleus can be inhibited by 
adrenoceptor antagonists (Strahlendorf et.al.,1980). Furthermore 
iontophoretic application of noradrenaline, adrenaline and 
dopamine into the ventral horn induces facilitation of 
motoneurone activity or motoneurone depolarization (Parry and 
Roberts, 1980; White and Neuman,1980; White and Neuman,1983; 
Kitazawa et.al.,1985). The site at which depolarisation of spinal 
neurones by catecholamines is effected may be the cell bodies or 
dendrites rather than the axons of the motoneurones (Kitazawa 
et.al.,1985). Furthermore, modulation induced by noradrenaline 
may be mediated through o'2-adrenoceptors in the spinal cord 
(Kitazawa et.al.,1985; Conway et.al.,1988; Clarke et.al.,1988). It 
has been demonstrated that intrathecal administration of the 0'2-
adrenoceptor agonist clonidine reduces tonic activity of the hind 
limb muscles but allows walking movements (Tremblay and 
Bedard,1986) indicating a role for lX2-adrenoceptors in locomotor 
function. It appears therefore that spinal noradrenergic pathways 
facilitate spinal motoneurone activity as do the serotonergic-
peptidergic pathways but that the effects of these two systems are 
mediated through different receptors (see Conway et.al.,1988). 
The role of the catecholamines in spinal cord sensory function 
Noradrenaline is thought to be involved in mediation of 
nociception in the dorsal spinal cord (Dennis et.al.,1980; Kuraishi 
et.al.,1979,85; Reddy et.al.,1980). Ionotophoretic application of 
noradrenaline increases the threshold of A- and C- nociceptive 
fibres in the dorsal hom (Curtis et.al.,1983; Jeftinija et. aI., 1981; 
Carstens et.al.,1987) and noradrenaline inhibits the responses of 
dorsal horn nociceptive neurones to noxious stimuli or electrical 
stimulation (Belcher et.al.,1978; Fleetwood-Walker et.al.,1985). 
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Intrathecal application of noradrenaline produces antinociception 
in a number of pain reflex tests (Kuraishi et.al.,1985). 
Furthermore, the analgesic action of noradrenaline is exploited 
clinically and both ~ ~-adrenoceptor agonists and adrenergic re-
uptake blockers are used in the treatment of pain (Coombes 
et.al.,1986; Feimann,1985). The analgesic action appears to be 
mediated through o(.-adrenoceptors (Reddy et.al.,1980; Howe 
et.al.,1983) and is mimicked by clonidine (Schmitt et.al.,1974; 
Reddy et.al.,1980; Fielding et.al.,1978). There is evidence that 
analgesia to different types of pain may be mediated 
independently through c/-1- and 0( 2-adrenoceptors (Paalzow and 
Paalzow,1982; Tasker and Melzack,1989). There is strong 
evidence indicating a role for descending noradrenergic 
pathways in the antinociceptive effects of noradrenaline. 
Electrical stimulation of the locus coeruleus produces an 
inhibitory effect on pain transmission in the spinal cord (Jones 
and Gebhart,1986; Mokha et.al.,1986). In addition neurotoxin 
depletion of spinal noradrenaline in the cat is accompanied by 
supersensitivity to the antinociceptive effect of intrathecally 
administered noradrenaline (Howe and Yaksh,1982). This result 
and others were taken to indicate that the effect was mediated 
through post-synaptic adrenoceptors, and in part at least through 
c:X.2-adrenoceptors (Howe and Yaksh,1982; Jones and Gebhart,1986; 
Fleet-wood Walker et.al.,1985). However, as the antinociceptive 
effect of clonidine was unaffected by lesion of the locus coeruleus 
(Sawynok and Reid, 1986) and as ot2-adrenoceptors were 
subsequently demonstrated to be unaffected by noradrenaline 
depletion in the spinal cord (Howe et.al.,1987) the mechanism of 
supra-spinal noradrenergic modulation of nociception is 
undetermined. There is also one report that noradrenergic 
modulation of the tail flick (painlheat) reflex is mediated through 
a noradrenergic pathway descending from the lateral reticular 
nucleus (LRN) in the ventral medulla independent of the locus 
coeruleus, though the presence of an adrenergic LRN projection to 
the cord is still controversial (see Janss and Gebhart,1988). 
The dopamine agonist apomorphine has also been shown to 
exert an anti-nociceptive effect in the spinal cord (Jensen and 
Smith, 1983). 
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Interaction between serotonergic and noradrenergic systems 
It may appear from this discussion that the spinal 
serotonergic-peptidergic and adrenergic systems are independent 
of each other but in fact there is evidence that the effects of the two 
systems are highly interactive. In the CNS in general there is 
regulation of (;."k. and B-adrenoceptors by serotonergic activity. 
i3erotonergic denervation results in modification of 0{1-, 0(2- and B-
adrenoceptor binding and modulation of noradrenergic activity 
affects 5HT mediated behaviour (Manier et.al.,1983; Rappaport 
et.al.,1985; Manier et.al,.1987). Serotonergic control of locus 
coeruleus activity may be effected through post-synaptic 5HT2 
receptors in the locus coeruleus (Gorea and Adrien,1988). In 
addition, the anti-nociceptive action of dopamine in the spinal cord 
may be under the tonic inhibitory control of descending 
serotonergic and noradrenergic systems (Jensen and Smith,1983). 
Furthermore, there is evidence that TRH elicited motor effects are 
mediated through dopaminergic or noradrenergic mechanisms. 
Motor behaviour including wet-dog shakes and forepaw licking 
induced by intrathecal TRH is attenuated both by compounds 
which deplete monoamine stores and by adrenoceptor antagonists 
(Fone et.al.,1989b). Nociception also appears to be modulated by 
interaction between serotonergic and noradrenergic systems. 
Spinal noradrenaline depletion attenuates 5HT agonist-induced 
analgesia in hot plate or tail flick measurements of pain 
sensitivity (Archer et.al.,1986) and intrathecal 5HT reduces the 
antinociceptive potency of intrathecal noradrenaline (Clatworthy 
et.al,1988). 
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Parkinson's disease 
Neurochemical changes and symptoms 
One in one thousand people suffer from Parkinson's disease 
(CaIne, 1970). This condition was described as early as 1817 
(Parkinson, 1817) on the basis of its classic symptoms but it wasn't 
until the 1960's that the discovery of the deficit of nigrostriatal 
dopamine in the post-mortem brains of Parkinsonian patients was 
reported (Ehringer and Hornykiewicz,1960). This discovery lead 
to great improvements in the control of the symptoms of this 
condition by treatments to reverse the deficit (Birkmayer and 
Hornykiewicz, 1961). The most apparent symptoms of 
Parkinson's disease are those relating to loss of motor 
coordination. Patients suffer bradykinesia (slowness in 
initiating and executing voluntary movements), resistance to 
muscle movement (rigidity), tremor and postural instability 
(Birkmayer and Reiderer,1983; Parkinson,1817). However, more 
recently sensory symptoms in Parkinson's disease are also being 
appreciated, especially the pain associated with this condition (see, 
pp.183-184). Confirmation of the loss of nigro-striatal dopamine 
and of pigmented dopamine containing cells of the substantia 
nigra in Parkinson's disease (Bernheimer et.a1.,1973; Fahn 
et.a1.,1971; Lloyd and Hornykiewicz,1970) has stimulated 
extensive investigation in the biochemistry of the CNS in attempts 
to find the causes and cures of a whole variety of neurological, and 
in particular basal ganglia disorders (see Marsden, 1981; Rossor 
and Emson, 1982). It has been subsequently confirmed that 
neurochemical changes in the CNS of Parkinsonian patients 
extend further than that of the dopaminergic striatal cells. In the 
post-mortem Parkinsonian brain there are lower levels of 
dopamine in the mesolimbic and mesocortical dopamine systems 
and in the lateral hypothalamus (Homykiewicz, 1982; Javoy-Agid 
and Agid,1980) and these changes are accompanied by cell loss 
and l.ewy bodies (Javoy-Agid and Agid, 1980; Javoy-Agid 
et.a1.,1983). These changes may be related to the psychiatric and 
cognitive disturbances associated with Parkinson's disease 
(Mayeux, 1982). In the Parkinsonian brain regions of 
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noradrenaline loss are widespread including the locus coeruleus, 
nucleus accumbens, amygdala, hippocampus and the cortical 
regions (Farley and Hornykiewicz,1976; Scatton et.al.,1983). 
Deficits of serotonin in the Parkinsonian brain have also been 
reported in a number of regions including the basal ganglia, 
hypothalamus, hippocampus, raphe nuclei and frontal cortex 
(Bernheimer et.al.,1961; Scatton et.al.,1983). In addition, loss of 
cells of both the raphe nuclei and locus coeruleus have been 
reported (Greenfield and Bosanquet, 1953). Furthermore, lower 
levels of noradrenaline and serotonin but not dopamine have been 
described in the post-mortem spinal cord of Parkinsonian patients 
(Scatton et.al.,1986). In addition, modifications in the GABA ( 1-
aminobutyric acid) and peptide systems including CCK 
(cholcystokinin) and substance P have been implicated in 
Parkinson's disease (Barbeau and Kastin,1976; see Agid and 
J avoy-Agid, 1985). 
Treatment of Parkinson's disease 
Discovery of the loss of striatal dopamine lead to treatment 
by replacement therapy in the form of L-dopa which is taken up by 
dopaminergic neurones and converted to dopamine (pp. 23). L-
dopa can also be taken up by adrenergic neurones in which it is 
converted to noradrenaline and dopamine can be formed from L-
dopa in serotonergic cells which also have decarboxylase 
enzymes. However, studies indicate that dopaminergic cells 
contain 80-90% of decarboxylase activity and that these cells are 
primarily responsible for the decarboxylation of L-dopa (Melamed 
et.al.,1980). L-dopa is administered in conjunction with dopa 
decarboxylase inhibitors which do not cross the blood brain barrier 
(benserazide, carbidopa) and so ensure that increased dopamine 
synthesis from . ~ : : t : e e is prevented in the periphery and 
restricted to the eNS. In addition dopamine agonists such as 
bromocriptine and dopamine releasing agents are also useful in 
the treatment of Parkinson's disease (Reynolds and Reiderer, in 
press; Hoehn, 1981) as are anticholinergic agents which redress 
the imbalance between the central dopaminergic and cholinergic 
systems (Reynolds and Reiderer, in press). Treatment with L-
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dopa has improved the quality of life of many sufferers immensely 
by controlling the symptoms and evidence indicates that it may 
slow the progression of the disease and increase life expectancy 
(Hoehn, 1985). However, L-dopa is not a cure for Parkinson's 
disease. L-dopa therapy in particular reduces bradykinesia and 
rigidity but results in end of dose akinesia and fluctuations 
between symptoms of deficiency and of over-activation of the 
dopaminergic system resulting in abnormal involuntary 
movements (dyskinesias) (Hornykiewicz, 1973; Reynolds and 
Reiderer, in press). 
Causes of Parkinson's disease 
The cause of Parkinson's disease has not yet been proven. 
The main possible causes which have been considered are 
heredity, environmental factors, a virus or an effect of aging of the 
nervous system. It now appears unlikely that the condition is 
transferred genetically (Duvoisin,1984). In only 5% of cases are 
both individuals from a pair of twins likely to develop 
Parkinson's disease and this is irrespective of whether the twins 
are monozygotic or dizygotic (Duvoisin et.al.,1981). There has 
been some difficulty in differentiating environmental influences 
on affected and unaffected twins (Bharucha et.al.,1986) because of 
similarities in their backgrounds. However, environmental 
toxins have been implicated in a number of selected populations of 
people exhibiting high incidence of parkinsonian symptoms 
(Martilla and Rinne,1981; Gajdusek and Salazar,1982; Spencer 
and Schaumburg,1980). As an epidemic of encephalitis lethargica 
in the 1920's resulted in a clinical syndrome resembling 
Parkinson's disease (post-encephalic parkinsonism) there has 
been a search for evidence of a viral cause of Parkinson's disease. 
However, viral infection suffered by people developing 
Parkinson's disease has not been confirmed (Duvoisin,1981) and 
no viral cause has been discovered. Many of the symptoms of 
Parkinson's disease appear to be exagerations of changes 
occurring with age and in normal aging dopamine levels in the 
striatum fall by approximately 13% per decade (see Snyder and 
D' Amoto, 1986). 
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The basal ganglia in the human appears to be specifically 
sensitive to neuronal degeneration. A number of markers of basal 
ganglia dopaminergic activity decline with age including the 
levels of dopamine and tyrosine hydroxylase, dopaminergic 
neurones in the substantia nigra and striatal D2 receptors 
(reviewed by Morgan et.al,.1987). Similarly there are age related 
declines in substance P and neurotensin in the putamen and 
substantia nigra of the human brain which are not apparent in 
other regions (Buck et.al.,1981). Furthermore, cellular state in 
human brain determined by wet weight, total protein and 
ganglioside NeuNAc content is unaffected by age except in the 
caudate nucleus where all three factors are diminished with age 
(Allen et.al.,1983). It has been proposed therefore that Parkinson's 
disease occurs due to aging of the nervous system and would 
develop in more people if they lived longer though most evidence is 
against this theory (see CaIne and Langston, 1983). A popular 
hypothesis at the present time is that Parkinson's disease develops 
with age as a result of an earlier exposure to substances toxic to the 
CNS. This may be a viral exposure (see above) or exposure to an 
environmental chemical. There are toxins which can cause 
irreversible Parkinsonism which is alleviated by L-dopa (see 
CaIne and Langston, 1983). This hypothesis is supported by the 
Parkinsonian syndrome apparent in subjects who have been 
exposed to the substrate MPTP (l-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) . 
MPTP 
Discovery of the effects of MPTP may prove important in 
elucidating both the causes of Parkinson's disease and the 
mechanisms resulting in specific neuronal degeneration. The 
Parkinsonian symptoms induced by MPTP were first observed in 
a group of people in California who had self-administered this 
chemical believing it to be synthetic heroin (Langston et.al.,1983). 
These subjects developed Parkinsonian motor symptoms 
including bradykinesia, rigidity and tremor in a matter of days 
and the symptoms were found to be alleviated by L-dopa (with 
similar complications to those experienced by Parkinsonian 
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patients) and by dopamine agonists (Langston and Ballard, 1984; 
Langston et.a1.,1984a). This produced excitement in the research 
world as it appeared that MPTP could be used as a tool to produce 
animal models of parkinsonism to aid the investigation of drugs 
to control the symptoms. Furthermore, it appeared that MPTP 
produces selective permanent degeneration of the dopaminergic 
nigro-striatal system in the monkey (Burns et.a1.,1983; Langston 
et.al.,1984a) and in one person who committed suicide 18 months 
after injecting MPTP (Davis et.al.,1979). This indicated that the 
symptoms could be elicited by degeneration in this region only and 
that MPTP had specific neurotoxic effects. Furthermore, MPTP 
produces a good animal model of Parkinsonism as symptoms are 
observed only after a massive reduction (more than 80%) of 
striatal dopamine as seen in clinical Parkinson's disease 
(Chiueh et.al.,1985; Hornykiewicz,1982) and in addition the 
symptoms respond to L-dopa therapy (Burns et.al.,1983; Chiueh 
et.a1.,1984). The effects of MPTP are species specific and cause 
degeneration of dopamine neurones, loss of striatal dopamine and 
related motor symptoms in primates (Burns et.a1.,1983; Langston 
et.a1.,1984a; Crossman et.al.,1985; Jenner et.al.,1984; Chiueh 
et.a1.,1983) and in mice at much higher doses and with prolonged 
treatment ( Heikkila et.al.,1984; Tadano et.al.,1987) but not in 
other species (Chiueh et.a1.,1983). Subsequently much effort has 
been expended to illucidate the mechanism of action of MPTP. 
The active form of MPTP appears to be the oxidized 
derivative MPP+ (l-methyl-4-phenylpyridine) to which MPTP is 
converted by MAO enzymes via the intermediate MPDP+ (1-
methyl-4-phenyl-2,3-dihydropyridinium ion ) (Langston,1985). 
This idea is consistent with the finding that the neurotoxic effects 
of MPTP can be prevented by the prior administration of MAO-
inhibitors which prevent the conversion to MPP+ (Heikkila 
et.a1.,1984; Langston et.al.,1984b). The transformation may occur 
in elements other than the dopamine neurones such as glia and 
serotonergic terminals surrounding dopamine neurones (Uhl et 
a1.,1985; Langston et.a1.,1985). MPP+ accumulates in the brain, is 
taken up by dopaminergic neurones (Javitch and Snyder,1985) and 
is detectable for some time after administration of MPTP 
(Lewin,1984; Markey et.a1.,1984). Selectivity of the effects of 
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MPTP between species and brain regions may be dependent on the 
differential retention of MPP+ (Johannes son et.al.,1985; Markey 
et.al.,1984; Langston et.al.,1984b) and the heterogeneous 
distribution of the MPTP receptor. There is strong evidence that 
MPP+ binding site is the MAO-B enzyme (Lewin,1984; Javitch 
et.al.,1984). The accumulation of MPP+ in the substantia nigra 
may be related to the specific suseptibility of the neurones in this 
region to the degeneration caused by toxins and age. 
Additionally, it appears that MPTP may have a specific affinity 
for melanin (Lyden et.al.,1983). 
More recently the neurotoxic specificity of MPTP to striatal 
dopaminergic neurones has been contradicted. MPTP has been 
reported to induce metabolic but not degenerative effects on the 
serotonergic system in the mouse CNS (Bara et.al.,1987) and 
degenerative effects on dopaminergic, noradrenergic and 
serotonergic systems in the rat eNS have been reported (N amura 
et.al.,1987). It has been demonstrated that in addition to the 
dopaminergic systems MPTP produces damage to the ventral 
tegmentum and locus coeruleus in the primate CNS producing a 
breadth of neurochemical changes similar to that seen in 
Parkinson's disease (Mitchell et.al.,1985). This evidence 
indicates that MPTP may produce a better model of parkinsonism 
than first anticipated. 
The evidence, in general, demonstrates that MPTP induced 
parkinsonism is very like the clinical syndrome and this 
indicates that one of the causes of Parkinson's disease may be 
exposure to substances which can be metabolised to the neurotoxic 
entity MPP+ or other pyridines, many of which are present in the 
environment. For example, 4-phenylpyridine is present in 
peppermint tea and has been shown to result in tyrosine 
hydroxylase depletion in the striatum when administered to mice 
(Snyder and D'Amato,1986). Symptoms may appear several years 
after a neurotoxic insult due to the further degenerative effects of 
aging. 
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Factors considered and procedures used in this study 
Factors considered in the use of human tissue 
To determine the effects of a neurological condition on 
neurotransmitter levels or receptor binding in the human CNS the 
effects on these parameters of a number of variables must be 
considered including the age and sex of the subject, the interval 
between death and post-mortem dissection of the tissue (post-
mortem interval, PM!) and drug treatment before death. The 
effects of these factors must be determined as it is unlikely that the 
group under investigation could be matched exactly with controls. 
Generally speaking, the levels of neurotransmitters in the brain 
fall in the first 24 hours post-mortem whereas peptide levels are 
relatively stable (see Rossor,1986 for review). However, when the 
effects of these factors on specific neurotransmitters and peptides 
are reviewed carefully it is obvious that the picture is more 
complicated. Studies have also been conducted in animal tissue in 
order to control the variables more closely. In investigations 
using rat spinal cord and mouse brain (Mitsuma et.al., 1984 and 
Emson et.al., 1981b) TRH levels were reported to increase and to 
remain constant respectively in similar post-mortem time 
periods. Although this may reflect species variation it is likely 
that it is also dependent on regional variation, a factor which 
appears to be very important in the consideration of the effects of 
both PM! and age on CNS transmitter levels. For example, the 
basal ganglia appears to be specifically sensitive to neuronal loss 
of both dopamine and peptides with age as discussed above 
(Morgan et.al,.1987; Buck et.al.,1981; Allen et.al.,1983). 
Similarly, Siddique et. al., (1988) reported that post-mortem 
noradrenaline, 5HT and dopamine levels vary from control 
values in a differential manner depending on the brain region 
analysed and the exact time post-mortem. Moreover Severson and 
co-workers (1985) proposed that the relationship between 
imipramine binding (an indication of brain 5HT uptake) and age 
in humans depended largely on the exact age range of the subjects 
selected. The evidence indicates that the effects of PM! and age on 
CNS transmitter levels vary depending on the CNS region studied 
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and furthermore that the effects depend on the exact ranges of age 
or PM! under study. Ante-mortem drug therapy has also been 
reported to affect post-mortem studies. One of the most conclusive 
findings is the increase in dopamine receptor number and affinity 
in the brains of schizophrenics which has been related to ante-
mortem neuroleptic medication. This finding is supported by 
studies in animals treated with neuroleptics (see Rossor,1986). 
Monoamine metabolites as indicators of monoamine turnover 
In this study it was intended to use monoamine metabolites 
as indicators of monoamine turnover. The monoamines 
noradrenaline, dopamine and 5HT are metabolised after release 
from nerve terminals and, as their metabolites do not rejoin the 
monoamine synthetic pathway, the concentrations of the 
metabolites are taken as an indication of the rate of release of these 
neurotransmitters. The final product of 5HT metabolism is 
5HIAA and CNS 5HIAA concentration is frequently used to 
determine 5HT activity and release (turnover). However, use of 
metabolites in this way has been questioned. There is convincing 
evidence for an intracellular supply of the degradative enzyme 
MAO so it is possible that 5HT could be metabolised before release. 
In that case increased levels of 5HIAA may indicate increases in 
intracellular 5HT metabolism by the degradative enzyme MAO 
unrelated to release (Wolf et.al.,1985; Commissiong,1985). In the 
intact untreated animal it is considered that 5HIAA concentration 
is indicative of 5HT release and metabolism (turnover) and 
DOPAC and HV A levels are indicative of dopamine turnover 
(Commissiong, 1985). However, in the treated animal these 
assumptions only hold if the drugs used do not (i) induce synthesis 
of the monoamine which is metabolised before becoming part of the 
releasable pool or (ii) stimulate monoamine synthesis in elements 
other than the monoaminergic neurones (Commissiong, 1985). In 
this study therefore some consideration will be given to the effect of 
L-dopa administered to Parkinsonian patients on monoamine 
metabolism. The major metabolites of noradrenaline metabolism 
were not determined in the present study. 
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Radio-ligand binding studies 
The present work utilises the technique of radio-ligand 
binding. The in vitro method of radio-ligand binding is well 
established and has been used extensively to investigate the receptors 
in the CNS through which the endogenous catecholamines and 
indoleamines are effective CRouot and Snyder, 1979; Giron et .a1., 
1985; Petrash and Bylund, 1986; Mann et.a1., 1986; Brown et. al1988). 
Primarily this technique is used to define the sites at which ligands 
bind in terms of the number of receptors and the affinities of the 
ligand for the site. Using Scatchard and Hill plot analysis of the data 
the saturability, reversibility and homogeneity of the sites can be 
assessed. Such studies may provide evidence for subtypes in the 
classification of these receptors. For example, the endogenous 
compound 5HT has varying affinities for different subclasses of the 
receptor at which it binds and with the use of specific ligands these 
have been classified into 5HT1A, 5HT1B, 5HT1C, 5HT1D, 5HT2 and 
5HT3 receptors (Peroutka and Snyder,1979; Leysen et. al.,1982; 
Gozlan et. aI., 1983; Hoyer et al., 1985b; Heuring and Peroutka, 1987; 
Peroutka and Hamik, 1988). Furthermore, with the development of 
specific ligands investigations into the anatomical location of the 
various binding site subtypes have been made. For instance pre- and 
post-synaptic locations of serotonergic receptors, their heterogeneity 
throughout brain regions and species variation have been studied 
(Leysen et. aI., 1982; Leysen.et.a1., 1983; Pazos et aI., 1984b). 
However, for the binding site to be considered as a receptor there must 
be evidence for correlation between the site and some physiological 
function. In the case of serotonergic binding sites functional 
correlates have been obtained from the physiological and behavioural 
responses induced or antagonised by the administration of specific 
ligands (Doods et .a1., 1985; Middlemiss, 1985; Benkirane et. aI., 
1986). For 5HT1A sites in particular multiple correlates have been 
established between its pharmacological characteristics and its 
specific physiological effects. There is also evidence for association 
of the 5HT2 site with hallucination (Glennon, 1987), phosphoinositide 
turnover (Kendall and Nahorski, 1985; Roth et a1.,1984) and 
depolarization of neuronal membranes (VanderMaelen and 
Aghajanian, 1980). It is agreed however that a definite classification 
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for serotonergic receptor subtypes will have to wait until a clearer 
correlation between binding sites and functional significance has 
been achieved (Bradley et. al., 1986; Peroutka, 1988). 
Autoradiographic localization of serotonergic and adrenergic 
receptors 
Autoradiography is also employed in this study to measure 
and locate serotonergic and adrenergic receptor binding sites. A 
knowledge of the anatomical distribution of receptor sites within 
the eNS is important in order to characterize the sites. Their 
anatomical location can be correlated with the physiological 
significance of the area indicating a possible functional role for 
the receptors. Also pharmacological characterization of receptors 
in binding studies can be facilitated using eNS areas enriched in 
one specific subtype. Autoradiography provides a high degree of 
anatomical resolution for mapping the distribution of receptors 
and can be used quantitatively to estimate receptor concentrations 
and affinities (Young and Kuhar, 1979; Pazos and Palacios, 1985; 
Stephenson and Summers, 1985.) 
Effects of transmitter changes on receptor number and affinity 
Long-term denervation of transmitter systems can be 
expected to be accompanied by changes in receptor number and lor 
affinity for the transmitter and such changes may be an 
indication of receptor location. Loss of pre-synaptic receptors and 
supersensitivity in post-synaptic receptors could be expected to 
parallel pre-synaptic neuronal degeneration. For example in the 
Parkinsonian brain it has been reported that there are reduced 
dopamine (D1) receptor sites in the pars compacta of the substantia 
nigra indicating that Dl receptors may be located on the terminals 
of striato- or pallidonigral neurones which have been reported to be 
destroyed in Parkinson's disease (Cash et.al.,1987). 
Alternatively, these results may indicate that Dl receptors are 
located on the nigral dopaminergic cell bodies which are lost in 
Parkinson's disease (Cash et.al.,1987). In addition, there is an 
increase in D2 receptor binding in the MPTP lesioned striatum 
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indicating upregulation of post-synaptic D2 receptors (Leenders 
et.al.,1988). Similarly, up-regulation of 0(.1- and ol2-adrenoceptors 
in the rat cerebral cortex after treatment with the neurotoxin 6-
hydroxydopamine indicates that these receptors are mainly 
located on structures other than noradrenergic nerve terminals 
(Dausse et.al.,1982). Receptor adaptation and developed tolerance 
also occurs in the TRH system as demonstrated by progressive 
attenuation of the motor behaviour elicited by TRH after its long-
term administration (Simasko and Horita,1985). Consideration 
is given to receptor adaptation in evaluation of spinal transmitter 
system changes in Parkinson's disease 
Aims of this thesis 
Catecholamine, indoleamine, substance P and TRH levels in the 
human spinal cord 
The initial aim of this thesis was to compare the levels of 
catecholamines, indoleamines, TRH and substance P in the 
human spinal cord from patients who had died with Parkinson's 
disease and from control subjects. This was performed to 
investigate (i) the report of reduced 5HT and noradrenaline in the 
spinal cord in Parkinson's disease and (ii) whether, in the light of 
co-existence of 5HT, substancerand TRH in the rat spinal cord, 
substance P and TRH depletion parallels 5HT depletion in the 
human spinal cord. In order to accomplish this a sensitive assay 
for detection of substance P was required and the development of a 
sensitive radioimmunoassay specific for substance P and with low 
cross-reactivity for other peptides which may be present in the 
spinal cord is described in chapter 2 part 1. Secondly, comparison 
of the changes in the levels of 5HT, substance P and TRH in the 
Parkinsonian cord necessitated an extractant in which 5HT, 
substance P and TRH could be extracted concomitantly from tissue 
samples. The development of such an extractant and rigorous 
analysis of its use in extraction of catecholamines as well as 
indoleamines and peptides from rat spinal cord tissue is described 
in chapter 2 part 2. Rat spinal cord tissue was employed in order (i) 
to spare the limited supply of human tissue; (ii) to validate 
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the methods by comparing results with previously published data 
and (iii) to extend the study of catecholamine, indole amine and 
peptide levels in the rat spinal cord as this region has been 
neglected somewhat for all species. 
There have been few reports of the distribution of 
catecholamines, indoleamines and substance P in the human 
spinal cord possibly because of the difficulty in dissection of this 
tissue. In chapter 3 the levels of these neurotransmitters and 
peptides in post-mortem cervical, thoracic and lumbar spinal cord 
from control human subjects are given. This is accompagnied by 
a full analysis of the effects of a number of factors, such as subject 
age, sex and the interval between death and post-mortem which 
may affect post-mortem levels of amines and peptides. 
Considering these factors the levels of noradrenaline, 
adrenaline, dopamine, DOPAC, 5HT, 5HlAA, substance P and 
TRH are compared in the post-mortem spinal cords from 
Parkinsonian patients and control subjects. The results are 
discussed with reference to the effects of Parkinson's disease on 
indoleamines, catecholamines and peptides in the spinal cord and 
consideration of co-existence of 5HT, substance P and TRH in the 
human spinal cord. 
Serotonergic and adrenergic receptor binding 
To illucidate further the neurotransmitter changes 
occurring in the spinal cord in Parkinson's disease an 
investigation of the adrenoceptors and serotonergic receptors in 
this condition was undertaken. The aims of this study were to look 
at 0<.1- and o<..2-adrenoceptors, and 5HT1A and 5HT2 receptors 
using selective ligands in both ligand binding and 
autoradiographic studies. The protocols were first carried out 
using rat brain tissue to validate the methods as there have been a 
number of reports of the specific binding of the selected ligands to 
rat brain for comparison. A number of modifications to improve 
the ligand binding protocol for use with human spinal cord tissue 
were also tested using rat brain homogenate and these are all 
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reported in chapter 4. The final experimental chapter reports on a 
comparison of cX2-adrenoceptor binding in spinal cord from 
Parkinsonian and control subjects with reference to the effects of 
Parkinson's disease and noradrenergic depletion on 0(2-
adrenoceptor binding. In chapter 5 the effects of subject age, sex 
and the PM! on ol2-adrenoceptor binding are also analysed and 
discussed. 
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Chapter 2 Methods used in the 
measurement of indoleamine, 
catecholamine, substance P and TRH levels 
in rat and human spinal cord 
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Introduction 
This chapter describes the development and validation of a 
number of methods which were subsequently used to measure 
catecholamines, indoleamines, substance P and TRH in human 
post-mortem spinal cord. The availability of the human spinal 
cord material was limited and so it was important to use it 
efficiently. For this reason all the methods which were to be used 
were first applied and refined using rat spinal cord material. The 
methods were validated by comparing the levels of neuroamines 
(catecholamines and indoleamines in neuronal tissue) and 
peptides measured in rat spinal cord with those previously reported 
(Marsden et. aI., 1982; Mouchet et. aI., 1982; Lighton et.al.,1984; 
Basbaum et.al.,1987). The various methods used are discussed in 
this chapter in two parts. The first part covers the substance P 
radioimmunoassay and the production of an antiserum with high 
specificity for substance P. In the second part the development of a 
common extractant for the neuroamines and peptides and the 
methods utilised in that study are described. The practical 
application of the methods is demonstrated by analysis of the 
catecholamine, indoleamine and peptide levels in rat spinal cord. 
Part 1 Substance P Radioimmunoassay 
Introduction 
Radio-immunoassay (RIA) is the only method suitable for 
routine quantitation of endogenous substance P levels in animal 
tissue samples and is well established as such (Powell et.al.,1973; 
Iversen et.al.,1976; Di Giulio et.al.,1985). Firstly this method is 
sensitive enough to measure the relatively low (pM) levels of 
substance P in the CNS. A limit of detection of less than 0.1 fmols 
substance P has been reported using RIA to measure substance P in 
diaIysates collected from rat brain (Brodin et.aI.,1983). Secondly 
RIA can, potentially, offer the degree of specificity required to 
differentiate between substance P and various other peptides with 
similar structures which may be present in CNS tissue. The assay 
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is based on displacement by substance P of a tracer, radio-labelled 
substance P, bound by antibodies. The concentration of 
endogenous substance P in samples is determined by comparing 
the displacement it produces with the displacement caused by 
known concentrations of synthetic substance P (standards). 
The quality of the assay, with respect to sensitivity, 
specificity and precision, depends on obtaining a high titre 
antiserum (As.) and a specific high activity tracer. A good 
antiserum is one that will bind the tracer with high avidity yet 
allow displacement of the tracer by substance P. The avidity of 
binding of the antiserum to substance P must be in the region of 
more than 100 fold better than that for other similar peptides or 
substance P fragments in order to be highly specific for substance 
P. Ideally, non-specific binding (NSB) to the buffer and assay 
vials should also be low and less than 10% of total tracer binding. 
Working with a high antiserum dilution ensures a low 
concentration of other components of the serum which may 
interfere with the antiserum-tracer interaction and so final assay 
antisera dilutions of 1 in several thousand are preferable for RIA. 
The sensitivity and precision of the antisera and the optimal 
assay conditions including antisera and tracer dilutions can be 
assessed using antisera titration and displacement (standard) 
curves (Fig.2.1). Primarily the tracer must be diluted such that its 
activity in the assay is at the level of maximum counting 
efficiency of the gamma counter (usually, approximately 10,000 
cpm). The proportion of the total amount of tracer that is bound by 
antibodies, the binding coefficient, depends on the dilution of 
tracer and antiserum used and in practice dilutions and 
conditions are selected such that (i) the binding coefficient is 30-
40% (ii) the range of substance P concentration over which the 
tracer is displaced is more than ten fold and (iii) the displacement 
curve is steep in order to produce a high precision assay. 
In addition to substance P many of the antisera used in 
substance P assays have been shown to bind substance P 
fragments or peptides containing amino-acid sequences present 
in substance P. Furthermore this cross-reactivity is often specific 
in that an antiserwn may selectively recognize either the N- or C-
terminal of the substance P molecule and any peptide containing 
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Fig.2.1 Substance P displacement curve 
This figure shows a typical substance P displacement or standard 
curve. Log. substance P concentration is plotted against %Bound; 
where % bound = BIBO expressed as a percentage; B = tracer bound 
in the presence of substance P and BO = tracer bound in the absence 
of substance P. Each point is determined from the mean of four 
replicates. This format is used for all the displacement curves of 
substance P and other peptides shown in this thesis. 
either or both of these elements (Lee et al., 1980; Toresson et al., 
1988). For this reason the RIAs are described as detecting 
substance P-like-immunoreactivity (substance P-LD. Using an 
antiserum with low substance P specificity would result in the 
substance P-LI measured being greater than the substance P 
concentration in the sample. 
This cross-reactivity of antisera with substance P-like peptides 
is especially important to consider in the light of the evidence for 
the presence of multiple forms of substance P in CNS tissue 
including (i) peptides with similar structures to substance P (i.e. 
other tachykinins), (ii) substance P or tachykinin metabolites and 
(iii) tachykinin precursor peptides. 
(i) Substance P is one of a group of peptides known as 
tachykinins which share the C terminal amino-acid sequence, 
Phe-X-Gly-Leu-Met-NH2 which is responsible for the aspects of 
biological activity that the tachykinins have in common. 
Recently tachykinins, other than substance P, including 
neurokinin A (also known as substance K) and neurokinin B (or 
neuromedin K) have been reported to be present in the mammalian 
central nervous system (Kimura et al., 1983; Kangawa et al., 1983; 
Tatemoto et.al.,1985) and may be responsible for effects previously 
accorded to substance P. Functionally, substance P, neurokinin A 
and neurokinin B are closely associated in that they produce 
similar effects in the periphery (Hua et. al., 1984) though they 
interact preferentially with different receptor sites (Quirion, 1983; 
Buck et. al.,1986). Furthermore both neurokinin A and substance 
P are derived from the same precursor polypeptide, 
preprotachykinin, in bovine brain and human carcinoid tumour 
though there are minor differences in the amino acid make up of 
the precursor in the two species (Nawa et al.,1983; Harmar 
et.al.,1986). The structures of these tachykinins are shown in 
Fig.2.2. 
(ii) Recent evidence also indicates the presence of 
membrane bound enzymes isolated from central nervous tissue 
which act to cleave substance P into smaller fragments 
(Arzumanyan et.al.,1985). Furthermore, Sakurada and co-
workers (1985) have reported that levels of C-terminal fragments 
in the areas of rat brain rich in substance Pare 1-2% of those of the 
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Fig.2.2 The structure of substance P and some related peptides 
Substance P 
ARG-PRO-LYS-PRO-GLN-GLN-PHE-PHE-GLY-LEU-MET-NH2 
Neurokinin A 
HIS-LYS-THR-ASP-SER-PHE-VAL-GLY-LEU -MET-NH2 
Neurokinin B 
ASP-MET-HIS-ASP-PHE-PHE-VAL-GLY-LEU-MET-NH2 
Substance P fragments 
1-4 ARP-PRO-LYS-PRO 
1-7 ARG-PRO-LYS-PRO-GLN-GLN-PHE 
7-11 PHE-PHE-GLY-LEU-MET-NH2 
Tyr-8-substance P 
ARG-PRO-L YS-PRO-GLN-GLN -PHE-TYR-GL Y -LEU -MET-NH2 
Residues common to substance P are under-lined. 
parent compound. While in the spinal cord levels of substance P 1-
7 were reported as 18% of those of substance P (Sakurada et.al., 
1985). Substance P may also be broken down into smaller 
fragments during extraction from tissue samples in the process of 
measuring tissue levels. 
(iii) In addition to reports of a tachykinin precursor present 
in bovine brain, substance P fragments extended at the N-
terminal or both the N- and C- terminal of substance P have been 
described in extracts of rat CNS tissue and in human 
cerebrospinal fluid (Nawa et.al.,1983; Harmar et.al.,1984; 
Toresson et al.,1988). 
It is therefore vi tal that the antiserum used in the substance P 
RIA is substance P specific and can distinguish between substance 
P and other similar peptide structures. Moreover, antisera known 
to be directed towards the N- or C- terminal of substance P can be 
valuable in assessing whether substance P-LI measured 
comprises non-substance P components. For example Hannar 
and co-workers (1984) used C- and N- terminally directed antisera 
in combination with enzymatic degradation of tissue extracts to 
identify a substance P sequence which is extended at the N-
terminal and present in rat hypothalamus. Many of the substance 
P fragments discussed above contain the C-terminal sequence of 
substance P and there would be little or no recognition of these 
peptides by an N-terminally directed substance P antiserum. This 
chapter therefore describes an attempt to raise antisera specifically 
directed against either the N- or C- terminal of substance P. A 
number of antisera were raised in sheep and subsequently 
evaluated for their specificity, titre and tracer binding capacity as 
well as for their use in RIA detection of substance P with respect to 
sensitivity and precision of the assay. 
For in vivo production of antisera against a peptide the 
immunogenicity of the peptide is enhanced by conjugation with a 
large immuno-reactive carrier protein such as haemocyanin 
before injection into the animal. A cross-linking agent is 
required to link the peptide and protein and the product of the 
linking reaction depends on the conjugating agent, the protein and 
the reaction mechanism (Williams and Chase, 1967). Different 
conjugating agents involve different residues of the peptide in the 
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peptide-protein link leaving the remaining residues free against 
which the immunogenic reaction is directed. Carbodiimide and 
glutaraldehyde used in peptide protein linkage tend to produce C-
and N- terminal linked protein conjugates respectively 
(Goodfriend et.al.,1964; Sternberger,1979) and were therefore used 
as conjugating agents because of this property. 
The antisera produced were then tested for cross-reactivity 
with the tachykinins neurokinin A and neurokinin B and with the 
substance P fragments 1-7, 1-4 CN-terminal) and 7-11 (C-terminal) 
as well as with tyr-8-substance P to evaluate their specificity. 
HPLC with RIA 
HPLC separation of peptides used in conjunction with RIA is 
a well established technique for determining the number of 
components of a sample contributing to the total immunoreactivity 
measured by RIA (Hua et.al.,1985; Toresson et.al.,1988). HPLC 
with U.V. detection is not very sensitive compared to RIA and is 
therefore not used for the routine measurement of tissue peptide 
levels. However, HPLC is invaluable for separating the large 
number of similar peptides and peptide fragments present in 
samples. By analysing the separated components for 
immunoreactivity using RIA the specificity and cross-reactivity 
of the assay can be assessed. Detailed in this chapter is an attempt 
to use HPLC with U.V. and RIA detection to separate substance P 
and other peptides which may be present in spinal cord extracts in 
order to determine the specificity of the antiserum used. 
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Methods 
Radio-active labelling of substance P 
Substance P was radio-labelled with 125iodine by the 
chloramine T method as described by Powell and co-workers 
(1973). Tyr-8-substance P (5J,!g) was incubated with 1mCi sodium 
125 I ( 1 0 ~ ) ) in phosphate buffer (0.5 M, pH 7.4) and 50J,!g of 
chloramine T. The reaction was stopped by the addition of 150J,!g of 
sodium metabisulphite after 15 seconds followed by 1ml of human 
plasma. Quso glass (lOmg) previously activated by heating to 
6000 c was added to the reaction mixture to adsorb the radio-active 
peptide. After centrifugation (lOOOg, 5minutes) the remaining free 
iodine was discarded in the supernatant and the pellet was 
resuspended and centrifuged in 1ml of distilled water (lOOOg, 
5mins). The labelled peptide was eluted from the second pellet in 
60% acetone /1% acetic acid (1m}) and the supernatant of the third 
spin (lOOOg, 10 mins.) containing the 125 I labelled tyr-8-substance 
P was stored at 40c. For RIA the tracer was diluted such that 50J,l1 
produced approximately 10,000 cpm on the gamma counter (LKB 
Clinigamma) and was used at an assay dilution of at least 1 in 
4000. 
Production of substance P antisera 
A. Substance P conjugation to haemocyanin 
Substance P was conjugated with haemocyanin using a 
modification of the method of Goodfriend (Goodfriend et.al., 1964). 
Either 0.5 mIs of 0.1 M glutaraldehyde or 0.5 mls of 50% 1-ethyl-3-
(3-dimethyl amino propyl) carbodiimide (referred to here as 
carbodiimide) were added slowly to 1.5 mg substance P, 10mg 
whelk haemocyanin and one drop of undiluted tracer in 1ml of 
deionised double distilled water. After 18 hours incubation at room 
temperature the reaction was terminated using dialysis by 
suspending the reagents in dialysis tubing (size 2-18/32") in 3 
litres of continuously stirred water at 40c for 48 hours. Twenty four 
and 48 hours after initation of dialysis samples of water were 
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tested for radio-activity which was compared with activity in the 
original conjugate. The percentage of total peptide which was 
conjugated to haemocyanin was calculated from the amount of 
labelled peptide retained in the tubing on the basis of two 
assumptions. These were firstly that the conjugated peptide 
(labelled or unlabelled) was retained within the dialysis tubing 
and thereby separated from the unconjugated peptide which passed 
through it. Secondly, it was assumed that the proportion of 
substance P conjugated to haemocyanin was the same for the 
labelled and unlabelled forms. Aliquots of the conjugate were 
stored at -800c. 
B. Ovine immunization 
For the production of antisera to substance P in young ewes a 
procedure similar to that used in rabbits by Bassiri and Utiger 
(1972) was employed. Each conjugate ( 7 5 0 ~ 1 ) ) was mixed with 4.5 
mls of Freund's complete adjuvant, a general immuno-
potentiator, and the total volume divided amongst six two year old 
ewes (sheep numbers 312C, 308C, 3l4C, 304G, 30SG, 3l0G). Three 
ewes each received one intramuscular and multi site subcutaneous 
injections of 1.S mls of either carbodiimide or glutaraldehyde 
conjugate. Subsequently five subcutaneous booster 
immunizations with either conjugate ( 3 0 0 ~ 1 ) ) emulsified in 
Freund's incomplete adjuvant were given at approximately 
monthly intervals. 
At 18 and 22 weeks after the initial immunization blood 
samples were taken from the jugular vein for determination of 
substance P antiserum titre. Serum production was discontinued 
in sheep no.S 312C and 308G after 18 weeks as the titre was very 
low. After 22 weeks sheep 304G and 308e were killed and 
exanguinated while the remainder received a booster of 0.5 mg 
substance P in Freund's incomplete adjuvant. These two were 
killed and bled 10 days later. 
Collected blood was allowed to clot and retract overnight at 40c. 
The serum was centrifuged (2000g, 30minutes, 40c.) and stored at 
40c in 0.1% sodium azide as preservative. 
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Evaluation of new antisera 
A. Titration Curves 
Eight antisera (As. 8A, 8B, 8i, 8ii,8iii, 9/80, 65/66, SP8) 
raised in rabbits (MRC, Cambridge) were tested with those raised 
in sheep as described above for use in RIA. Initially the optimal 
antisera dilutions for RIA, those producing a value of 30-40% for 
the ratio of antibody bound tracer to total tracer (binding 
coefficient) were determined from antiserum titration assays. 
A series of dilutions from 1 in 100 to 1 in 10,000 of each 
antiserum was made in RIA buffer containing 0.825% sodium 
barbital, 0.5% bovine serum albumin. Fifty ~ l l of each antiserum 
dilution was incubated with 1 0 0 ~ 1 1 RIA buffer and 5 0 ~ 1 1 diluted 
tracer overnight at 40 c. The antibody-tracer conjugate was 
precipitated by addition of Iml ice cold ethanol and separated by 
centrifugation (lOOOg, 4oc, 15 mins.) The bound tracer was 
determined by counting on a LKB gamma counter for 90 seconds. 
The ratio of antibody-bound tracer to total tracer in a 5 0 ~ ~
standard was calculated for each antiserum dilution and plotted 
against antiserum dilution. From the titration curves optimal 
antiserum dilutions resulting in binding coefficients of 30-40% 
were selected for use in substance P displacement curves. 
B. Displacement curves 
The ability of the antibody bound tracer to be displaced by 
substance P was determined using a radioimmunoassay based on 
a modification of the method of Powell and co-workers (1973) with 
antiserum dilutions producing a binding coefficient of 30% , or 
greater dilutions if reproducible displacement curves could be still 
obtained. Antiserum dilutions used in displacement curves were 
as follows: As. 314C, 1 in 100; As. 308C, 1 in 100; As. 304G, 1 in 1000; 
As. 306G, 1 in 750, As. 8A, 8C, 8ii, 9/80, 65/66 SP8, 1:1000; As.8iii, 
1:2500. 
Fifty microlitres of antiserum were incubated with 5 0 ~ 1 1 of 
diluted tracer and 1 0 0 ~ 1 1 of unlabelled substance P standard (10-
2000pg) or buffer overnight at 40 c. Bound tracer was separated 
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from unbound using ethanol and measured as above. The ratio of 
bound tracer in the presence and absence of substance P (BIBO) was 
calculated for each concentration of substance P. Displacement 
curves were obtained by plotting BIBO against the log. of substance 
P concentration (Fig. 2.1). 
Specificity of the new antisera 
Six batches of antisera of which the displacement curves 
covered at least a ten fold substance P concentration range with a 
maximum displacement of approximately 70% were selected for 
testing for cross-reactivity with other peptides. Four of the six 
batches As. 306G, 304G, 308C and 314C comprised sera collected at 
the end of the immunization period. Batches were also selected 
from blood samples collected at 18 weeks from 2 of the same sheep 
(As.306G2 and 304G2). All six batches of antisera were tested for 
cross-reactivity with the substance P fragments substance P 7-11, 
1-7 and 1-4 and the substance P-like peptides neurokinin A, 
neurokinin Band tyr-8-substance P (see Fig.2.2 for structures). 
The peptides were incubated within a range of 10-2000 pg/tube with 
tracer and antiserum diluted as described for substance P 
displacement curves. A higher concentration (20ng/tube) of 
peptide was used for those producing insignificant displacement at 
2ng/tube. Percentage cross-reactivity of the antisera with the non-
substance P peptides was calculated as the ratio of the 
concentration of substance P producing 50% displacement to that of 
non-substance P peptides and expressed as a %. Where the greatest 
displacement obtained was less than 50% the respective 
concentrations p r o d u c i n ~ ~ maximum displacement were used. 
This ratio was determined as the mean value from duplicate 
assays. The cross-reactivity of the antisera to substance P was 
taken as 100%. Displacement assays with the peptides at a 
concentration of 200 ngltube were performed in quadruplicate 
using As.304G. 
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Radio-immunoassay modifications 
The effect of the following treatments on the sensitivity and 
precision of the substance P assay was assessed by comparing the 
displacement curve profiles and NSB in treated and control 
assays. 
1. Filtering antisera through 0.45 J.Un millipore glass fibre 
filter before use. 
2. Twenty four hour incubation of antiserum and substance 
P standards followed by a further 24 hour incubation period after 
addition of the diluted tracer instead of overnight incubation of 
standards, tracer and antisera. 
Antisera 306G and SA were used at 1 in 750 and 1 in 1000 dilutions 
respectively following the RIA methods described above. 
Assay Reproducibility 
Inter-assay and intra-assay variation was determined as a 
measure of reproducibility of the substance P assay using a 1 in 
1000 dilution of As. 3040 (final dilution, 1 in 4000). 
Inter-assay variation was calculated as the coefficient of 
variation (standard deviation/mean) of 6 identical measurements 
made in separate assays using different batches of tracer over a 
period of 5 months. The measurement made was the substance P-
LI ofa substance P standard (500 pg/tube) selected as the mid-point 
of the steep portion of the substance P displacement curve. 
Intra-assay variation was determined as the coefficient of 
variation of values obtained for the substance P-LI of 4 identical 
standards (500 pg/tube) determined in the same assay. The 
coefficient was calculated as the meant SEM of 9 assays. 
Evaluation of antisera specificity using HPLC 
HPLC with U.V detection was used to separate substance P from 
other peptides present in human spinal cord extracts. To find the 
optimal wavelength at which to detect the peptides within the HPLC 
mobile phase solutions of tachykinins and substance P fragments 
(100 ~ g / m l ) ) were scanned to determine the wavelength at which 
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their absorbance of light was greatest. A number of potential 
constituents of the mobile phase including methanol, ethanol, 
propan-1-01, propan-2-01 and phoshate buffer were also scanned to 
determine the wavelength of peak light absorbance. Absorbance 
over the range 190-340nm of solutions of peptides and solvents in 
glass cuvettes were made against water as a reference using a CE 
500 scanning spectrophotometer. 
Synthetic substance P, neurokinin A and neurokinin Band 
substance P fragments 1-4, 1-7 and 7-11 (10 ~ g g each) were separated 
by high performance liquid chromatography (HPLC) using a 
mobile phase of 55% HPLC grade methanol, 0.3% 
trifluoroaceticacid, pH 2.0 delivered at a rate of 1.5 mIs/minute to a 
Waters Z module employing a 10 I.lm Bio-Rad ODS (250x 4mm) 
cartridge. Peptides were detected by a Beckman 160 ultra-violet 
detector set at 0.1 A.U. using a 240 nm filter and time taken for 
samples to travel through the system was determined by the 
interval between sample injection and detection of the solvent 
front. 
An extract of control human spinal cord in ethanol and 
acetic acid (prepared as described in chapter 3, pp. 94-95) was dried 
by evaporation under vacuum at 600c, resuspended in Iml of 
mobile phase, centrifuged (1300g, 3mins.) and filtered through an 
ACS acrodisc before injection onto the HPLC system. With the 
detector disconnected 1 minute fractions of mobile phase were 
collected from the end of the cartridge for sixty minutes starting 2 
minutes after injection. Cocktails of substance P, substance P 
fragments 1-7, 1-4 and 7-11 and neurokinin A and neurokinin B at 
concentrations of either 10 ~ g g or 40 ng/injection were separated 
and collected in the same manner. The system was washed with 
mobile phase overnight between injections of high and low 
concentration peptides. Fractions were dried and stored at -BOoc. 
Fractions were assayed for substance P-LI by RIA after 
resuspension in 500 ~ l l of RIA buffer. Those of the high 
concentration cocktails were diluted 1 in 1000. Substance P 
displacement curves using As. 304G were produced as described 
except that standards were made in dried down mobile phase 
resuspended in RIA buffer to be comparable with the samples of 
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HPLC fractions. Standard curves were also produced in dried 
mobile phase diluted 1 in 1000 with RIA buffer. To detect substance 
P-LI in the fractions 100111 of each resuspended fraction (in 4 
replicates) were incubated with antiserum and tracer and assayed 
alongside the displacement curves. The ratio of bound tracer in 
the presence of the sample to that in the absence of substance P 
(BIBO) was calculated. The concentration of substance P-LI in the 
sample was determined by interpolation from the appropriate 
(diluted or undiluted) displacement curve. 
Drugs 
The peptides substance P, neurokinin A, neurokinin Band 
tyr-8-substance P and the substance P fragments 1-4, 1-7 and 7-11 
were obtained from Peninsula Laboratories Europe Ltd. Antisera 
8A, 8B, 8i, 8ii, Siii, 65/66, 9/80 and SP8 were obtained from Dr. P 
Emson, MRC Neurochemical Pharmacology Unit. Cambridge. 
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Results 
Antisera production 
After 24 and 48 hours respectively of dialysis against water 
there was 58 and 31% recovery of the tracer from the 
glutaraldehyde conjugate and 10 and 8% recovery from the 
carbodiimide conjugate. 
Although antiserum titre itself was not measured directly, 
an indication of titre was determined from antisera titration 
curves. Larger antisera dilutions producing a binding coefficient 
of 30% are indicative of higher serum antibody content. Therefore 
the antisera dilution factor producing a binding coefficient of 30% 
determined from titration assays using consistent conditions and 
tracer dilution was used to represent serum titre. This value is the 
final dilution of the antisera as it is used in the assay. Eighteen 
weeks after initial immunization serum samples from the six 
sheep showed a wide variation in antiserum titre defined in this 
way (Fig.2.3) and the titres from the sheep receiving the 
glutaraldehyde conjugate (no.s 304G, 306G and 310G) were higher 
than of those receiving carbodiimide conjugate (314C, 308C and 
312C). The titres in the latter case being less than 1 in 400. 
Antiserum production was discontinued in the sheep (no.s 312C 
and 310G) producing the lowest titre for each of the two treatments. 
Four weeks later although the titres of the antisera raised against 
carbodiimide conjugate (carbodiimide-antisera) had increased 
moderately they were still both less than 1 in 600. Sheep no. 304G 
had a stable titre but that of 306G had fallen to 1 in 800. Ten days 
after the final booster immunization with substance P the 
antiserum titre of sheep no.s 306G and 314C had increased 
moderately but were still low with values of approximately 1 in 
1400 and 1 in 400 respectively. 
Evaluation of antisera 
The antibody titre and/or binding coefficient determined 
using 1 in 4000 final antiserum dilution are given in Fig.2.3 for 
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Fig. 2.3 The titre* and binding coefficients of a number of antisera 
Rabbit Antisera 
8A 8B 8i 8li 8iii 9180 65/66 SP8 
*Titre 4(0) 24000 
Binding 00 m m 18 55 6.2 7.5 12 
Coefficient (%) 
Sheep Antisera 
Interval after 
immunization 3000 304G 3lOG 308C 312C 314C 
(weeks) 
--- -- ----- -- --
*Titre 18 2BOO 4000 400 <400 <400 <400 
~ ~ BOO 4000 5 ~ ~ <400 
23.5 1400 400 
Binding 22 28 28 11 
Coefficient (%) 
*Titre is expressed as the dilution factor producing a binding coefficient of 30%. The binding coefficient 
given is that produced by a final assay serum dilution of 1 in 4000. 
the rabbit antisera, As. 8A, 8B, 8i, 8ii, 8iii, 9/80, 65/66, and SP8 . 
Only As.8A and 8iii had titres of 1 in 4000 or more. The 
displacement curve of As.8iii was relatively flat with a maximum 
displacement of only 30% (Fig.2.4) whereas that of As. 8A was 
sigmoidal with a maximum displacement of 85%. The straight 
part of this curve was steep and covered a substance P 
concentration range of 100-600 pg/tube (Fig.2.4). 
Reproducible displacement curves over the substance P 
concentration range 30-2000 pg/tube were obtained for sheep 
antisera As. 304G, (Fig.2.9), 306G, 308C and 314C with maximum 
displacements of over 80% for each at the highest substance P 
concentration. 
Antisera specificity 
There were no differences in peptide cross-reactivity 
between the batches of serum collected from the same sheep at 18 
and 22 weeks after initial immunization for either sheep 306G or 
304G despite differences in titre and they will therefore be 
discussed as As. 306G and 304G only. 
The % cross-reactivity of the carbodiimide- and 
glutaraldehyde-antisera with neurokinin B, neurokinin A, tyr-8-
substance P and substance P 1-7, 1-4 and 7-11 is shown in Fig.2.5. 
With respect to the antisera raised against the 
glutaraldehyde conjugate (glutaraldehyde-antisera) As.306G and 
304G, there was no discernible displacement of the ,antibody bound 
tracer by the substance P fragments 1-4, 7-11 and 1-7 or by the 
peptides neurokinin A and neurokinin B in the concentration 
range 10-2000 pg/tube, the concentration range of the substance P 
standard curve. There was still no discernible displacement of the 
As. 304G bound tracer by any of these peptides at concentrations of 
20ng and 200ng/tube (See Fig.2.6). In the case of As.306G there 
was displacement by substance P 7-11 (17%) and neurokinin B 
(14%) only at 20ng/tube but no displacement by the other peptides. 
Peptide cross-reactivity of the carbodiimide-antisera 
differed from that of the glutaraldehyde-antisera with respect to 
displacement of the bound tracer by substance P 7-11, neurokinin B 
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Fig. 2.4 Substance P displacement curves 
using two different antisera SA and Siii. 
Fig.2.5 %Cross-reactivity of anti-sera with peptides 
Anti-sera 
306G 304G 314C 308C 
Peptides 
Substance P 100 100 100 100 
Neurokinin A 0 0* 0 1.0 
Neurokinin B 0.5 0* 1.0 1.2 
Tyr-8-substance P 100 122 185 
Substance P 
fractions 
14 0 0* 0 0 
1-7 0 0* 0 0 
7-11 0.6 0* 19.6 ~ ~
Cross-reactivity of an antiserum with a peptide was calculated as 
the ratio of the concentration of substance P producing 50% 
displacement of binding to that of the peptide and is expressed as a 
%. Cross-reactivity of substance P was defined as 100%. For 
further details see methods. A value of zero is given where there 
was no displacement of the antisera bound tracer with 20 or 200* 
ng/tube peptide concentration. 
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Fig.2.6 Cross-reactivity of antisera 304G and 308G with 7 
peptides 
This figure compares the displacement of antisera 304G (A) and 
30Se (B) bound tracer by substance P and 6 other peptides named 
in the key. The major differences between the two antisera is in 
the displacement by the C-tenninal substance P fragment 7-11 
and by neurokinin A and neurokinin B. 
and neurokinin A. There was no discernible displacement with 
the N-terminal fragments substance P 1-7 and 1-4 at any 
concentration up to 20ng/tube. In contrast the C-terminal 
fragment substance P 7-11 displaced the carbodiimide antisera 
bound tracer in a concentration dependant manner as illustrated 
in Fig.2.6 for As.30SC. The degree of displacement at each 
concentration was less than that by substance P. Neither 
neurokinin A or neurokinin B displaced carbodiimide-antisera 
bound tracer at concentrations up to 2ng/tube. However at 
20ng/tube neurokinin A displaced As. 30SC only by 25% and 
neurokinin B produced 29% and 24% displacement respectively of 
As.30SC and 314C bound tracer (Fig.2.6). 
Tyr-S-substance P displacement curves exhibited a similar 
profile to the substance P displacement curves for the three antisera 
tested with this peptide (As. 306G, 304G and 30SC). The gradients of 
the two curves were similar but tyr-S-substance P generally 
produced greater displacement of tracer at each point than 
substance P (Fig.2.6). 
RIA Modifications 
Neither filtering the antisera nor varying the incubation 
period of the RIA affected either non-specific binding or the 
displacement profile of As. 304G or SA as illustrated in Figs. 2.7 
and 2.S. 
AS.304G Displacement curve 
The binding coefficient of the tracer using As. 304G at a 
final dilution of 1 in 4000 was between 20-30%. Variation within 
this range occurred using different batches of tracer. 
Reproducibility of the assay was good with inter- and intra-assay 
variability of S.O% and 12.0±2% respectively calculated as 
described in the methods. The steep part of the curve covered a 10 
fold concentration range from 100-1000 pgltube and the maximum 
displacement was approximately 82%. See Fig.2.9. Sensitivity of 
the assay was 74 fmols/tube. 
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Fig.2.7 Effect on substance P RIA of filtering antisera 
Substance P displacement curves obtained using antisera 306G. 
Each point is the mean from two assays. The antisera was either 
filtered (m ) or unfiltered (.) before use. Non-specific binding 
(NSB) was the same in each case 
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Fig.2.8 Effect on substance P RIA of prolonged incubation 
period 
Substance P displacement curves obtained using antisera SA and 
two treatments. 
• Antisera standards and tracer were incubated overnight. 
III Antisera and standards were pre-incubated for 24 hours and 
the incubation period was extended for a further 24 hours after 
addition of tracer. Each point is the mean of two assays. 
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Fig. 2.9 
Substance P displacement curve using antisera 304G 
This curve shows the mean and SEM of 9 substance P displacement 
curves performed on different occasion using antisera 304G at a 
dilution of 1 in 4000. [1251] substance P 4ilution varied with 
the batch used and was no less than 1 in 4000. 
HPLC with RIA 
The absorbance of light by substance P, neurokinin B, 
neurokinin A and substance P fragments 1-4, 1-7 and 7-11 as 
measured with a scanning spectrophotometer increased sharply 
over the range 210-240nm, with maximum absorbance at 225-230 
nm compared with the reference cell. Typical scan profiles of 3 
peptides are given in Fig.2.10. Maximum light absorbance by 
ethanol, methanol, propan-1-o1 and propan-2-01 occurred between 
190-240nm with the peak at 190-220nm whereas for phosphate buffer 
it occurred at 190-200nm and fell to zero compared with the 
reference cell above 205nm. 
Substance P fragments 7-11,1-7 and 1-4 eluted within 5 
minutes after sample injection (Fig.2.11). Neurokinin A, 
neurokinin B and substance P eluted over the intervals 3-5, 5-7 and 
10-16 minutes after injection respectively (Fig.2.11). The limit of 
U.V. detection was approximately 600ng for substance P and as 
low as 60ng for the other peptides depending on their elution time. 
The later the peptides eluted from the column the wider and 
smaller were the corresponding chromatographic peaks thereby 
resulting in less sensitive detection levels. 
After injection of the high concentration (10 Ilg/injection) 
cocktail of pep tides substance P-LI was detected in fractions 10-15 
but not in any other fraction (Fig.2.11). Fractions 10-15 
corresponded to the time interval over which substance P was 
eluted from the column. These HPLC fractions were diluted 1 in 
1000 before RIA. There was, however, very little binding in any of 
the fractions which were not diluted before assay. This included 
those collected after injection of low concentration 
(40ng/injection) peptide standards and samples of spinal cord 
extract. The binding in the standard curve made using dried 
undiluted mobile phase was also very poor and maximum 
displacement by synthetic substance P was approximately 20%. 
For this reason substance P-LI in the extract of human spinal cord 
was not quantifiable though there was some displacement of 
binding in fractions 10-15 only. 
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Fig. 2.10 Ultraviolet scan profiles of substance P, neurokinin A 
and substance P 7-11. 
*J 
substance P 
I I I I 
240 260 280 :m 
A, substance P 7-11 i t 
200 220 240 260 280 300 
neurokinin A 
200 220 240 260 280 300 
wavelength (nm) 
Absorbance of light by substance P, substance P 7 .. 11 and neurokinin 
A ( 1 0 0 ~ g / ~ ) ) over the wavelength range 190-300nm. Peptides were 
dissolved in water and absorbance was measured against a reference 
cell of water. *Scale is 0.2 Absorbance Units 
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Fig. 2.11 HPLC separation of peptides with U.V. and 
R.I.A detection 
(i) HPLC separation of synthetic neurokinin A (A, 10J.lg), 
neurokinin B (B, 3J.Lg) and substance P (SP, BJ.lg) in a mobile 
phase of 55% methanol, 0.3% TFA, pH 2.0 delivered to a 1 0 ~ ~
Bio-Rad ODS cartridge at 1m11min. Peptides were injected 
at time zero and detected by U.V. absorbance at 240nm. The 
scale is in absorbance units (A.U). 
(ii) U.V detection of substance P fragments 1-7 (2Jlg), 1-4 
(2Jlg) and 7-11 (1J.Lg) injected separately on to the HPLC 
system at time zero. Each fragment eluted within 5 mins of 
injection. 
(iii) Substance P-like immunoreactivity in one minute 
fractions of eluate collected from the HPLC system after 
injection of a cocktail of 10Jlg neurokinin A, neurokinin B, 
substance P and substance P fragments 1-4, 1-7 and 7-11. 
Fractions were diluted 1: 1000 before RIA. 
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Discussion 
The sensitivity of a radioimmunoassay is dependent as much 
on the properties of the radio-labelled peptide used as on the 
antiserum. The tracer must be as pure as possible to ensure low 
levels of non-specific binding. Synthetic substance P itself cannot 
be labelled directly with radio-active iodine because of the absence of 
either a tyrosine or histidine residue so a substance P analogue with 
a tyrosine residue at position 8, tyrosine-8-substance P, was used as 
described in the methods. The products of the chloramine T method 
of iodination of tyr-8-substance P are labelled substance P, tyr-8-
substance P, damaged peptide and free 1251. Even after purification 
with quso glass the tracer may be contaminated with free 1251 and a 
proportion of the tracer may also degenerate during storage. It is 
therefore important that the tracer can be used in high dilutions to 
minimize the effects of components other than tyr-8-substance P on 
the antisera -tracer binding. For this reason only batches of tracer 
which produced 10-15,000 cpm at dilutions of 1 in 4000 or more were 
used and batches of this standard were produced in 4 out of 5 
attempts. The level of non-specific binding varied with different 
antisera but was less than 10% with As. 304G. Substance P iodinated 
using Bolton Hunter reagent is available commercially 
(Amersham International pIc.) but is more expensive to use. The 
tracer was kept at 40c and used wi thin six weeks of production after 
which time the binding coefficient fell to less than 10%. Storage of 
the tracer in frozen aliquots did not improve its viability after 6 
weeks. 
Of the eight antisera raised in rabbits only two, As.8A and 8iii, 
had antibody titres which were reasonably high enough for RIA 
enabling use of 1 in 4000 antisera dilutions. With As.8iii there was 
little displacement of bound tracer by the highest substance P 
concentration resulting in an insensitive assay. In contrast the 
assay using As. 8A was more sensitive with a steep substance P 
displacement curve displacing 85% of total binding within less than 
an 8 fold concentration range. An assay with a steep displacement 
curve is very precise as small changes in peptide levels produce 
large changes in % displacement. However t such a precise assay 
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can be less practical to use as it provides a very small concentration 
range within which the endogenous substance P content of samples 
must fall if it is to be measured. It is more practical to use an assay 
of which the steep part of the displacement curve covers more than a 
ten fold concentration range. 
Comparison of glutaraldehyde and carbodiimide as conjugating agents 
An immunogenic response was stimulated in all sheep 
injected with the substance P conjugates used in this study but the 
antisera varied markedly in their titre and specificity to substance 
P. 
The highest titre of antisera raised against the carbodiimide 
conjugate was less than 1 in 600. The failure to produce an 
antiserum of high titre against the carbodiimide conjugate is 
probably due to the low yield of conjugate produced (indicated by the 
substance P tracer loss of more than 90% by the end of dialysis). It 
appears that this method is not appropriate for conjugation of 
carbodiimide with substance P in the production of antisera for RIA 
as a repeated attempt produced the same result. The method was 
adapted from that used by Goodfriend (Goodfriend et.al.,1964) who 
raised antibodies to bradykinin and angiotensin using 
carbodiimide hydrochloride to conjugate the hap tens with rabbit 
serum albumin. An adaptation of this method was used 
successfully by Lee and co-workers (Lee et.al., 1980) to produce 
substance P antisera by conjugating the peptide to bovine serum 
albumin using carbodiimide. The presence of whelk haemocyanin 
in place of serum albumin may not facilitate the covalent bonding 
of carbodiimide to substance.P. Haemocyanin was initially 
selected as the immunogenic protein as it is a foreign protein to the 
sheep further removed than BSA or thyroglobulin and was therefore 
expected to produce a stronger antigenic response. It is also an 
inexpensive peptide to obtain. 
The conjugation of substance P to haemocyanin using 
glutaraldehyde was more successful than using carbodiimide and 
though tracer loss indicated that only 30% of the peptide had been 
conjugated with the hapten this is a reasonable level for practical 
purposes. The variation in immunogenic response between sheep is 
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illustrated by the difference in titre of the antiserum produced in 
sheep receiving the same glutaraldehyde conjugate. The 
immunogenic response to the glutaraldehyde conjugate varied 
widely from one sheep to another and after 18 weeks exposure only 
moderate increases in titre could be stimulated by further injections 
of the conjugate. 
Low specificity of substance P antisera may account for 
variations in CNS substance P-LI levels reported by different 
workers (See Toresson et.al.,1988 for review). For this reason 
carbodiimide and glutaraldehyde were selected for conjugation of 
substance P to an immunogenic protein in an attempt to produce 
antisera which specifically recognized either the N - or C-terminal 
of substance P respectively. The results of the cross-reactivity study 
indicate that there was some evidence of selective recognition of the 
C- terminal residues by the carbodiimide antisera but not by the 
glutaraldehyde antisera raised. 
Antisera specificity 
The carbodiimide-antisera had 20-30% cross-reactivity with 
the C-terminal amino acid sequence substance P 7-11, and a 
smaller degree of cross-reactivity with neurokinin Band 
neurokinin A which have a similar C-terminal to substance P. 
This is a clear indication that these antisera are directed towards 
the C-terminal of the substance P structure. The residues towards 
the N-terminal of neurokinin B and neurokinin A may interfere 
with the antiserum binding with the C-terminal residues, this would 
explain why the cross-reactivity with substance P 7-11 is greater 
than that of neurokinin A and neurokinin B (Fig.2.6). The results 
also indicate that antisera recognition of the residues must be partly 
dependent on configuration as there was no discernible recognition 
of substance P fragments 1-4 or 1-7 yet bound-tracer displacement by 
substance P was greater than that by fragment 7-11 alone (Fig.s 2.6). 
Cross-reactivity of the glutaraldehyde antisera with peptides 
other than substance P was much lower than that of the carbodiimide 
antisera. Antiserum 304G showed less than 0.5% cross-reactivity 
with neurokinin A, neurokinin B and substance P fragments 1-7, 
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1-4 or 7-11 producing a sensitive and reproducible substance P assay 
covering a ten fold concentration range. Exact values for cross-
reactivity could be determined by repeating the assays using the 
pep tides at higher concentrations until the bound tracer was 
displaced. 
Antisera recognition oftyr-8-substance P was expected to be 
great because of the close structural similarity to substance P. In 
fact the cross-reactivity with tyr-8-substance P was greater than that 
with substance P itself. The reason for this may be that tyr-8-
substance P resembles the substance p-glutaraldehyde conjugate, 
against which the antiserum was raised more strongly than 
substance P itself. The hydroxyl group on the substituted tyrosine 
residue may produce similar configurational changes in the 
substance P structure as conjugation to the carrier protein. The 
ability to differentiate between such similar analogues is an 
indication of the high specificity of the antiserum. 
In this study, which attempted to use glutaraldehyde as a 
linking agent at the C-terminal of substance P, an antiserum 
(As.304G) has been produced which appears to have low recognition 
of the C-terminal residues. Antiserum 304G appears to be directed 
against the whole of the substance P molecule. Lack of cross-
reactivity with C- or N-terminal fragments or with the tachykinins 
neurokinin A or neurokinin B support this claim as does the high 
degree of cross-reactivity with tyr-8-substance P. This antiserum 
was therefore selected for use in all subsequent substance P assays 
in this project. The other glutaraldehyde antiserum 306G, which 
also showed low cross-reactivity to the peptides tested, was retained 
for possible use in immuno-histochemical techniques which do not 
require such high antisera titre.· 
It has been proposed that substance P itself is inactive within the 
CNS and that its effects are produced by its degradation into active 
components (Stewart et. al.,1982). Nyberg and co-workers (1984) 
have characterized an endopeptidase in human CSF which degrades 
substance P to residues 1-7, 1-8,8-11 and 9-11 and there is also 
evidence that N -and C- terminal fragments of substance P may 
produce opposite effects in behavioural paradigms such as isolation 
induced fighting and passive avoidance behaviour (Hall et.a!., 
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1987; Gaffori et.al.,1984). A recent publication reports the effects of 
intrathecal administration of selected substance P fragments 
compared to substance P itself in the rat tail flick test. Substance P 
1-7 produced similar effects to that of substance P. Administration 
of both peptides resulted in a large transient decrease in reaction 
time whereas fragments 8-11 and 1-9 had no effect and 7-11 produced 
a small prolonged decrease in reaction time (Cridland and Henry, 
1988). These results support the claim that the effects of substance P 
in the CNS may occur after degradation into smaller fragments and 
that the resulting peptides may have different effects. The 
availability of radioimmunoassays specific for selected amino acid 
sequences could therefore be important in clarifying the relative 
roles of substance P and other tachykinins and substance P 
fragments in mediating eNS effects previously associated with 
substance P. 
Antisera specific for N - and C- terminal substance P 
fragments are useful experimental tools and have been used to 
identify precursors and metabolites (Harmar et.al.,1984; Toresson 
et.al.,1988). Many attempts to produce substance P antisera result in 
the production of C-terminally directed antisera which cross-react 
with C-terminal fragments and tachykinins (Lee et.al., 1980; 
Brodin et.al.,1983; Harmar et.al.,1981; Sakurada et.al.,1985). 
Carbodiimide can be used as the linking agent between hapten and 
carrier protein. Carbodiimide can couple with a number of 
functional groups including carboxylic acids, amines and 
alcohols. Although the exact reaction mechanism with substance P 
is not known it probably proceeds through more than one 
intermediary to produce an amide link between hapten and protein 
(Goodfriend et.al.,1974). Antisera raised against carbodiimide 
conjugated substance P have been shown in the present study to 
cross-react with C-terminal residues of substance P, indicating that 
the carbodiimide tends to form N-terminallinkages. This is 
obviously a problem for accurate measurement of substance P in 
systems containing a number of C-terminal substance P 
metabolites and precursors. The production of an antiserum in this 
study which has low cross-reactivity with substance P fragments 
and other tachykinins is therefore a great advantage. Although the 
reaction mechanism for conjugation of substance P with 
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glutaraldehyde is not clear it seems likely that a number of 
different bonds are made in different molecules. In this way 
consistent masking of specific amino acid sequences is avoided 
and the antiserum produced recognizes the whole of the substance P 
structure. However, whatever the nature of the reaction mechanism 
the advantage of glutaraldehyde over carbodiimide as a 
conjugating agent in the production of specific substance P antisera 
has been demonstrated here. 
Development of the RIA 
A solid phase RIA for quantitation of substance P has been 
reported by Oblin and Zivkovic (1983) as an improvement of the 
standard substance P assay. Solid phase RIA is based on the 
partition of substance P antisera between free substance P and 
insoluble substance P immobilized in a polyacrylamide gel. 
125Iodinated protein A (a cell wall component) replaces 125I-tyr-8-
substance P for use in quantifying the amount of antibody bound 
substance P-insoluble complex. Cross-reactivity of the assay is still 
dependent on the antisera employed and is no different from that in 
a standard assay using the same antisera. The solid phase assay is 
however marginally more sensitive than the assay described in this 
chapter and does not require overnight incubation. Therefore its use 
in combination with As.304G may prove to be an improvement on 
the present assay. 
All antisera were stored at 40c but some samples were found to 
have formed growths despite the presence of 0.1% sodium azide. It 
was decided that the sera should be filtered to remove the growth. 
Small aliquots of antisera were first filtered to test whether this 
produced any adverse or advantageous effects on the RIA with 
respect to sensitivity or precision. Filtering these samples through 
0.45 ~ ~ filters removed the growths as well as other sediment which 
had settled out during storage without affecting displacement 
profiles or NSB (Fig 2.7). The remaining sera were then also 
filtered though this was a time consuming process as the filters were 
very rapidly saturated with particles. In some cases the growths 
returned in time and as the future effects of these are not known it 
63 
may be necessary to store some aliquots at -16oc as described by 
William and Chase (1976). 
In the substance P assay generally used in our laboratory 
diluted tracer and antiserum are added to substance P standards or 
samples and incubated overnight. Many workers however incubate 
antiserum and samples for 24 hours before addition of the tracer 
and/or incubate the three components together for up to 72 hours 
(Powell et.al.,1973; Brodin et.al.,1983). Comparison was made 
between two assays set up simultaneously and incubated either 
overnight or for 24 hours before addition of tracer with a further 24 
hours afterwards. There were no differences in displacement 
profile or NSB of either assay (Fig.2.8). Therefore in all further 
assays our original protocol was adopted. 
Monoclonal Antibodies 
A major problem arising in the use of RIA methods is the lack 
of specificity of the antisera as discussed here. Antibodies to an 
antigen raised in an animal are not homogeneous as they are 
produced from a large population of lymphocytes and are therefore 
polyclonal. There is now the possibility of obtaining greatly 
improved antiserum specificity with the recent development of 
monoclonal antibodies. Monoclonal antibodies are obtained from a 
single clone of cultured cells. The principles of immunizing the 
animal with the antigen are essentially the same as described in 
this chapter. However, after the immunization period spleen cells 
containing lymphocytes which are producing antibodies are fused 
with myeloma cells. Then individual hybrid myeloma/spleen 
cells are cloned so that a cell line producing homogeneous 
antibodies to the antigen is established. The binding properties of 
monoclonal antibodies are identical and thus highly specific. They 
can also be reproduced indefinitely so that the radio-immunoassay 
can be standardized on an international level. However problems 
of biological specificity may arise from the use of monoclonal 
antibodies in RIA since the antigenic detenninant of a monoclonal 
antibody consists of only approximately 5 amino acid residues. As 
every antibody in a monoclonal culture is identical this means the 
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monoclonal antisera are directed very specifically to a short amino 
acid sequence. In the case of small peptides such as thyrotrophin-
releasing hormone this could result in a very specific antiserum 
directed against the whole molecule. Unfortunately in the case of 
larger peptides such as substance P the result would be an antiserum 
directed specifically at one short section of its structure. This is 
illustrated by a report from Courand et.al., (1987). These authors 
raised 5 monoclonal antibodies to substance P which were all 
directed to the C-terminal pentapeptide of substance P. Accordingly 
they were reported to cross-react with neurokinin A and neurokinin 
B. Therefore as yet the development of monoclonal antibodies can 
not improve the specificity of antisera to larger peptides such as 
substance P. 
Evaluation of antiserum specificity by HPLC with RIA detection 
The isocratic HPLC method for peptide separation was adapted 
from that used by Bennett and co-workers (1989). These authors 
measured electro-active peptides using HPLC with electro-chemical 
detection. However, as substance P does not contain oxidizable 
tyrosine, cysteine or tryptophan residues it is not electro-active so 
U.V. detection was employed. A number of factors determined the 
HPLC conditions. 
The mobile phase had to be volatile, to allow eluate 
concentration for subsequent RIA , and have a low absorbance 
within the peptide absorbance range for sensitive U.V. detection of 
peptides. The phosphate mobile phase of Bennett et. al.(1989) left a 
white residue after evaporation and so was replaced by a 
TFAlmethanol mixture. Using the scanning spectrophotometer the 
peptides were found to have a peak absorbance at 225-230nm but to 
obtain a greater differential between the sample absorbance and 
baseline absorbance a 240nm filter was used. At this wavelength 
both the absorbance of solvents in the mobile phase (of methanol in 
particular) and the corresponding absorbance offset were lower. 
The sensitivity of the system to the peptides may however have been 
improved by detection at 220nm. TF A was chosen as a mobile phase 
component as it has a low absorbance at 220-240nm and is routinely 
used in HPLC separation with U.V. detection of pep tides. 
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For HPLC separation of peptide standards high concentrations 
were used because the U.V. detector sensitivity was low compared to 
RIA. After separating the peptides and collecting the column eluate 
in fragments it was diluted 1 in 1000 before RIA. However when 
samples were not diluted some component of the eluate badly 
disrupted the antiserum-tracer binding. RIA could only be 
performed accurately with samples collected in the eluate and 
diluted 1 in 1000 though a number of lower dilutions were tested. 
This effect may have been caused by disintegration of the cartridge 
at the low pH used or by the NaOH in the mobile phase when it was 
concentrated. It was not practical to dilute spinal cord extracts 1 in 
1000 as such large amounts of tissue would be required. 
Difficulties arose when trying to modify the mobile phase as it 
had to be appropriate to HPLC separation as well as both U.V. and 
RIA detection of peptides. A number of peptides including substance 
P were separated by HPLC with U.V. detection by Meek (1980). He 
reports however that N aCL04 is an essential component of the 
mobile phase to produce sharp peaks of substance P and as it is not 
volatile the eluate can not be concentrated for RIA. Peptide 
separation in the present study was poor and the peaks were not 
sharp (Fig.2.11). Although substance P was separated from 
neurokinin A, neurokinin B and the substance P fragments 
because of the width of the chromatographic peaks the latter peptides 
could not be distinctly identified when injected in a cocktail 
(Fig.2.1l). The best separation was obtained using a mobile phase of 
pH 1.6 but this was not employed as the manufacturers suggest that 
cartridge damage may occur at levels less than pH 2. 
Due to the problems described we were unable to fully validate 
by HPLC the substance P specificity of the assay using antiserum 
304G. However, standards of substance P, substance P 1-4,1-7 and 7-
11, and neurokinin A and B were separated by HPLC, collected in 
one minute fractions and assayed by RIA using antiserum 304G. 
Substance P-LI was detected only in HPLC fractions 10-15, the 
fractions which corresponded to the time interval over which 
substance P eluted from the column. In support of the results from 
the RIA cross-reactivity studies, no substance P-LI was detected in 
the HPLC fractions in which the tachykinins or substance P 
fragments eluted. 
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On injection of the extract of human spinal cord onto the HPLC 
column we were unable to detect any peptides by U.V absorbance 
because the levels were lower than the limit of detection. Substance 
P-LI in the collected HPLC fractions could not accurately be 
determined due to the poor binding caused by assaying the samples 
without dilution of the mobile phase. There was however some 
indication of displacement in fractions 10-15 without displacement 
in the other fractions but this was not conclusive evidence of 
antiserum specificity. As the binding was disrupted the assay was 
not representative of the substance P RIA under normal conditions. 
If normal binding had been achieved and substance P-LI was 
detected only in fractions 10-15 this would be evidence that the assay 
is specific for substance P. The results obtained using standards do 
not account for antiserum recognition of any other tachykinins, 
metabolites or precursors which may be present in the spinal cord 
samples. For complete validation of specificity of the antiserum, 
for substance P HPLC separation of peptides in spinal cord samples 
with RIA of the HPLC fractions needs to be accomplished. 
Separation of peptides including substance P by HPLC has been 
reported using a linear gradient of mobile phase eluting different 
peptides from the column at increasing concentrations of, for 
example, acetonitrile (Hua et. a1.,1985; Toresson et. aI., 1988). 
This technique is more flexible than isocratic HPLC as the gradient 
can be easily modified to obtain the optimal resolution of the peaks 
and it has been shown that peptide retention times can be predicted 
from their amino acid composition (Meek,1980). The retention time 
depends on the sum of the hydrophobicity of the constituent amino 
acids and 'retention coefficients' for 100 peptides have been 
determined and found to correspond closely to values estimated 
from amino acid composition (Meek and Rossetti,1981). 
Linear gradient HPLC with U.V. detection is therefore the 
appropriate method for separation of peptides. Using an isocratic 
system is impractical although it can be used successfully with 
sensitive electro-chemical detection of certain electro-active 
peptides. The major problem using the isocratic system was 
probably that peptide separation depended on achieving a very low 
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pH. U sing a linear gradient system peptide retention times can 
easily be manipulated by changing the organic solvent content of 
the mobile phase. As methanol is volatile even high concentrations 
would not affect RIA binding in the HPLC fractions after 
evaporation. 
In conclusion, an antiserum (304G) has been raised in sheep 
using a substance P-glutaraldehyde-haemocyanin conjugate. The 
antiserum is specific for substance P with less than 0.5% cross-
reactivity with neurokinin A, neurokinin B or the substance P 
fragments 1-4,1-7 and 7-11. Antiserum 304G appears to recognize 
the whole of the substance P structure and can be used for RIA of 
substance P at a 1 in 4000 assay dilution. The resultant assay is 
sensitive, precise and reproducible. Unfortunately the specificity of 
the antiserum has not been fully validated using HPLC separation 
of pep tides in conjunction with RIA. However, the results obtained 
so far using this technique support those obtained in RIA antisera 
cross-reactivity studies. 
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Part 2 A common extraction method for the measurement 
of indoleamines, catecholamines, substance P and TRH 
Introduction 
The supply of post-mortem human spinal cord material 
available for the measurement of its neuroamine and neuropeptide 
content as described in the next chapter was limited. This was due 
partly to the necessity that the donor subjects fulfilled a number of 
criteria and secondly to the difficulty and time involved in 
dissecting the spinal cord. In addition, different protocols were 
reported for the extraction of substance P, TRH and the 
neuroamines from tissue samples (Gilbert et.al., 1982; Lighton 
et.aI., 1984; Bennett et.al.,1986). As part of the intention of the 
investigation was to study the inter-relationship of the 
indoleamines with substance P and TRH known to co-exist in rat 
spinal cord neurones (Gilbert et.al.,1982) as discussed in the 
general introduction an extraction process common to the peptides 
and amines was required. A common method for extracting 
neuroamines and neuropeptides from one sample of tissue would 
therefore enable the measurement of their levels and the 
investigation of their inter-relationship, whilst simplifying the 
methodology and making most effective use of the material 
available. To satisfy these aims a method described in this chapter 
was developed by which 5HT, 5HIAA, noradrenaline, adrenaline, 
dopamine, DOPAC, substance P and TRH can be extracted using a 
common medium and measured using HPLC (indoleamine and 
catecholamines) and RIA (TRH and substance P ). 
In this chapter the levels and percentage recoveries of 
substance P, TRH and indoleamines and catecholeamines 
extracted from rat spinal cord in the common extractant, a mixture 
of ethanol, acetic acid and sodium metabisulphite (NaMBS) and in 
a number of more generally used solutions are compared. The 
effect of the common extractant on the HPLC chromatography of the 
amines is also discussed. 
All the methods which were to be used to measure peptide, 
indoleamine and catecholeamine levels in the human spinal cord 
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including the common extraction method, substance P and TRH 
radioimmunoassay, HPLC separation and detection of 
neuroamines and the protein assay were first performed using rat 
spinal cord material. This enabled problems arising in the 
methodology to be rectified without wasting any human tissue. 
Radioimmunoassay was used for the detection of TRH 
because it is sensitive enough to measure the pg/mg levels found in 
rat and human CNS tissue. The TRH is well established and has 
been used for such analysis since its development (Jeff coate et. 
al.,1973) and subsequent improvement (Lighton et.al.,1984). The 
antiserum used in the TRH radio-immunoassays was raised in 
sheep in Nottingham (Lighton, 1985) and the RIA using this 
antiserum was sensitive and reproducible (Lighton, 1985) . 
Similarly, HPLC with electrochemical detection (ED) has 
been used to measure catecholeamines and indoleamines for a 
number of years and has a limit of detection of 0.1-10 pmols though 
lower limits can be achieved. 
Principles of HPLC 
Separation of indoleamines by reverse phase column HPLC 
depends on separation of the analytes by partition between the 
hydrophobic stationary phase of the column and the aqueous mobile 
phase. Elution is in the order of increasing hydrophobicity. As 
catecholamines are highly positively charged at the pH range of 
the mobile phase (pH 2-8) they are hydrophilic and eluted rapidly 
and are therefore both inseparable and indistinguishable from the 
solvent front. However, with the addition ofion pair reagents to the 
mobile phase (e.g. sodium octyl sulphate) the hydrophobic side 
chain and negatively charged group selectively retards the elution 
of the catecholeamines enabling their separation. Ion pair 
reagents in the mobile phase make the retention time for 5HT very 
long and so separate systems are described in this chapter for the 
separation of indoleamines and catecholeamines. 
Electrochemical detection of noradrenaline, adrenaline, 
dopamine and 5HT and their metabolites is achieved by oxidation 
at a carbon based electrode. They oxidize at relatively low 
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potentials of 0.25- 0.65V, their ring hydroxyl groups producing 
orthoquinone derivatives and two free electrons which are detected 
by auxilliary and reference electrodes and recorded as an 
amplified current. The use of both glassy carbon and carbon paste 
working electrodes have been recommended (Marsden and 
Joseph,1986). The carbon paste electrode can achieve greater 
sensitivity than the glassy carbon but is more suseptible to surface 
damage and degeneration. Both types were used here to assess 
which was the most appropriate for the detection of neuroamines at 
levels present in the rat spinal cord. 
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Methods 
Sample Preparation 
Male wistar rats between 220-2S0g were killed by 
decapitation after stunning. The spinal column was dissected out 
and the spinal cord removed on a cool tray after cutting away the 
lo.C'ni..no-
dorsal Mm of the vertebrae and the nerve roots (Fig.2.12). The 
first 2.5cm and the last 2cm of the cord were removed as cervical 
and sacral cord and the remainder was separated into thoracic 
and lumbar regions by identifying the enlargement and 
coloration (distinct white spinal roots) of the lumbar region. The 
cord was cut longitudinally in two along .the ventral median 
fissure and then into ventral and dorsal (lumbar cord) or dorso-
intermediolateral (thoracic cord) areas by bisecting the exposed 
gray matter. The tissue was snap frozen in liquid nitrogen and 
stored at -Sooc until extracted later the same day. 
Extraction 
The tissue was sonicated (NSE Soniprep 150) in small tubes 
containing 2 mIs of extraction medium (see l a ~ r r w i t h h the 
indoleamine and catecholamine internal standards added (see 
amine recovery) and placed within a beaker of ice. After 
centrifugation (1000g, 40 c, 15 minutes) the supernatant was 
decanted and divided into aliquots. _.A half ml was taken for ('0" 
indoleamine detection and 0.65 mIs each for substance P and TRH 
analysis. For catecholamine detection tissue was extracted in 0.5 
" . 
mIs of extraction medium and the whole sample was used because 
of the low concentrations in the rat cord. The pellets were assayed 
for protein content with Folin-phenol reagent after alkaline copper 
treatment according to the method of Lowry et. a1., (1951) (See 
Appendix 1). 
The supernatant from the aliquots for indole amine analysis 
was filtered using ACRO LC35 filters from Gelman Sciences and 
injected onto the HPLC column. 
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Fig. 2.12 Dissection of the rat spinal cord from the vertebrae. 
Catecholamines were extracted and concentrated from the 
samples on alumina. A half ml of Tris-HCL pH 8.6 was shaken 
with 0.5ml of supernatant and 20mg of alumina (final pH 8.45) for 
5 minutes. The alumina was washed twice by shaking in double-
distilled water and the catecholamines were eluted in 0.3mI of 
perchloric acid (O.lM PCA) containing 0.02% sodium 
metabisulphite (NaMBS). Samples were cleaned on alumina by 
spinning at 1000g for 2 minutes and filtering (ACRO LC35 filters). 
Standards were stored on ice until injected onto the column. 
Comparisons were made of the % recovery after alumina 
extraction and stability over 7 hours of standards made up in 
perchloric acid (0.1 M) containing sodium metabisuphite (0.2 gil 
i.e. 0.02%) (PCAlNaMBS) and in the selected common extraction 
medium. The latter was composed of absolute ethanol (450 ml), 0.1 
M acetic acid (450 mn made up to one litre with double distilled 
water (DDD) and sodium metabisulphite (0.02%) 
(eth/ AAlN aMBS). 
After extraction, samples for peptide analysis were dried 
down in a Buchler vortex evaporator at 700 c and stored at -20oc for 
RIA. 
Extraction Media 
Comparisons of the levels and % recoveries of TRH, 
substance P, 5HT and 5HIAA in rat tissue using different 
extraction media were made. The media compared were: 
(1) 90% methanol. 
(2) 50% ethanol I 50% 0.1 M acetic acid. 
(3) 0.1 M PCA with NaMBS (0.02%) (PCA I NaMBS). 
(4) Methanol (450 ml) 10.1 M acetic acid (450 ml) with 
NaMBS (0.02%) made up to 1 litre with DDD (meth I AAlNaMBS). 
(5) Ethanol (450 mI) I 0.1 M acetic acid (450 ml) with 
NaMBS (0.02%) made up to 1 litre with DDD (ethlAAINaMBS). 
(6) 90% methanol containing 0.1 M PCA (methIPCA). 
Media 1,2 and 3 are the media used previously for the extraction of 
TRH (Lighton et. al.,1984) substance P and indoleamines 
respectively (Bennett et.al., 1986). The other 3 are variations of the 
former. 
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Indoleamine and catecholamine determinations 
An ACS 110 pump delivered mobile phase at a constant flow 
rate of 1.0 mlImin to a reverse phase column packed with 5 ~ m m
Spherisorb ODS 2. Electrochemical detection was performed using 
a BAS amperometric detector with a working electrode maintained 
at a positive potential ofO.65V versus a Ag/AgCI electrode. At this 
potential the indoleamines and catecholamines to be measured are 
all oxidized. The detector was set at 1 nA full scale and the output 
from the detector was recorded on both a pen recorder and a 
Spectra-Physics 4290 programmable integrator. 
Mobile phase was made up with HPLC grade solvents and 
DDD. After filtering through 0 . 4 5 ~ m m filters (Millipore), mobile 
phase was degassed in a sonic water bath for 20 minutes prior to 
use. Increasing the methanol content of the mobile phase reduces 
the retention time of all analytes, whereas decreasing pH and 
increasing ion-pair reagent concentration suppresses their 
ionization and so selectively increases their retention time. 
According to these parameters methanol content, pH and ion pair 
reagent content where appropriate were adjusted until the optimal 
amine separation was attained. 
5HT, 5HIAA and an internal standard 5-hydroxy-N-
methyl oxalate (5HNMO) were separated in a mobile phase ofO.1M 
sodium acetate, 0.1 M citric acid, 10% methanol, pH 4.6 and 
detected using a carbon paste working electrode. 
Noradrenaline, adrenaline, DOPAC, dopamine and the 
internal standard dihydroxybenzoic acid (DHBA) were separated 
and detected on a reverse phase ion pair column using a glassy 
carbon working electrode and a mobile phase of 0.1 M sodium 
dihydrogen orthophosphate, 1mM EDTA, 1.6 mM 1-
octanesulphonic acid sodium salt (ion pair reagent), 9% methanol, 
pH 3. 
Standards and Calculations 
Standards of 10-7 M catecholamines and indoleamines 
were prepared in the same medium as tissue samples were 
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extracted, from stock solutions stored at 10-3 M. Twenty III (2 pmol) 
were injected onto the column before and after the samples (20 III of 
each sample). The amine and metabolite levels in the samples 
were calculated by comparing the heights and areas of the peaks in 
the samples with the heights and areas of the peaks in the standard. 
The levels were related to the protein content of the sample and 
expressed as pg/mg protein. 
Calibration 
Standards of indoleamines and catecholamines at a series 
of known concentrations between 2xlO-8 and 5x10-7 M were 
injected onto the systems to determine the linearity of the detector 
response. 
Amine Recovery 
An internal standard was used to determine the % loss of 
amines caused by the extraction process. For the indoleamines 
and catecholamines 5HNMO (2 pmols) and DHBA (4 pmols) 
respectively were added to the tissue samples before extraction. 
The internal standard in the sample was compared to a fresh 
standard and the ratio used to determine % recovery. The recovery 
of 5HT and 5HIAA was assumed to be the same as that of 5HNMO. 
A cocktail of catecholamine standards including the 
internal standard DHBA was injected on to the column before and 
after extraction on alumina. The % recoveries of noradrenaline, 
adrenaline, DOPAC, DHBA and dopamine were determined and 
the ratio of each % recovery to that of DHBA calculated. In each 
subsequent experiment DHBA was added to both the tissue samples 
and the standard allowing the determination of the % recovery of 
DHBA and of the catecholamines using the above ratios. 
A separate study was made of % recovery of catecholamines 
after extraction from rat spinal cord without concentration on 
alumina. The spinal cord was bilaterally dissected and synthetic 
noradrenaline, adrenaline, DOPAC and dopamine was added at 
approximately twice the endogenous level to one half (200 pmols.). 
The tissue was extracted in PCAIN aMBS and processed as above 
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but the extracted sample was not concentrated on alumina. 
Catecholamine levels were determined and the endogenous level 
subtracted from the levels in the paired spiked sample. Percentage 
recovery of the added catecholamines was calculated from the ratio 
of determined level to the known amount added. 
Effect of storage at -800c 
One half of each extract of the rat spinal cord spiked with 
catecholamines as described above was stored at -BOOc with a 
cocktail of catecholamine standards at IO-7M.Fresh samples 
were analysed by HPLC on the same day that they were extracted 
whereas frozen samples were analysed after storage at -800c for 48 
hours. The levels of noradrenaline, adrenaline, nop AC and 
dopamine were determined as pmols/J,J.l in the paired fresh and 
frozen extracts by comparison with fresh and frozen standards 
respectively. 
Peptide determinations 
Diluting and pipetting procedures for RIA were performed 
using the programmable Microlab 1000 (Hamilton). 
TRH was measured by a modification (Lighton et.al.,1984) 
of the radioimmunoassay method of Jeffcoate et.a!., (1973). 
Standards were produced by serial dilution of synthetic TRH (0-10 
ng/ml). All dilutions were made in RIA buffer of 0.04 M phosphate 
buffered saline containing 0.1% bovine serum albumin (BSA). 
Standards (50 ~ ) ) and samples resuspended in 0.5-1.0 m1 of RIA 
buffer (50 JlI) were incubated with diluted TRH antiserum (50 J.1l) 
and diluted tracer, 125I-TRH ( 5 0 ~ ) ) in quadruplicate. Tubes 
containing tracer only (50 Jll) and tracer (50 ~ ) ) and buffer (100 Jll) 
only were used to determine total and non-specific binding 
respectively. 
All tubes were incubated overnight at 40c after which time 
tracer bound to antiserum was separated from free tracer by 
precipitation in 0.75 ml. ice-cold ethanol and centrifugation (40c, 
1000g, 15 minutes). The supernatant was discarded and the bound 
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tracer content of the pellet determined by counting radio-activity 
on an LKB gamma counter. 
Radio-labelling of TRH 
TRH was iodinated with 1251 using the Chloramine T 
method ofBassiri and Utiger (1972). To 11lg of synthetic TRH 15 III 
ofO.4M phosphate buffer pH 7.4 and 1 mCi sodium 125iodide (10 jJ.l) 
were added. The addition of 10 JlI of chloramine T (2.5 mg/mn 
initiated the oxidation of sodium 125iodide to 1251 which was 
stopped after exactly 30 seconds by the addition of250 jJ.l ofNaMBS 
(2mg/ml). Surplus iodine in the mixture was diluted with 100 JlI of 
potassium iodide (10 mg/ml). 
A sephadex G10 column (10 cm) in a 10 ml glass pipette was 
prepared and prewashed prior to the iodination with 5 m1 each of 
0.04 M phosphate buffer, 0.04 M phosphate buffered saline 
containing 1% BSA and 0.04 M phosphate buffered saline 
containing 0.1% BSA. The iodination mixture was placed on the 
column to separate iodinated TRH and 1251. The latter buffer was 
placed in a reservoir above the column, allowed to flow through at a 
rate of 0.5 mllminute and collected in 1 minute intervals for 20 
minutes. The radio-active elution profile was determined by 
counting the fractions in a well gamma counter (Mini 
Instruments type 6-20) for 10 seconds. Fractions occurring on the 
shoulder of the first radio-active peak were tested for their ability to 
bind TRH antiserum and to be displaced by synthetic TRH in the 
TRH RIA. These were stored at -20oc in aliquots for use in RIA. 
Iodinated TRH was diluted prior to use such that 50 J1.l produced 
approximately 10,000 counts per minute. 
The TRH antiserum was raised in sheep using a peptide 
conjugate prepared by the method of Bassiri and Utiger (1972) in 
which TRH is coupled to bovine thyroglobulin using diazotized 
benzidine. The TRH conjugate was emulsified in the general 
immuno-potentiator complete Freund's Adjuvant and ewes 
received the conjugate (300 J,1g/animal) in one intramuscular and 
multiple subcutaneous injections. Subsequently booster 
immunizations were administered subcutaneously at monthly 
intervals and after 6 months the antibody titre of the ewes was 
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tested at weekly intervals. The resultant antiserum had a high 
titre, was used at a 1 in 20,000 dilution and in cross-reactivity 
studies was found to be specific for TRH, cross-reacting only with 
peptides containing both the C and N terminal residues of synthetic 
TRH. The sensitivity of the TRH radioimmunoassay was 
28fmolsltube and the intra-assay and inter-assay coefficients of 
variation were 2.1% and 12% respectively. (Lighton et.al.,1985). 
Substance P 
Substance P was measured using a modification (Gilbert 
et.al.,1982) of the method of Powell and co-workers (Powell et.al., 
1973). Standard displacement curves were produced as described 
on page 49 using a final dilution of 1 in 4000 of substance P 
antiserum 304G. Samples were resuspended in 0.5-2.0 mlof 
substance P RIA buffer (page 49) and 100 III were added to 50 Jll of 
diluted antiserum and 50 III of [125I]-tyr-8-substance P. Tubes 
containing tracer only (50 Jll) and tracer (50 Ill) and buffer (150 Ill) 
only were used to determine total and non-specific binding 
respectively. Samples and standards were incubated overnight 
and then antiserum bound tracer was separated from free tracer 
and measured as described (page 49). 
The substance P antiserum (304G) was shown to have less 
than 0.5% cross-reactivity with both C and N terminal fragments 
of substance P and with certain tachykinins as described in detail 
in the first part of this chapter (pp. 55-56). Assay sensitivity and 
reproducibility are given on page 56. 
Radio-labelling of substance P: see page 47 
Calculations 
The substance P-LI or TRH like immunoreactivity (TRH-
LI) in the samples was determined by interpolation of their 
respective standard displacement curves. Levels were expressed 
as pmol/mg protein. 
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Peptide recovery 
The percentage of the total peptide detectable after the 
extraction process and RIA was determined for TRH and 
substance P in rat spinal cord using exogenous peptide. 
The spinal cord was biiaterally dissected and synthetic 
peptide was added at approximately 10 fold the estimated 
endogenous levels to one half of the tissue samples ~ - 2 ( } n g ) . .
Tissue was processed and assayed as above. Peptide levels were 
determined and the endogenous l e v ~ l s s subtracted from the levels 
(in the paired spiked sample. Percentage recovery of added peptide 
was calculated from the ratio of the determined level to the known 
a ~ o u n t t added. Percentage recovery determined in this way was 
assumed to be that of peptide recovery in subsequent peptide 
measurements in both rat and human (chapter 3) tissues . 
. '.
Statistics 
Data were analysed using the Student t-test for paired or 
unpaired data as appropriate. 
Chemicals 
5HT, 5HIAA, 5HNMO, noradrenaline, adrenaline, 
DOPAC, DHBA and dopamine, were purchased from Sigma. 
Substance P and TRH were obtained from Peninsula Laboratories 
Europe Ltd. The radio-labelled peptides were produced using 1251 
obtained from Amersham International. 
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Results 
HPLC with ED 
The lower limit of detection for 5HT and 5HIAA was 0.4 
pmols/injection (signal: noise ratio, 3: 1). The detector response to 
5HT and 5HIAA was linear over the range 0-10 pmol. The lower 
limit of detection for noradrenaline, adrenaline, DOPAC, DHBA 
and dopamine was 0.09, 0.1, 0.12, 0.14 and 0.15 pmol respectively. 
The detector response to noradrenaline, dopamine and DOPAC 
was linear over the range 0-10 pmol. The HPLC separation of 5HT 
and 5HIAA and of noradrenaline, adrenaline, DOPAC, DHBA 
and dopamine is shown in Figs.2.13 and 2.14. 
Approximately 4 fold lower limits of detection could be 
obtained using the carbon paste rather than glassy carbon electrode 
enabling measurement of 0.1 pmol/injection of indoleamines. 
This level of sensitivity required careful and patient polishing of 
the electrode to achieve and was not easy to maintain. Detection 
levels given above are those routinely attained. 
TRH Radio-immunoassay 
After iodination ofTRH the separation of 125I-TRH from 
1251 produced a radio-activity profile with two peaks (Fig.2.15). 
The fractions from the trailing shoulder of the first peak, fractions 
6,7 and 8 were found to have the greatest binding coefficient, 15-
25%, and competed with synthetic TRH for antiserum binding. 
Displacement of the label was at least 65% as illustrated in 
Fig.2.16. The fractions were stored in aliquots at -20oc. 
Development of a common extractant 
A. 90% methanol I 0.1 M PCA 
An attempt to extract peptides from rat spinal cord in 90% 
methanol/0.1M PCA failed as the PCA did not evaporate and was 
oxidized to a concentrated brown liquid in the vortex evaporator. 
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sodium metabisulphite (0.02%), B) ethanol plus acetic acid (O.lM) 
plus sodium metabisulphite (0.02%). Two pmols of each standard 
were injected onto the column with the following mobile phase: 
0.1M sodium acetate, 0.1M citric acid, 10% mehtanol, pH 4.6 using 
Sperisorb 5 ODS column ( 5 ~ ) ) and the detector potential set at 
+0.65V. 
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This figure shows a displacement curve from a typical TRH RIA. 
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determined from the mean of four replicates. [1251] TRH was 
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A typical separation of A) a standard ~ ~ of NA, ADR, 
DOP AC, DHBA (internal standard) and DA; B) a sample of whole 
rat thoracic cord. The catecholamines were extracted using 
ethanol plus acetic acid (0.1M) and sodium metabisulphite (0.02%) 
followed by a l ~ a a extraction as descn"bed in the text. The 
separation was obtained on a Spherisorb 5 ODS 2 column using the 
following mobile phase: 0.1M sodium. dihydrogen orthophosphate, 
lm.M EDTA, 1.6mM IPR, 9% methanol, pH 3.0. The glassy carbon 
electrode was held at +O.65V. 
NA=noradrenaline; ADR=adrenaline;DA=dopamine 
B. Methanol or ethanol/acetic acid / NaMBS 
A composition of methanol or ethanol with acetic acid and 
NaMBS was shown to be suitable for indole amine extraction but it 
produced wider peaks on the amine HPLC chromatogram than 
PCNNaMBS (Fig.2.13). When ethanol was substituted for 
methanol it was found that there was no significant difference 
between the levels of 5HT or 5HIAA extracted from rat tissue using 
either methanol or ethanol (Fig.2.17). However the variation in 
the measured levels, determined as the coefficient of variation 
(standard error/mean), was marginally less using ethanol in the 
extraction medium (Fig.2.17). In subsequent studies the recovery 
and tissue levels of the amine and peptides using the common 
ethanol/acetic acid INaMBS extraction medium was compared 
with the previously established individual media (Figs.2.18, 2.19 
and 2.20). 
C. Indoleamines 
The medium of ethlAAlNaMBS was compared with 
PCAlNaMBS for stability of indoleamine standards, 
chromatography and indoleamine, including internal standard 
(5-HNMO) extraction from rat tissue samples. The area of the 
peaks on the chromatograms were not significantly different 
though the peaks of standards prepared in eth! AAIN aMBS were 
slightly lower and wider. The variability in peak area of 
standards (measured over seven hours) was low (Fig.2.18). There 
was no difference in the recovery of the internal standard or the 
5HT levels measured in rat spinal cord but 5HlAA levels 
measured were significantly higher in spinal cord samples using 
ethlAAlNaMBS (Fig.2.18). 
D. TRH 
Comparison of TRH extraction in eth! AAIN aMBS and the 
medium generally used, 90% methanol, indicates that there is no 
significant difference in % recovery or TRH levels measured but 
81 
-c: 100 
0> 
...... 
a 
~ ~
0- 80 
0> 
E 
-en 60 (5 
E 
a. 
---en 40 
Q) 
> 
0> 
0> 20 
::l 
en 
en 
i= 0 
5HT 5HIAA 
Fig.2.17 
Comparison of the levels of 5HT and 5HIAA in rat lumbar spinal 
cord measured using two extractants; a mixture of ethanol D or 
methanol 0 with acteic acid and sodium metabisulphite. See text 
for exact composition. There was no significant difference 
between compared results. n=5 in each case. 
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(A) Comparison of peak areas of standards (2 pmols) , (B) % recovery of the internal standard 5-hydroxy-N-methyl 
oxalate (5HNMO) and (C) rat thoracic cord levels of 5HT and 5HIAA extracted in either 0.1 M perchloric acid plus 
sodium metabisulphite (0.02%) 0 or ethanol plus 0.1 M acetic acid and 0.02% sodium metabisulphite [ill. Figures in 
brackets refer to number of determinations or animals. *p<O.05. 
TRH levels and % recovery tended to be slightly greater (Fig.2.19) 
using ethJAAINaMBS extraction medium. 
E. Substance P 
Comparison of substance P extraction in ethJAAINaMBS 
and the medium generally used(50% ethanolJ50% O.lM acetic acid) 
indicates no significant difference in % recovery or substance P 
levels measured (Fig.2.20). 
F. Catecholamines 
(i) Alumina Extraction 
In the present study catecholamines were measured in rat 
spinal cord tissue after concentration on alumina following their 
initial extraction using ethJAAlNaMBS. Alumina treatment 
produced a much clearer chromatogram with less baseline 
interference and removal of peaks other than those of the 
catecholamines being measured. Catecholamine extraction on 
alumina was compared using standards made up in either 
ethJAAlNaMBS or PCAlNaMBS (Table 2.1B&C). In each case % 
recovery was greatest when standards were made up in 
PCAINaMBS (p<O.05, n=5), though there was no significant 
difference for DOPAC standards (Table 2.1B&C). However, 
consistent recovery of between 53 and 62% were attained for all the 
catecholamines and DHBA when the standards were made up in 
ethlAA/NaMBS and eluted off alumina with PCAINaMBS (Table 
2.1C). Catecholamines extracted in the common media and 
injected onto the column in PCAlNaMBS produced better 
chromatograms than using ethlAAlNaMBS to elute the 
catecholamines off the alumina (Fig.2.21). 
There was no significant difference (p<O.05; n = 5) in 
percentage recovery of catecholamine standards made up in 
ethl AAIN aMBS whether the standards were eluted off alumina 
(into PCAlNaMBS) immediately after alumina extraction or 
retained on the alumina and eluted just prior to injection onto the 
HPLC system (Table 2.1C&D). 
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Fig.2.19 
(A) Levels of TRH measured in rat thoracic dorso-
intermediolateral (T.D-I) and ventral (T.V) cord using two 
different extraction media; 90% methanol 0 and ethanol, O.IM 
acetic acid and. 0.02% sodium metabisulphite I2J n=12 in each 
case. (B) Comparison of the recovery of exogenous TRH added to 
bilaterally paired pieces of rat whole thoracic cord. n=5 in each 
case. There were no significant differences in any of the 
comparisons made. 
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Fig.2.20 
(A) Levels of substance P measured in rat thoracic 
dorsointermediolateral (T.D-D and ventral (T.Y) cord using two 
different extraction media; ethanol, 0.1M acetic acid 0 and 
ethanol, 0.1M acetic acid and 0.02% sodium metabisulphite '0'. 
n= 11 in each case. (B) Comparison of the recovery of exogenous 
substance P added to bilaterally paired pieces of rat thoracic dorso-
intermediolateral and ventral cord, n=12 in each case. There 
were no significant differences in any of the comparisons made. 
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Chromatograms of standard mixtures of NA (1), ADR (2), DOPAC 
(3), DHBA (4), and DA (5) eluted off alumina into two different 
extraction media: A) perchloric acid (0.1 M) plus sodium 
metabisulphite (0.02%), B) ethanol plus acetic acid (0.1 M) plus 
sodium metabisulphite (0.02%). Two pmols of each standard was 
injected onto a spherisorb 5 ODS 2 column using the following 
mobile phase: 0.1 M sodium dihydrogen orthophosphate, 1 mM 
EDTA, 1.6 roM IPR, 9% methanol, pH 3.0. The glassy carbon 
electrode was held at 0.65 V. 
Table 2.1 Catecholamine extraction 
Comparison of % recovery of catecholamines from rat spinal cord sample spiked with catecholamine standards 
(lOOpmols) without alumina extraction (A) and standards made up in either PCAJNaMBS (B) or ethJAAINaMBS (C&D) 
with elution in PCAlNaMBS. Catecholamines were eluted off alumina immediately after extraction (B&C) or stored on 
alumina and eluted just prior to HPLC analysis (D). n=5 in each case 
NA 
ADR 
DOPAC 
DHBA 
DA 
A. PCAlNaMBS 
No extraction 
76.7±6.1 
75.6±6.9 
91.9:!:4.B 
B4.5!5.7 
% Recovery 
B. PCAIN aMBS 
Alumina extraction 
74.3:t4.2 
7 4 . ~ 3 . B B
5 B . ~ 1 . 7 7
7 4 . ~ 4 . 3 3
80.5!5.2 
C. ethJAAINaMBS 
Alumina extraction 
6 2 . ~ 3 . 6 6
58.1:t3.6 
56.2!:5.4 
6 0 . ~ 4 . 2 2
53.0!4.6 
D. ethlAA/NaMBS 
stored on a1 umina 
62.9!:6.1 
5 8 . ~ 3 . 7 7
5 8 . ~ 4 . 2 2 . 
62.3!3.6 
54.2i'4.2 
Percentage recovery of catecholamines measured in rat 
tissue spiked with synthetic catecholamines and extracted without 
alumina extraction was not significantly different from recovery 
after alumina extraction (Table 2.1A&B) except in the case of 
DOPAC recovery which was significantly reduced after alumina 
extraction (p<O.Ol, n=5). 
(ii) Effect of frozen storage 
There was no significant difference (p<O.05, n = 5) between 
the levels of noradrenaline, adrenaline, DOPAC and dopamine 
measured in extracted tissue samples spiked with catecholamines 
(lO-7M) and either analysed on the same day or stored at -800 c for 
48 hours before analysis (Fig.2.22). Catecholamine levels were 
determined by comparison with standards (2 pmolslinjection) 
either made fresh or stored frozen with the samples as appropriate. 
Peak areas of frozen standards were 5-8% less than those of the 
fresh standards. 
Rat spinal cord 
Using eth/ AAIN aMBS the levels and % recoveries of 
substance P, TRH, 5HT, 5HlAA, noradrenaline and dopamine 
were measured in rat thoracic and lumbar spinal cord and the 
results are given in Tables 2.2 and 2.3. 
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NA ADR DOPAC DA 
Effect of freezing on catecholamine levels 
Catecholamine levels measured in the rat spinal cord after 
spiking the tissue with exogenous catecholamine standards 
(lOOnM). There were no significant differences in levels 
determined by HPLC immediately D or after storing the samples 
at -80oc for 48 hours 121 1 n=5 in each case. 
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Fig 2.23 Levels of 5HT and SHIAA in rat spinal cord 
measured using sanification or homogenisation of the 
tissue. 
Levels of 5HT and 5HIAA in the rat lumbar spinal cord were 
determined by :HPLC after sanification 0 or homogenisation I2l 
of the tissue in the common extractant. There were no significant 
differences in the levels measured usiQ,g these methods. n=6 for 
each value. 
Table 2.2 Levels of substance P and TRH in the rat spinal cord measured using an extraction medium of 
ethanol! 0.1 M acetic acid/ sodium metabisulphite. 
Levels are expressed in pmolslmg protein and are corrected for recovery at the values of % recovery given. Values are 
the mean ± SEM, n values are given in brackets. 
Region TRH Substance P 
Thoracic ventral 10.86 ± 1.84 (12) 0.9±0.24 (11) 
Thoracic dorso-
intermediolateral 8.47± 1.5 (12) 3.65 ± 0.51 (12) 
Lumbar ventral 13.7±0.75 (6) 1.12 ± 0.09 (12) 
Lumbar dorsal 8.85±0.89 (6) 3.41 ± 0.22 (11) 
% Recovery 45.2 58.7 
Table 2.3 Levels of indoleamines and catecholamines in the rat spinal cord measured using an extraction 
medium of ethanol/ 0.1 M acetic acid/ sodium metabisulphite 
Levels are expressed in pmols/mg protein and are corrected for recovery at the values of % recovery given. Values are 
the mean ± SEM, n=6 for indoleamine results and 5 for catecholamine results. 
Region 5HT 5HIAA NA DA 
Thoracic 22.3 ±2.12 16.1 ± 1.15 25.9±0.7 4.36 ±0.34 
Lumbar 93.2 ±'3.9 40.2± 1.5 18.1± 1.5 2.58±0.49 
% Recovery 101.9 58.0 50.0 
Discussion 
Consideration of the methods 
The HPLC systems were sensitive enough to detect 5HT, 
5HIAA, noradrenaline and dopamine in rat spinal cord the levels 
of which fell within the range over which electro-chemical 
detection was linearly related to amine concentration. Greatest 
sensitivity was attained using the carbon paste rather than glassy 
carbon electrode. However great care was needed when polishing 
the carbon paste electrode as any irregularities in the surface 
resulted in high baseline noise. In addition the electrode surface 
was easily damaged by variations in pump pressure and the 
passage of air bubbles across it when either remounting the 
electrode or making changes to the column or mobile phase. The 
glassy carbon electrode retained its sensitivity for longer (several 
weeks) and would therefore be the one to use wherever detection 
limits of O.lpmol or less are indicated. 
Similarly the limits of detection of, and the peptide 
concentration range covered by, the radioimmunoassays for 
substance P and TRH enabled the measurement of these peptides 
in the rat spinal cord. The TRH and substance P antisera were 
specific for TRH and substance P respectively with low cross-
reactivity with other peptides and the assays were reproducible as 
illustrated by the small inter-assay and intra-assay variability. 
The levels of the amines and peptides in the spinal cord were 
determined after sonication of the samples in extractant. The 
spinal cord is more difficult to degrade than brain tissue, possibly 
because of the spinal meningues. Sonification of the spinal cord 
takes some time (up to 5 minutes) and the sample must be kept cool 
to avoid breakdown of the amines and peptides. Degradation of the 
tissue using an homogenizer (Ultra-turax) proved to be quicker 
though the tissue indoleamine levels and % recoveries measured 
in rat cord using homogenization or after sonification of samples 
kept on ice were not significantly different (Fig.2.23). It was 
decided that sonification would be employed as the methods were 
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developed for future use with human tissue. Due to the potential 
biohazard associated with working with human tissue only 
equipment that could be cleaned and decontaminated could be used 
and this was easier with the probe of the sonicator than the 
grinding parts of the homogenizer. 
The levels of catecholamines in extracts of rat tissue 
analysed immediately were not significantly different to those 
analysed after storing the samples at -BOoc when compared with 
standards treated in the same way. Although the peak areas of the 
frozen standards were 5-S% less than those of the fresh standards 
this may have been a result of changes in the sensitivity of the 
HPLC system rather than an indication of the effect of freezing. 
Frozen samples could have been analysed with freshly extracted 
samples to avoid HPLC sensitivity changes but this would prevent 
the use of paired samples. A fresh standard should have been run 
with the frozen standards though a small variation in standards 
made on different days could also be expected. In the light of the 
results it was assumed that catecholamines in extracted samples 
were stable when stored at -Sooc. 
Properties required of a common extractant 
The extraction media selected for testing in the development 
of a common extractant for substance P, TRH, indoleamines and 
catecholamines were combinations of media generally used in our 
laboratory for the analysis of various compounds. The original 
media have been used to measure peptides, indoleamines and 
catecholamines for a number of years but a common medium for 
the extraction of peptides and amines would be a great advantage. 
A common medium has to incorporate several factors. Firstly a 
large part of the mixture must be an organic solvent such as 
ethanol or methanol which will evaporate completely in the vortex 
evaporator and thereby enable sample concentration. Secondly it 
must include an acid to facilitate protein precipitation which must 
also evaporate. Thirdly NaMBS must be present to protect the 
labile amines from oxidation. Fourthly, the common media 
should not compromise the HPLC chromatography and the 
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reproducibility of the determinations should be preserved. 
Finally, using the selected common medium peptide and amine 
levels and recoveries should not be very different from those 
obtained using each of the original media. 
PCA, originally used for amine extraction was not volatile 
but acetic acid was found to be particularly suitable as the volatile 
acid component. Using methanol or ethanol in combination with 
acetic acid and NaMBS produced little difference in levels 
measured CFig.2.17) or the chromatography of 5HT and SHlAA. 
Ethanol was chosen for further evaluation as the organic solvent of 
a common extractant because it produced marginally better 
reproducibility of results. 
Compari ng the common extractant and other extractants 
The ability of the indoleamines and catecholamines to be 
easily oxidized, the very property which enables their electro- . ~ ~ a P . d ~ ~
chemical detection, means that they are susceptible to metehelifilBl 
The variation in peak area of standards injected repeatedly over 
several hours during analysis of tissue amine levels was therefore 
determined as an indication of their stability. 
Although the indole amine standards prepared in 
ethlANNaMBS produced slightly smaller and wider peaks on the 
chromatogram than those in PCNNaMBS (Fig.2.13) there was no 
significant difference in peak area. The variability in peak area 
was also low indicating that the stability of the standards in 
ethlANNaMBS was at least as good as in PCNNaMBS (Fig 2.18) 
and that the indoleamines were protected from air oxidation. 
While there was no significant difference in % recovery of the 
internal standard which was approximately 100% using the two 
extractants, the levels of 5HT and 5HIAA measured in spinal cord 
were the same (5HT) or greater (5HlAA) using ethlAA/NaMBS 
demonstrating an advantage over PCAlNaMBS which may cause 
some oxidation of 5HIAA. 
Using ethlAA/NaMBS, catecholamines extracted from rat 
tissue, concentrated on alumina and eluted in PCAlNaMBS 
produce clear sharp chromatography (Fig.2.14) with % recoveries 
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of between 53 and 62% (Table 2.1C). These values were 
reproducible which is more important than obtaining high % 
recovery. Variation in peak area of catecholamine standards over 
time was also low indicating that they were protected from 
oxidation. 
Substance P and TRH levels and recoveries were not 
significantly different when extracted in ethJAAINaMBS 
compared with the original media though both levels and % 
recoveries were generally slightly greater using ethJAAINaMBS 
for both substance P and TRH extraction. It is possible that peptides 
are metabolised after tissue extraction by membrane bound 
peptidase enzymes and the common extractant may provide 
greater protection against metabolism than more generally used 
media. This extractant has also been used to measure other 
peptides including calcitonin gene related peptide levels in the rat 
spinal cord (Fone et.al., 1988b) and it is reasonable to assume that 
it is appropriate for the extraction of other neuropeptides from tissue 
samples. 
Alumina extraction cleans up the sample and removes 
everything but the catecholamines. It also allows concentration of 
the sample which means that the HPLC system can be used at a 
lower sensitivity which is easier to maintain. There is up to 25% 
loss of catecholamines during extraction from tissue samples 
(Table 2.1A) and being able to concentrate the sample compensated 
for this loss. The degree of loss was always determined using the 
internal standard DHBA. Either storing the catecholamines on 
alumina or eluting them immediately into PCAlNaMBS did not 
affect the % recovery which meant that batches of samples could be 
extracted together, stored on ice and eluted into PCAlNaMBS when 
convenient between injecting samples onto the HPLC system. 
These results suggest that, in combination with alumina 
extraction of catecholamines, ethlAAlNaMBS can be used as a 
common medium for the extraction of the catecholamines, 
indoleamines and certain neuropeptides. 
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Amine and peptide levels in the rat spinal cord 
Comparison of absolute levels reported in this paper with 
previous studies for catecholamines, indoleamines and 
neuropeptides in rat spinal cord is difficult because there is a great 
deal of variation in methods used in the regional dissection of cord 
and in the method of expressing the results (Marsden et. al.,1982; 
Di Guilio et.al., 1985). Preliminary studies have shown that when 
measuring peptides in the human spinal cord significantly higher 
levels were obtained when cores of tissue were taken from the gray 
matter than when white matter was included (Bennett et.al., 1986). 
However, 5HT levels reported here (Table 2.3) in lumbar cord are 
similar to those reported in lumbar ventral cord (Lighton et.al., 
1984). TRH levels in lumbar and dorsal cord (Table 2.2) are 
approximately twice those reported by Lighton et.al., (1985) but the 
relative distribution between dorsal and ventral cord is similar in 
that thoracic and lumbar TRH levels are approximately 1.5x that 
of the dorso-intermediolateral or dorsal regions respectively 
(Table 2.2). The regional distribution of substance P is also 
similar to that previously reported (Helke et. al., 1982; Marsden 
et.al.,1982) in that substance P dorsal levels invariably exceed 
ventral levels in both lumbar and thoracic cord by 3-4 times. 
The levels of catecholamines in rat lumbar cord shown in 
Table 2.3 are similar to those reported by Mouchet et.al.; (1982) and 
of the same order of magnitude as reported by Commissiong and 
Neff (1979) and Fleetwood-Walker and Coote (1981) with 
noradrenaline levels approximately 7 fold greater than those of 
dopamine. 
As discussed in part 1 (pp. 43-44), care must be exercised in 
comparing levels of peptides measured in different studies using 
RIA methods. The values obtained are of peptide-like 
immunoreactivity and how closely this reflects the actual level of 
the peptide will depend on the specificity of the antiserum being 
used which is not always stated in the literature. 
Another factor which may affect the level of radio-
immunoactivity measured is the quality of the peptides used. 
Using amino acid analysis, mass spectrometry and HPLC, Brown 
and co-workers (1986) analysed a number of commercially 
88 
available peptides. They reported discrepancies between what the 
peptides were and what they were supposed to be in three areas; (1) 
the absolute content could vary as much as 3.6 fold, (2) peptides 
were supplied with incorrect amino acid sequences and (3) in 
samples of [3H] substance P from 5-95% of the radio-activity was 
not associated with authentic substance P. As they suggested, 
researchers can reduce the possibility of these errors by only 
accepting peptides accompanied by amino acid, mass spectrometry 
and HPLC analysis but this information is not always available 
when comparing published data. 
As determined from the recovery of 5HNMO, the recovery of 
the indoleamines was approaching 100% whereas that of the 
catecholamines and peptides was nearer 50%. The common 
extractant obviously offered a higher degree of protection from 
metabolism for the indoleamines but catecholamine and peptide 
loss occurred in the process of extraction from tissue samples. The 
peptide recovery determined in this study was that of exogenous 
peptide. Endogenous peptide present in vesicles may be more 
highly protected from peptidase activity than exogenous peptide 
and therefore the % peptide recovery determined using exogenous 
peptide may be lower than that for endogenous peptide. All the 
measured levels given in Tables 2.2 &2.3 have been corrected for 
% recovery and it is important to note when comparing results 
whether this factor has been accounted for by other authors. 
In conclusion, using the medium ethlAA/NaMBS it was 
possible to extract the neuropeptides TRH and substance P , 5HT 
and 5HIAA as well as noradrenaline and dopamine from tissue 
samples. It should also be possible to measure adrenaline and 
DOPAC in the rat spinal cord by eluting the alumina extracts into 
very small volumes and thereby concentrating the samples 
further. Greater sensitivity of the HPLC system can be achieved if 
necessary by using a carbon paste rather than a glassy carbon 
working electrode. This medium maintained the peptides through 
the extraction and RIA procedure, facilitated protein precipitation 
and drying down of the supernatant and protected the amines and 
peptides from breakdown. A common medium for the extraction of 
these substances reduced considerably both the amount of tissue 
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required and the assay time. The method described was as 
effective as the original media in terms of % recovery, although 
there was some loss in chromatographic clarity with respect to peak 
sharpness. In the case of catecholamine extraction this problem 
was overcome by re-elution of the sample from alumina in 
PCAlNaMBS. From the results obtained in the development of both 
a specific substance P RIA and a common extractant for 
indoleamines, catecholamines and peptides it was considered that 
the methods had been satisfactorily validated for future use with 
human spinal cord tissue. 
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Chapter 3 Post-mortem spinal cord levels 
of catecholamines, indoleamines, 
thyrotrophin-releasing hormone and 
substance P in Parkinson's disease 
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Introduction 
In the rat spinal cord two neuropeptides, TRH and substance 
P are reported to co-exist with 5HT in a large proportion of the 
serotonergic neurones that descend from the medullary raphe 
nuclei to the ventral spinal cord (Gilbert et. a1.,1982; Johansson 
et.al.,1981; Helke et.a1., 1986). Similarly noradrenergic and 
dopaminergic neurones descend from brainstem nuclei to 
innervate the ventral and dorsal horns of the spinal cord (Mouchet 
et.al., 1982; Westlund et.al., 1983; Nakazato, 1987; Takada et.al., 
1988). Evidence indicating the presence of serotonergic-
peptidergic, noradrenergic and dopaminergic descending 
pathways in animals and their role in motor control is discussed 
fully in the General Introduction. Recent studies have shown that 
the distribution of 5HT, TRH and substance P in human spinal 
cord is similar to that in rat (Przewlocki et.a1., 1983; Bennett et aI., 
1986). Furthermore, a possible role for the descending aminergic 
neurones in motor control in the human is indicated since in a 
previous report (Scatton et.a1., 1986) the levels of NA and 5HT in 
post-mortem Parkinsonian lumbar spinal cord were lower than 
the levels obtained in control subjects and the most marked 
symptoms seen in patients with Parkinson's disease include loss 
of motor control and co-ordination (Parkinson, 1817). 
In the present study catecholamines, 5HT and its metabolite 
5HIAA and the neuropeptides TRH and substance P were 
measured in both thoracic as well as lumbar ventral and dorsal 
horn tissue of spinal cord obtain from patients who had died with 
Parkinson's disease or from non-neurological control subjects. 
These studies were undertaken to extend the previous analysis of 
amine levels in Parkinsonian spinal cord and to determine 
whether the neuropeptides, reported to co-exist in animal 
descending bulbospinal neurones, are also altered in Parkinson's 
disease. The levels of catecholamines, indoleamines, substance P 
and TRH measured in the human spinal cord in this study are 
compared with reported levels in the rat and human brain and 
spinal cord. 
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In addition, there are a number of important factors to 
consider when analysing the results of biochemical 
measurements made in post-mortem human tissue. These 
include the effects on the parameters being measured of: the sex of 
the subject; their age at death; the interval between death and 
removal of the tissue for storage (PM!); and ante-mortem drug 
therapy. These factors have been taken into account in this study 
and a rigorous statistical analysis of the effects of age, sex 
and PMI on post-mortem amine and peptide levels has been made. 
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Methods 
Donor details 
Sections of cervical, thoracic and lumbar spinal cord were 
obtained post-mortem from patients with Parkinson's disease and 
from control subjects with no history of neurological or psychiatric 
illness. Informed consent for the post-mortem removal of tissue 
for experimental purposes was obtained from subjects before death 
or from their next-of-kin in all cases. The mean and range of the 
age and interval between death and autopsy for control and 
Parkinsonian patients is shown in Table 3.I. 
The causes of death of the control subjects were heart failure, 
pneumonia, septicaemia and one road traffic accident. Causes 
given for patients having died with Parkinson's disease, apart 
from the condition itself were heart failure, pneumonia, 
pulmonary embolism and post-operatative peritonitus. All 
patients with Parkinson's disease, with one exception, were 
receiving either Sinemet or Madopar (which contain Levodopa in 
conjunction with peripheral dopa-decarboxylase inhibitors) or 
Levodopa itself. Bromocriptine, a dopamine agonist was also 
prescribed to 2 of these patients and to the one patient not on 
Levodopa therapy. The time of the last dose of treatment 
administered varied from 48 to only 6 or 7 hours before death. All 
patients were confirmed post-mortem as having Parkinson's 
disease by determination of dopamine 108s in the striatum and 
cell loss in the substantia nigra. 
Dissection procedures 
Cords, dissected into cervical, thoracic, lumbar and sacral 
segments were obtained frozen on dry ice from the Cambridge 
Brain Bank and the Parkinson's Disease Society Brain Bank 
(Professor C.D. Marsden) and stored at -800C until dissection. 
Other cords were obtained from the mortuary at Nottingham 
University Hospital immediately after they had been removed 
from the body. 
These fresh cords were dissected into cervical, thoracic and 
lumbar segments after removing the dura mater by cutting the 
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Table 3.1 Age, sex and interval between death and 
autopsy (PMI) for control and Parkinsonian patients 
Control Parkinsonian 
Age mean 63.5 75.4 
(years) range 37 -81 61-89 
PM! mean 33.0 35.8 
(hours) range 6-53 9.5 -78 
n total 12 9 
females 6 5 
males 6 4 
cord between the spinal nerves CB and Tl, T12 and Ll and L5 and 
81 with the aid of the diagram shown in Fig. 3.la. The tissue was 
'slow frozen' to prevent it from fragmenting by storing it first at 
-20oc for 3-5 hours before transferring it to a -BOoc freezer for 
storage in sealed plastic bags to prevent dehydration. Tissue was 
stored from 6 months to 2 years. 
The tissue was dissected on a metal surface over a mixture 
of ice and dry ice within a microbiological hood in order to 
maintain a partially frozen condition during dissection. The 
cords were cut into 5mm slices and 2mm diameter punches were 
taken from the gray matter in the dorsal (posterior) and ventral 
(anterior) horn regions of cervical, lumbar and mid-thoracic 
segments using a stainless steel punch as illustrated in Fig.3.1b. 
The method used has been described by Bennett and co-workers 
(1986). 
Tissue Extraction 
The tissue was sonicated (NSE 8oniprobe 150) in 2mls of an 
extractant developed previously for the concomitant extraction of 
catecholamines, 5HT, 5HIAA, substance P and TRH from rat and 
human spinal cord (Chapter 2.part 2). The composition of this 
extractant is ethanol (450 ml), O.IM acetic acid (450 ml) with 
sodium. metabisulphite (0.02%) made up to one litre with deionised 
double distilled water. After centrifugation (1000g, 15 mins, 40 C) 
the supernatant was divided into 500 III aliquots and either stored at 
-BOoc or analysed immediately for the measurement of 
indoleamines and catecholamines by HPLC with electrochemical 
detection and of substance P and TRH by radio-immunoassay 
(R.I.A.). The tissue pellets were retained for protein analysis by 
the method of Lowry et al., (1951, Appendix 1). To determine % 
recovery of the amines, DHBA (2xlO-BM) and 5HNMO (lO-7M) 
were added to tissue samples before sonication as internal 
standards for the catecholamines and 5HT and 5HIAA 
respectively. 
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Fig 3.1 a (above) Identification of spinal roots for dissection of 
spinal cord into cervical, thoracic, lumbar and sacral regions. This diagram, 
taken from Grays ~ a t o m y y (Eds. Longmans, 1967), illustrates cervical (C: 1-8), 
thoracic (T:1-12), lumbar (L:1-5 ) and sacral (8: 1-5) nerve roots. 
Fig 3.1 b (right) Diagram of the areas dissected from the dorsal and 
ventral horns of the grey matter of the spinal cord. The dissection employed a 
2mm diameter steel punch. 
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Measurement of 5HT, 5HIAA and catecholamines. 
HPLC with electrochemical detection was performed as 
described for detection of the levels and % recoveries of 
indoleamines and catecholamines in rat tissue in chapter 2 
(pp. 74-75) with the following modifications: 
1. A l O O ~ 1 1 injection loop was used in the HPLC system. 
2. A glassy carbon electrode was utilised. 
3. After extraction on alumina, samples were resuspended 
in l 5 0 ~ 1 1 ofPCAINaMBS (chapter 2, page 73). 
An attempt was made to measure indoleamines in the 
supernatant from the alwnina extraction of samples. After the 
extract had been shaken with alumina and centrifuged (lOOOg, 
2min.) the supernatant was removed, centrifuged again 
(lOOOg,2min.), filtered (ACRO LC35 filters) and injected onto the 
indole amine HPLC system. 
Percentage recovery of the indole amine internal standard, 
5HNMO, was compared in samples run on the day the extracted 
samples were taken from storage at -800c and in the same samples 
stored overnight at 40 c. 
Measurement of peptides. 
TRH and substance P were measured by R.I.A. as described 
in chapter 2 (pp.76-79). 
Biohazard Procedures 
Samples of frozen spinal cord were transferred to the human 
tissue laboratory on dry ice in a sealed container. Dissection of 
sections of the cord was carried out in a microbiological safety 
hood with the extractor fan on in the human tissue laboratory. 
Dissected tissue was transferred to tubes containing extractant 
and sonicated within the hood. All tubes were capped before 
removal from the safety cabinet for centrifugation. Pipetting of the 
supernatant and all fluid transfers took place within the 
microbiological hood over a plastic tray with a disposable plastic 
insert. Disposable apron, gloves and mask were worn during 
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these procedures. Sterilisation and disposal procedures for the 
equipment and waste are described in Appendix 2. 
During RIA, HPLC and protein determination of the 
samples any process which may have lead to the production of an 
aerosol of the sample, such as centrifugation or vortex mixing was 
carried out in sealed tubes. 
Statistics 
For comparison of tissue levels of amines and neuropeptides 
between Parkinsonian and control or treatment and control 
groups the data were analysed using the Student t-test for unpaired 
samples. 
The data were analysed for evidence of correlations between 
post-mortem tissue levels of the amines and peptides and (i) age of 
subject at death (ii) interval between death and autopsy (PM!) and 
(iii) sex of the subject. Initially, Pearsons correlation coefficient 
was used to investigate the degree oflinear relationship between 
age and PMI and the levels of 5HT, noradrenaline, dopamine, 
substance P and TRH. This analysis was then refined by 
removing potentially biasing data. For example to investigate the 
relationship between noradrenaline levels and age at death, data 
from subjects with extreme values for PMI (less than 8 or more 
than 46 hours) were removed. Data exhibiting evidence of a 
correlation with either PM! or age were analysed by regression 
analysis employing the least squares method with t-values 
indicating the goodness of fit of the data to the line. Points were 
plotted with distinct symbols for female and male subjects to 
highlight any gender related bias. Secondly multivariate 
regression was performed on the data. This test can be used to 
investigate whether a set of values (e.g. noradrenaline levels) is 
dependent to some degree on 2 variable factors (e.g. age and PM!). 
These analyses indicated the positive or negative direction of any 
correlation. Finally analysis of covariance (ANeDV A) was 
performed to compare data from control and Parkinsonian 
subjects considering the effects of PMI, age and sex and to 
determine whether correlations between transmitter levels and the 
above factors were statistically significant. This test can be used 
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to analyse the effect of a treatment when the values are correlated to 
variable factors. It relies on comparison of the slope and intercept 
of the regression lines from 2 or more sets of data to determine 
whether they are from the same population. The contribution of 
each parameter (age, sex, PM! or Parkinson's disease) to the 
variation in concentration of each neuroamine and neuropeptide 
measured was determined as the mean square (MS) where 
MS = SS/d.f 
and SS and d.f are the sum of squares from the regression line and 
the degrees of freedom respectively. Statistical significance for 
the effect of a variable was determined from the F ratio test where 
F=MSpIMSr 
and where: MSp is the mean square of the variance of each 
parameter; MSr is the mean square of the residual variance (the 
variance not accounted for); and F is the F-value. 
Analysis of correlation coefficients, simple and 
multivariate regression were performed on a BBe microcomputer 
using the Unistat statistical package from University Software. 
ANCOVA was performed on the University mainframe VAX 
computer using GLIM from the Numerical Algorithms Group. 
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Results. 
Preliminary studies of the methodology 
The effect of overnight storage at 40c on % recovery of 
indoleamines in extracted samples was determined by measuring 
% recovery of 5HNMO in samples of extracts from cervical tissue. 
Comparisons were made between the results from samples 
analysed on the same day that they were removed from frozen 
storage and from the same samples re-analysed on the following 
day after storage at 40 c. There was no significant difference 
between the values obtained (92.5.±2.7, 94.7±O.9%, n=5; same day 
and following day analysis respectively). 
The levels of 5HT and 5HIAA were compared in extracts of 
thoracic spinal cord and in the first supernatant produced by 
alumina processing of the same extracts. The levels of 5HT 
measured in each case were not significantly different (31.7±5.3, 
28.8+4.6 pmols/mg; extract and supernatant respectively, n=4) 
whereas the level of 5HIAA was significantly lower after alumina 
extraction than in the original sample (36.3±5.72, 23.1±3.2 
pmols/mg; extract and supernatant, n=4, p<O.05). 
Percentage recovery of indoleamines measured using 
5HNMO was 103±3.8% (n=10). 
Indoleamine, catecholamine and peptide levels in human 
spinal cord 
HPLC chromatographs of samples of indoleamines and 
catecholamines extracted from the human spinal cord are 
illustrated in Fig.3.2. 
Substance P levels increased down the cord from cervical 
through thoracic and lumbar cord in the ventral horn compared 
with a similarity in substance P levels in the dorsal horn in 
cervical and thoracic regions (Table 3.2). Levels of TRH and 5HT 
were also lowest in cervical spinal cord with little difference 
between respective thoracic and lumbar levels. In contrast, 
noradrenaline levels were significantly greater (p <0.05) in 
lumbar compared with thoracic spinal cord (Taple 3.2). 
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Fig. 3.2 Typical HPLC chromatograms of i n d o l e a ~ i n e e :and 
catecholamine standards and extracts of human thoracIc spinal cord. 
SHT 
A B 
SHIAA SHT 
5HIAA 
I ~ ~
20 15 10 5 0 
Chromatograms of standard 5HT and 5HIAA, 2 pmols (A) and an extract of 
human thoracic spinal cord (B). Samples and standard were injected onto the 
column with the following mobile phase: 0.1 M sodium acetate, 0.1 M citric acid, 
10% methanol, pH 4.6 using a Spherisorb 5 ODS column (5 jlm) and the detector 
potential set at +0.65 V. The arrow indicates the time of injection. 
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Chromatograms of a standard mixture of 0.4 pmols of NA, ADR, DOPAC DHBA and 
DA (A) and an extract of human thoracic spinal cord (B) injected onto a 
Spherisorb 5 ODS 2 column in a mobile phase of 0.1 M sodium dihydrogen 
orthophosphate., lrnM EDTA, 1.6 mM ion pair reagent, 9% methanol, pH 3. The 
detector potential was held at +0.65 V. The arrow indicates the time of injection. 
NA=noradrenaline; ADR=adrenaline; DA=dopamine' DHBA 's th . t al 
t d d ,Ie In ern san ar 
Table 3.2 Distribution of Substance P, TRH, Indoleamines 
and Catecholamines in the Human Spinal Cord 
The levels of substance P (S.P), thyrotrophin-releasing hormone 
(TRH) , 5-hydroxytryptamine (5HT), 5-hydroxyindole acetic acid 
(5HIAA), noradrenaline (NA), adrenaline (ADR), 
dyhydroxyphenyl acetic acid (DOPAC) and dopamine (DA) 
measured in the post-mortem spinal cord from control subjects. 
Values are mean ± SEM and are expressed as pmols/mg protein, n 
values are given in brackets. 
Segment 
CERVICAL 
Ventral 
Dorsal 
THORACIC 
Ventral 
Dorsal 
LUMBAR 
Ventral 
Dorsal 
THORACIC 
Ventral 
Dorsal 
LUMBAR 
Ventral 
Dorsal 
S.P TRH 5HT 
2.1:!"O.5 (4) 2.5±O.3 (4) 24.8±7.8 (4) 
9.2±1.2 (4) O.9±O.2 (4) I2.B±4.3 (4) 
3.1±O.6 (6) B.1±O.9 (12) 36.0±4.9 (11) 
9.2±2.2 (B) 1.5±0.5 (10) I9.1±3.4 (10) 
I8.3±4.0 (5) 7.5tl.O (5) 30.2±4.6 (5) 
2.5±OA (5) 22A±2.8 (5) 
NA ADR DOPAC 
1.73±.aI O.12±.O5 0.32t·12 
(11) (11) (11) . 
0.70to.14 O.56t.03 0.24±.09 
(11) (11) (9) 
4.78tO.74 O.ll±o.ll 1.54t1.03 
(5) (5) (5) 
4.43±1.05 O.10±o.06 O.2I±o.14 
(5) (5) (5) 
5HIAA 
33.7±3.6 (12) 
21.8±2.4 (12) 
40.5±8.B (5) 
39.I±6.4 (5) 
DA 
O.lltO.OB 
(9) 
0.07±.04 
(B) 
2.l6±1.l2 
(4) 
0.85±0.49 
(4) 
The following comparisons of amine and peptide levels in 
Parkinsonian and control subjects were made using the Student t-
test. 
A. Thoracic Spinal Cord. 
Indoleamines 
In the thoracic spinal cord from control subjects 5HT and 
5HIAA levels were greater in the ventral hom (36.0 and 33.7 
pmols/mg protein respectively) than in the dorsal horn (19.1 and 
21.8 pmols/mg protein respectively) while in the Parkinsonian 
tissue compared with the control cord both 5HT and 5HIAA were 
significantly lower in the ventral horn (approx. 40% less, p<0.05 
in each case, student t-test. See Fig.3.3). In contrast 5HT and 
5HIAA levels in dorsal thoracic cord were not significantly 
different in Parkinsonian compared with control tissues. In 
addition, there was no apparent change in the rate of metabolism of 
5HT in the Parkinsonian ventral cord since the ratio of 5HIAA to 
5HT was similar to that in equivalent control tissue (Table 3.3). 
Peptides. 
The levels of substance P and TRH were between 2 and 10 
fold lower than the 5HT and 5HIAA assayed in the same tissue 
samples. Substance P levels in dorsal cord (9.2 pmols Img protein) 
were three fold greater than in ventral cord (3.1 pmols/mg 
protein). In contrast TRH levels were approximately 4-5 fold 
greater in ventral (8.1 pmolslmg protein) compared with dorsal 
cord (1.5 pmols/mg protein). In thoracic spinal cords from 
Parkinsonian patients the peptide levels were not significantly 
different from those measured in control samples (Fig.3.3). 
Catecholami nes. 
Noradrenaline was the most abundant catecholamine 
present in human spinal cord. The levels of noradrenaline in 
control ventral hom from thoracic spinal cord (1.73 pmols/mg 
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Fig. 3.3 Levels of 5HT, 5HIAA, substance P (SP) and TRH 
measured in control ( D) and Parkinsonian ( eI) human thoracic 
ventral and dorsal spinal cord. 
The n values are respectively, for ventral and dorsal hom spinal 
cord from Parkinsonian subjects ; 7 & 8 (5HT); 7 & 8 (5HIAA); 9 
& 9 (SP); 6 & 8 (TRH). The n values for the control subjects are 
given in Table 3.2. 
p* <0.05. 
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Fig.3.4 . Levels of noradrenaline (NA), adrenaline (ADR) 
dihydroxyphenylacetic acid (DOPAC) and dopamine (DA) 
measured in control (0) and Parkinsonian (rJ) human thoracic 
ventral and dorsal spinal cord. 
The n values for ventral and dorsal hom spinal cord from 
Parkinsonian subjects are; 8 (NA); 8 (ADR); 8 (DOPAC); 6 (DA). 
The n values for the control subjects are given in Table 3.2. p* 
<0.05. 
protein) were approximately twice those in dorsal cord (0.7 
pmolslmg protein). These noradrenaline levels were over five 
fold greater than the levels of adrenaline, dopamine or its 
metabolite DOP AC in the ventral horn of control spinal cord 
(Fig.3.4). In the ventral hom tissue from patients with 
Parkinson's disease the noradrenaline levels were approximately 
half those present in controls (p<0.05) while the dorsal horn levels 
of noradrenaline were not significantly different between groups 
(Fig.3.4). In contrast with noradrenaline distribution the levels of 
dopamine in the Parkinsonian cord were significantly greater 
than control values in both the ventral and dorsal gray matter 
(Fig.3.4). In addition there were no differences in the levels of 
adrenaline or DOPAC in either dorsal or ventral cord tissue from 
Parkinsonian and control subjects. Furthermore, there was no 
significant difference between the % recovery of the catecholamine 
internal standard DHBA measured in either control or 
Parkinsonian spinal cord. Percentage recovery was 48.6±4.0 
(mean±SEM, n=10) and 45.3±6.2 (mean±SEM, n=8) for control and 
Parkinsonian tissue respectively. 
B. Lumbar Spinal Cord. 
Catecholamines and indoleamines 
The number of cords used in the study of the lumbar region 
was low, there being only 5 control and 5 Parkinsonian cords. The 
differences in amine levels in the ventral hom from lumbar cord 
between tissue from Parkinsonian and control subjects paralleled 
those in thoracic cord. Compared with the levels of 5HT and 
5HIAA in the ventral hom of control cords (30.2 and 40.5 
pmols/mg protein), the tissue from subjects with Parkinson's 
disease showed lower levels of 5HT and its metabolite though these 
did not reach significance (Fig.3.5) possibly due to the low 
numbers used. The noradrenaline levels, however, in 
Parkinsonian ventral hom were markedly reduced ( -80%, 
Fig.3.6) compared with that in equivalent control tissue (4.78 
pmols/mg protein in control cord). 
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Fig. 3.5 Levels of 5HT, 5HIAA, SP and TRH measured in 
control (0) and Parkinsonian (rJ) human lumbar ventral and 
dorsal spinal cord. The n values are respectively, for ventral and 
dorsal horn spinal cord from Parkinsonian subjects; 3 & 3 (5HT); 
3 & 3 (5HIAA); 3 & - (SP); 3 & 3 (TRH). The n values for the 
control subjects are given in Table 3.2. 
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Fig. 3.6 Levels ofNA, ADR, DOPAC and DA measured in 
control (D) and Parkinsonian (Ea) human lumbar ventral and 
dorsal spinal cord. The n values for ventral and dorsal hom 
spinal cord from Parkinsonian subjects are; 5 (NA); 5 (ADR); 3 
(DOP AC); 4 (DA). The n values for the control subjects are given 
in Table 3.2. p* <0.01. 
In the dorsal horn of lumbar cord from control subjects 5HT 
levels were similar to equivalent thoracic tissue (22.4 pmols/mg 
protein) whereas noradrenaline levels were greater than in 
equivalent thoracic tissue (4.43 pmols/mg protein). In contrast 
with the findings in thoracic dorsal tissue there were significantly 
lower levels of 5HT and noradrenaline in the Parkinsonian 
lumbar dorsal horn samples compared with controls. 5HT and 
noradrenaline levels were approximately 3 and 7 fold lower 
respectively (Fig.3.5 and 3.6). As 5HIAA levels were only 
moderately (and not significantly) diminished the mean ratio of 
5HIAA to 5HT in the Parkinsonian lumbar dorsal cords was over 
twice that in the equivalent control cords (Table 3.3). The levels of 
adrenaline and DOPAC in the lumbar cords were approximately 2 
-30 % of the noradrenaline levels (Fig.3.6) and there were no 
significant differences in the levels between control and 
Parkinsonian lumbar cord in either the dorsal or ventral horns. 
Dopamine levels in control lumbar cord were very much 
greater than those in equivalent regions of the thoracic cord (2.76 
and 1.09 pmols/mg protein, ventral and dorsal horn respectively) 
and in contrast to the findings in the thoracic cord, in the lumbar 
cord the dopamine levels were lower, but not significantly so, in 
Parkinsonian compared with control cord in both the ventral and 
dorsal horns. 
Substance P and TRH 
Substance P levels were determined only in the ventral horn 
(18.3 pmols/mg protein, in controls) due to experimental error. 
The relative distribution of TRH in the lumbar cord of control 
subjects was similar to that in thoracic cord (7.54 and 2.48 
pmols/mg protein, ventral and dorsal horns respectively). 
Moreover, the substance P and TRH content of the Parkinsonian 
cord was no different from controls in either dorsal or ventral 
samples (Fig.3.5). 
In summary, the levels of 5HT, 5HIAA and noradrenaline 
were significantly lower in the ventral horn of thoracic spinal 
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Table 3.3 Ratio of 5HIAAI 5HT in spinal cord 
Ratio of 5HIAAI 5HT in different regions of post-mortem spinal 
cord from Parkinsonian and control subjects. Significant 
differences (p<0.05) from control are indicated by * and n values 
are given in brackets. 
Region Parkinson's disease Control 
Thoracic ventral 1.19±0.21 (7) 1.06± 0.14 (11) 
Thoracic dorsal 1.68 ± 0.38 (8) 1.23 ± 0.21 (10) 
Lumbar ventral 1.69± 0.46 (3) 1.51 :to.38 (5) 
Lumbar dorsal 3.76 ±0.60* (3) 1.58 ±0.10 (5) 
cord from Parkinsonian patients compared with control subjects 
with no difference in the dorsal horn levels (Fig.3.3 and 3.4). In 
contrast, dopamine levels were significantly greater in thoracic 
spinal cord from Parkinsonian compared with control subjects in 
both the ventral and dorsal horns (Fig.3.4). The significant 
differences in neuroamine content in the lumbar spinal cord from 
Parkinsonian compared with control subjects were (1) lower levels 
of noradrenaline in both the ventral and dorsal horns (Fig.3.6) 
and (2) lower levels of 5HT in the dorsal horn (Fig.3.5) with an 
increase in the ratio 5HIAAl5HT (Table 3.3). 
Effects of age, sex and PMI on amine and peptide levels in 
the spinal cord 
Using Pearson's correlation coefficient analysis there was 
no correlation between sex and either TRH, substance P, 
noradrenaline or dopamine levels. Pearson's correlation 
coefficients (c) and regression coefficients (r) indicated that levels 
of noradrenaline increased with age (c =0.79, p<0.05) and that 5HT 
levels decreased with both age (r=-0.84, p<O.Ol) and PMI (c = -0.81, 
p<0.05). Multivariate analysis indicated a positive correlation 
between TRH levels and both PM! and age (r= 0.69, p<0.05) when 
these factors were considered together but not separately. There 
was no evidence for correlations between dopamine or substance P 
with either age or PM!. 
Using ANCOVA the effect of each of the factors age, sex, PMI 
and Parkinson's disease on noradrenaline, 5HT and TRH levels 
was statistically determined after accounting for the correlations 
with each of the other factors. Results of factors for which there was 
evidence of some degree of correlation are given in Table 3.4. 
There was clearly no parallel between the sex of the subject and 
neurotransmitter levels in either thoracic or lumbar, dorsal or 
ventral spinal cord regions. 
Effects of age and PMI on noradrenaline levels 
In the thoracic and lumbar ventral horns noradrenaline 
levels tended to increase with age but not to a significant degree 
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and they were not correlated with PMI (Table 3.4). Furthermore, 
in the thoracic and lumbar dorsal horns there was no relationship 
between either age or PMI and noradrenaline levels. Considering 
these factors there were significant differences in noradrenaline 
levels in the thoracic and lumbar ventral horn (p<O.05, Table 3.4) 
and in the lumbar dorsal horn (p<O.Ol, Table 3.4) between 
Parkinsonian and control subjects . 
Effects of age and PMI on 5HT levels 
In thoracic ventral and dorsal horns there was a significant 
decline in 5HT levels with the age of the subject (p<O.05, Table 3.4). 
Such was the fall in levels with age that it accounted for the lower 
5HT levels in the Parkinsonian thoracic ventral cord and 
considering this factor there was no significant difference 
between 5HT levels in Parkinsonian and control cord in the 
thoracic ventral horn attributable to Parkinson's disease. 
However in lumbar cord there was no parallel between 5HT levels 
and age in either the dorsal or ventral horns. 5HT levels were 
lower in Parkinsonian cord than in control cord in both the 
ventral and dorsal horns but this difference was significant 
(p<O.05) only in the dorsal horn (Table 3.4) after accounting for the 
effects of age and PMI, possibly because of the low numbers used. 
In addition there was no effect of PM! on 5HT levels in any region 
measured. 
Effects of age and PMI on TRH levels 
In the thoracic ventral hom TRH levels increased 
. significantly with age (p<O.Ol) and PM! (p<O.05) whereas in the 
lumbar ventral cord the tendency for TRH to increase with age 
and PMI did not reach a significant level (Table 3.4). In the 
thoracic and lumbar dorsal horns however there was no 
correlation between TRH and either age or PMI. In none of these 
regions were there any differences between TRH levels in 
Parkinsonian and control cord. 
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Table 3.4 Correlation between neurotransmitter levels and 
PMI, age and Parkinson's disease. 
ANCOV A details for analysis of correlation between 
neurotransmitter levels and (A) PM! (B) age and (C) Parkinson's 
disease (Pd) in regions of the thoracic and lumbar spinal cord. 
Statistical information given in the table includes mean square 
(MS), degrees of freedom (d.f), and the residual variance (res.var) 
from which the F value was calculated. Details are given where 
there was a statistically significant correlation and for selected 
data which showed no correlation. Data from analysis of the effect 
of sex on transmitter levels are not given here as there was no 
correlation between these factors. Statistical significance is 
indicated by * (p<0.05) or ** (p<O.Ol). 
A PM! region 
NA thoracic 
5HT 
TRH 
TRH 
ventral 
thoracic 
ventral 
thoracic 
ventral 
lumbar 
ventral 
res.var 
res.var 
res.var 
res.var 
MS d.f. 
0.00 1 
0.83 ]2 
ffi 1 
154 n 
37.0 1 
4.91 12 
11.2 1 
4.84 3 
F value 
0.00 
0.56 
7.54* 
2.31 
Table 3.4 continued 
B Age region MS d.f. F value 
NA thoracic 1.53 1 1.84 
ventral res.var 0.83 12 
NA thoracic 0.39 1 1.70 
dorsal res.var 0.23 12 
NA lumbar 3.97 1 1.84 
ventral res.var 2.16 4 
NA lumbar 3.43 1 1.47 
dorsal res.var 2.33 3 
5HT thoracic 121)5 , 1 6.45* 
ventral res.var 100 12 
5HT thoracic f87 1 5.73* 
dorsal res.var 12) 11 
5HT lumbar 717 1 4.29 
ventral res.var 167 3 
TRH thoracic 61.1 1 12.4** 
ventral res.var 4.91 12 
TRH thoracic 2.69 1 1.49 
dorsal res.var 1.B1 11 
TRH lumbar 22.7 1 4.69 
ventral res.var 4.84 3 
Table 3.4 continued 
C. Pd regIon MS d.f. F value 
NA thoracic 4.54 1 S.47* 
ventral res.var 0.83 12 
NA thoracic 0.24 1 1.04 
dorsal res.var 0.23 12 
NA lumbar 30.1 1 13.9* 
ventral res.var 2.16 4 
NA lumbar 43.8 1 22.1 ** 
dorsal res.var 1.98 4 
5HT thoracic 400 1 2.54 
ventral res.var 100 12 
SHT lumbar &.18 1 5.18 
ventral res.var 125 3 
5HT lumbar ali 1 14.9* 
dorsal res.var 13.8 3 
TRH thoracic 11.9 1 2.42 
ventral res.var 4.91 12 
TRH thoracic 0.00 1 0.00 
dorsal res.var 1 11 
In summary, (1) there were no significant effects of either 
age or PMI on noradrenaline levels but (2) there were 
significantly lower levels of noradrenaline in the spinal cords 
from Parkinsonian patients in the thoracic ventral (p<O.05) and 
lumbar ventral (p<O.05) and dorsal horns (p<O.Ol). Furthermore, 
(3) 5HT levels decreased with age in the thoracic ventral and 
dorsal horns (p<O.05 in each case) but not in the lumbar cord and 
(4) the decrease with age in 5HT levels accounted for the lower 
levels of 5HT in the thoracic ventral horn of spinal cords from 
Parkinsonian patients which were therefore not attributable to 
Parkinson's disease. In addition, (5) in the thoracic ventral horn 
TRH levels increased significantly with age (p<O.Ol) and PMI 
(p<0.05) and (6) accounting for these correlations there were no 
differences in the levels of TRH in the spinal cord of 
Parkinsonian and control subjects. Finally, (7) there were no 
effects of either age, sex or PMI on substance P or dopamine levels 
and therefore the effects of Parkinson's disease on substance P 
and dopamine are as determined by t-test analysis above. 
The % of the total intra-subject variation in the levels of 
noradrenaline, 5HT and TRH due to PM!, sex, age and 
Parkinson's disease was determined from the residual variance 
after accounting for all these factors. PM!, sex, age and 
Parkinson's disease accounted for 56.5±17%, 64.0±12% and 
52.6+10% of the intra-subject variation in the levels of 
noradrenaline, 5HT and TRH respectively (n=4 regions in each 
case). 
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Discussion. 
In this chapter the levels of substance P and TRH and of 
5HT, the catecholamines and their metabolites were studied in 
post-mortem spinal cord from subjects who had died with 
Parkinson's disease. This was performed to investigate the 
proposal that 5HT and noradrenaline levels are reduced in the 
spinal cord in Parkinson's disease (Scatton et.al., 1986) and to 
determine whether changes in 5HT levels are accompanied by 
changes in the levels of TRH and substance P. 
Preliminary experiments to improve the methods 
Preliminary investigations and modifications were made 
in order to refine the methods and these will be discussed first. 
Initially, problems were experienced in obtaining a high enough 
level of HPLC sensitivity to detect dopamine, DOPAC and 
adrenaline levels. This was overcome in several ways; a glassy 
carbon electrode was used with which higher levels of sensitivity 
were attained; samples were made as concentrated as possible on 
alumina; a 1 0 0 ~ 1 1 injection loop was employed so that greater 
volumes of the sample could be injected on to the HPLC column; 
and the catecholamines were extracted in a more specific medium 
in which the % recovery of catecholamines was significantly 
greater than in the common extractant (previous chapter, page 82). 
The % recovery of the internal standard for the catecholamines 
was within an acceptable limit but the levels of dopamine in the 
thoracic cord samples were in some cases below the level of system 
sensitivity assuming a signal to noise ratio of 3:1. Therefore for 
dopamine only a lower level of precision in measurement was 
employed (signal to noise ratio of 2:1) in order to measure the low 
levels. The tissue levels of DOPAC were determined in this study 
as a metabolite of dopamine. However although DOPAC is the 
major metabolite of dopamine in the rat brain (Wilk et.al.,1975), 
in the human CNS current evidence indicates that the major 
dopamine metabolite is HV A (homovanillic acid) and that HV A is 
present in concentrations 10-100 fold those of DOPAC (Wilk and 
Stanley, 1978; Scatton et. al.,1983; Gibson et. al.,1985). It may 
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therefore have been more appropriate, and easier in terms of the 
HPLC system sensitivity required, to determine the levels of HV A 
instead of DOPAC. A description of the metabolic pathway of the 
catecholamines is given in the General Introduction (pp. 23-24). 
Thirdly, the % recovery of the peptides was not determined directly 
in the human spinal cord because this would necessitate spiking 
the tissue with exogenous peptide and using a considerable 
proportion of limited amount of tissue available. Peptide levels 
were therefore corrected using the % recoveries determined in the 
rat spinal cord. These values are likely to err on the low side, if at 
all, as recovery from bisected samples of the whole cord (as used in 
the rat samples) would be expected to be lower than from punches of 
tissue as degradation of the myelin sheath surrounding the cord 
required prolonged sonification. 
An attempt was also made to utilize the supernatant from the 
alumina extraction of samples to measure 5HT and 5HIAA. After 
shaking a sample of tissue extract with alumina and Tris-HCL the 
supernatant, usually discarded, contains the indoleamines and 
other non-catecholamine components. 5HT was detectable in the 
supernatant after injection onto the HPLC system at a 
concentration not significantly different from that determined in 
tissue extract. However, the levels of 5HIAA were significantly 
lower in the supernatant than in tissue extract indicating its 
instability in acidic solutions as discussed in the previous chapter. 
This procedure could not therefore be used to measure indoleamine 
levels. 
Levels of indoleamines, catecholamines, substance P and TRH 
The levels of substance P, TRH and of 5HT, noradrenaline, 
dopamine, adrenaline and their metabolites were determined in 
the human spinal cord. Levels of 5HT, 5HIAA, peptides and 
catecholamines measured in control human spinal cord tissues 
exhibited a similar range, and regional distribution as previously 
reported in humans considering differences due to variation in the 
exact regions dissected (Przewlocki et. al.,1983; Bennett et al., 
1986; Scatton et al., 1986; Mitsuma et.a1., 1984). 
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There was a widespread and characteristic distribution of 
substance P in the human spinal cord. Higher levels of substance 
P in the dorsal compared with the ventral horns corresponds to the 
distribution described previously in humans (Przwelocki 
et.a1.,1983; Anand et.al., 1983; Helme and White 1983; Bennett 
et.a1.,1986) in rats (Helke et.a1., 1982; Marsden et a1.,1982; this 
author, Table 2.2 ) and in the rabbit (Fone et.al.,1987b). Substance 
P has also been located in non-human primates in the dorsal and 
ventral horns of the spinal cord (DiFiglia et.a1.,1982; Bowker 
,1986). The increase in substance P levels from the cervical 
through to lumbar spinal segments seen in this study has been 
reported by others for the human (Anand et.al.,1983; Przewlocki 
et.al.,1983) and rabbit (Fone et.al.,1987b). 
In contrast TRH levels in the human spinal cord were 
greater in the ventral than in the dorsal horns. This corresponds 
to the distribution of TRH in the spinal cord of the human (Yates 
et.al.,1983; Bennett.et.al.,1986; Mitsuma et.al.,1986), the rat 
(Marsden et.a1.,1982; Lighton et.al.,1984; this author, Table 2.2), 
the rabbit (Fone et.al.,1987b) and the monkey (Lechan et.a1.,1984). 
Thoracic and lumbar TRH levels were similar and were greater 
than cervical levels. 
In this study 5HT levels were 1.3 -2 fold greater in the 
ventral compared with the dorsal horns of cervical, thoracic and 
lumbar segments of the human spinal cord which corresponds to 
the regional distribution of 5HT described in the human (Bennett 
et.al.,1986; Scatton et.al.,1986), the rat (Gilbert et.al,.1981; 
Marsden et. a1.,1982; Lighton et a1.,1984) and the rabbit (Zivon et 
a1.,1975; Fone et.al.,1987b). Furthermore, 5HT levels were 
similar in equivalent regions of the thoracic and lumbar spinal 
cord segments in this study as reported in the rabbit (Zivon 
et.al.,1975; Fone et.al.,1987b) but not the rat (Basbaum et.al.,1987, 
see General Introduction page 6). The ratio of 5HIAA to 5HT was 
consistent between dorsal and ventral regions of the thoracic and 
lumbar spinal cord in the human which contrasts with evidence of 
a higher ratio in the ventral cord in the human (Bennett 
et.al.,1986). However, the region in the latter study included white 
matter in which the relative levels of transmitters can be very 
different compared to that in gray matter (Bennett et.al.,1986). 
108 
Of the catecholamines measured, the levels of 
noradrenaline were the greatest in the human spinal cord and 
corresponded to those reported by Scatton and co-workers (1986). 
However, the levels of noradrenaline were one tenth or less cf 
those measured in the rat or cat spinal cord (Commissiong 
et.al.,1978a; Mouchet et.al.,1982; Basbaum et.al.,1987; Fleetwood-
Walker and Coote,1981). In the thoracic cord noradrenaline levels 
were approximately 10 times greater than dopamine levels which 
is consistent with the relative distributions of noradrenaline and 
dopamine in the spinal cord of the human (Scatton et.al.,1986) and 
rat (Commissiong et.al.,1978a; Mouchet et.al.,1982; Basbaum 
et.al.,1987; this thesis, chapter 2, Table 2.3). The distribution of 
dopamine in the human was not similar to that described in the rat 
in which dopamine levels are reported to be lower in the ventral 
than the dorsal horn (Commissiong et.al.,1978a; Commissiong 
and Neff, 1979; Mouchet et.al.,1982; Basbaum et.al.,1987). In the 
lumbar cord in this study the relatively larger dopamine levels are 
due to (i) 2 possibly spuriously large values out of 5 in each region 
and (ii) the exclusion of low values which were below the level of 
HPLC system sensitivity. For these reasons the values for 
dopamine levels in the lumbar cord may not be accurate. 
Adrenaline levels were very low in the human ventral and dorsal 
spinal cord being 14 - 47 fold lower than those of noradrenaline. 
This is in accordance with the reports of sparse adrenergic 
innervation to these regions in the rat (Coote et.al,.1981; Ross 
et.al.,1984; Kohno et.al.,1988). 
Amine and peptide levels in Parkinson's disease 
This study has demonstrated that the content of specific 
amines in spinal cords from patients having died with 
Parkinson's disease was significantly different from that from 
non-neurological control subjects in selected regions. The content 
of 5HT, 5HIAA and noradrenaline was approximately 50% less in 
thoracic ventral cord from Parkinsonian patients compared with 
control subjects with no significant difference in the ratio of 
5HIAA to 5HT, while no change in the levels of these amines were 
observed in the dorsal cord. In contrast the content of dopamine in 
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the thoracic ventral and dorsal cord was greater in the 
Parkinsonian than the control cord. In Parkinsonian lumbar 
cord 5HT and 5HIAA levels tended to be lower in ventral horn 
tissue and 5HT alone was significantly lower in dorsal horn 
tissue thereby resulting in an increase in the ratio of 5HIAN 5HT 
in the dorsal horn only. However, the most marked reduction was 
with respect to noradrenaline in lumbar spinal cord where the 
noradrenaline content of both ventral and dorsal regions was less 
than 20% of control levels. No significant differences were 
demonstrated between Parkinsonian and control tissue in the 
content of dopamine in the lumbar spinal cord or of TRH, 
substance P, adrenaline or nop AC in any region. 
The lower level of 5HT in Parkinsonian thoracic ventral 
and dorsal cord compared with control values was dependent on 
the age of the subjects. When the two groups (Parkinsonian and 
control) were adjusted for age differences there was no significant 
difference between 5HT levels in either thoracic region. In the 
lumbar cord, however, the level of 5HT was unaffected by age and 
the difference in levels between Parkinsonian and control cords 
was attributed to Parkinson's disease. In contrast, noradrenaline 
levels tended to increase with age in lumbar and thoracic ventral 
spinal cord though not to a significant degree. The difference in 
noradrenaline levels between Parkinsonian and control cords 
was, therefore, accentuated considering that the mean age of the 
Parkinsonian patients was greater than that of the control subjects 
by 12 years. Furthermore, TRH levels increased significantly 
with both PMI and age in the thoracic ventral cord but there was no 
effect on the levels attributable to Parkinson's disease. 
The results indicate that the lower levels of indoleamines in 
the thoracic and lumbar Parkinsonian cord compared with 
equivalent control cord are due to different factors. The reduction 
in thoracic cord being due to age and the reduction in lumbar cord 
being due to Parkinson's disease itself. In a similar study of 
indoleamine levels in lumbar cord Scatton and co-workers (1986) 
found 50% loss of 5HT and 5HIAA in lumbar ventral and dorsal 
spinal cord which they attributed to the effects of Parkinson's 
disease. They reported that patient age, sex and PMI did not affect 
5HT levels without, however, providing evidence that they had 
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used statistical analysis to make this conclusion and the dangers 
of this are discussed below. Nevertheless, their Parkinsonian and 
control subjects were well matched for age, in fact the control 
subjects were on average older than the Parkinsonian patients. It 
is likely therefore, that the 5HT reduction in the lumbar cord in 
their study and this one is due to the effects of Parkinson's disease 
and the increase in the ratio of 5HIAA to 5HT may indicate a 
compensatory increase in the rate of 5HT turnover. 
Co-existence of substance P, TRH and 5HT in human spinal cord 
The reductions in the levels of 5HT and 5HIAA found in the 
Parkinsonian cords may result from degeneration of bulbospinal 
neurones.llowever, in the light of evidence of a concomitant 
unaltered peptide state it may be that the dysfunction is more 
complex. The distribution of descending serotonergic and 
peptidergic neurones in the raphe nuclei of the rat suggest that a 
large fraction of the raphe-spinal neurones contain serotonin co-
existing with substance P and/or TRH in the same cell as 
discussed previously (pp.9-11). If this were the case in humans, 
spinal serotonergic depletion may be expected to be accompanied by 
a loss in spinal peptide content, which has not been demonstrated. 
It is not surprising that dorsal hom substance P levels do not 
parallel loss of 5HT in this region as the major innervation in rat 
(50-80%) of substance P in the dorsal hom is from the dorsal root 
ganglion ( Jessell et. a1.,1979; Ogawa et.a1.,1985; Tessler et.al., 
1984) or intra-spinal neurones (Hunt et.al., 1981; Tessler et.al., 
1984). Whether there is a descending serotonergidsubstance P 
innervation of the dorsal hom is undetermined but at most, it 
makes a small contribution to dorsal hom substance P in rat 
(Gilbert et.a1.,1981; Marsden et.al.,1982; Helke et.al., 1986). 
Similarly, dorsal hom TRH is probably largely independent of the 
bulbo-spinal serotonergic system (Helke, 1986; Harkness and 
Brownfield, 1986). The origins of substance P and TRR in the 
ventral cord in the rat are mainly supra-spinal including nuclei 
in the medulla (the raphe magnus, raphe obscurus and raphe 
pallid us) and the ventrolateral medulla (nucleus reticularis 
gigantocellularis [NG] and the nucleus interfascicularis 
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hypoglossi [NIH] also known as nucleus reticularis ventralis pars 
alpha) (Hokfelt et.al.,1978;Gilbert et.al., 1981; Hokfelt et.al.,1981; 
Bowker et.al.,1983; Helke et.al.,1982). Part of this innervation is 
co-existent with serotonin innervation from the descending 
ventral medullary nuclei and the selective serotonergic 
neurotoxin 5,7-DHT substantially reduces ventral horn substance 
P and TRH (Hokfelt et.al., 1978; Helke et.al., 1986; Gilbert 
et.al.,1982; Harkness and Brownfield,1986). However, there are a 
number of possible reasons why in this study reductions in peptides 
levels did not parallel those in 5HT. Firstly, massive destruction 
of serotonergic neurones using 5,7-DHT and the accompanying 
loss of peptides occurs within days of toxin administration. The 
effects of aging or Parkinson's disease on neuronal integrity is 
most likely to occur over a period of years and may not therefore be 
comparable with neurotoxin induced serotonergic denervation. It 
is possible that unaffected peptidergic intra-spinal and supra-
spinal innervation of the spinal cord has time to adapt and 
compensate for long term neuronal changes. Davis and co-
workers (1984) found that after mechanical lesions of the cervical 
cord substance P-LI in the intermediolateral cell column was 
unchanged or elevated and proposed that intraspinal substance P 
neurones were capable of compensating for loss of spinal 
substance P. Furthermore, the present study has demonstrated an 
increase in ventral spinal cord TRH levels with age which may be 
evidence of a homeostatic mechanism compensating for loss of 
serotonergic innervation with age. Secondly, although a large 
proportion ofTRH projection to the ventral hom is co-existent with 
serotonin this region also receives non-serotonergic TRH 
innervation from the NIH (Harkness and Brownfield, 1986; 
Holets et.al.,1987). Changes in TRH metabolism in this non-
serotonergic TRH projection to the spinal cord may compensate for 
TRH loss due to destruction of serotonergic trRH neurones. 
Alternatively, the observation that the neuropeptide levels do 
not show parallel reductions with the 5HT and 5HIAA levels and 
further that the 5HT loss is only partial may indicate that any 
possible spinal degeneration in Parkinson's disease (or aging) 
may be restricted to a selective sub-population of neurones 
containing 5HT alone. The heterogeneous distribution of the 
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transmitters throughout the raphe system in rodents indicates 
various sub-populations of raphe spinal neurones containing 5HT, 
substance P and TRH either together, separately or in various 
combinations (Bowker et a1., 1982). In addition there is evidence of 
a descending serotonergic projection from the locus coeruleus 
(Leger et.al,1979; Wiklund et.a1.,1981; Lai and Barnes, 1985). 
Thus rather than being indicative of a lack of spinal serotonin-
peptide co-existence in humans, the unaltered peptide levels in 
Parkinsonian cord may result from preservation of 5HT neurones 
which also contain substance P and/or TRH. Such a proposition is 
consistent with the evidence that certain peptide containing 
neurones may be spared in Parkinsonian brain (Studler et aI., 
1982). It is possible that the peptides TRH and substance P which 
have been reported to have trophic functions (Jonsson and 
Hallman, 1982; Schmidt-Achert et aI., 1984; Fone et a1.,1988a) may 
help to maintain the integrity of selective descending serotonergic 
neurones in disease or normal aging. 
The different effect on 5HT levels in the thoracic compared 
to the lumbar cord could be explained by differences in the degree 
of serotonergic innervation to each cord segment from the various 
medullary nuclei. There is evidence that neurones from the three 
raphe neurones send collaterals to different spinal segments and 
innervate the different segments in varying degrees in the cat 
(Bowker et.al.,1987). In addition, Di Carlo (1983) reported a 
possible additional source of serotonergic innervation of the 
lumbar cord from the dorsal root ganglia. The evidence therefore 
indicates that projections from the raphe nuclei to the different 
segments of the cord are not evenly distributed and that some of the 
lumbar serotonergic fibres do not originate in the raphe. 
Catecholamine levels in Parkinson's disease 
The dramatic diminution of noradrenaline levels in the 
Parkinsonian lumbar compared with thoracic cord may indicate 
noradrenergic neuronal loss which is more progressive down the 
cord. This difference in degree of noradrenergic depletion of the 
lumbar and thoracic cord in Parkinson's disease may reflect 
differences in the nuclei of origin of the thoracic and lumbar 
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noradrenergic projections. The pontine noradrenergic cell 
groups, in particular the caudal and ventral locus coeruleus and 
subcoeruleus are cited as sources of spinal noradrenaline 
innervation though in immunocytochemical studies in the rat no 
obvious differences in source nuclei has been seen for different 
cord segments (Commissiong et.al., 1978; Westlund et.al., 1983; 
Nakazato, 1987). 
Contrary to the effects on the other amines, dopamine levels 
were significantly greater in the thoracic ventral and dorsal 
spinal cord in Parkinson's disease compared with controls and 
these levels were not correlated with age, sex or PM!. It is possible 
that this result is dependant on pre-morbidity drug treatment. 
Differences in the interval between the last dose of L-dopa and 
death may account for the variations demonstrated between 
Parkinsonian patients in spinal cord dopamine levels. Post-
mortem striatal dopamine levels are 9 - 15 times higher in 
Parkinsonian patients treated with L-dopa than in untreated 
patients (Lloyd et.al.,1975). Furthermore, the levels of dopamine 
in a number of brain regions in patients having died of 
Parkinson's disease have been shown to be related to the interval 
between the last dose of L-dopa and death, levels being greater in 
those patients who received medication nearer to the time of death 
(Lloyd et.al., 1975; Scatton et aI., 1983). In addition, it has been 
demonstrated that L-dopa can be converted to dopamine in the 
spinal cord in elements other than dopaminergic neurones, 
probably glia and non-monoaminergic nerve terminals 
(Commissiong, 1985). It would have been preferable to use tissue 
only from patients who had not received medication within the 24 
hours preceding death but this would not have been practical due to 
the small sample size. Scatton and co-workers (1986) who were 
able to work within these limitations reported no differences 
between dopamine levels in the lumbar spinal cord of 
Parkinsonian and control subjects. The evidence indicates that 
exogenous L-dopa is mainly converted to dopamine and not to 
noradrenaline and that the synthesis and metabolism of 
noradrenaline in the CNS is unaffected by L-dopa administration 
(see Commissiong and Neff, 1979 for references; Scatton 
et.al.,1983). More-over, the effects of L-dopa treatment on spinal 
114 
cord motor reflexes are probably mediated through dopamine alone 
and not noradrenaline (see Commissiong and Neff, 1979). Other 
sources indicate that synthesis of noradrenaline may be 
stimulated in the spinal cord and brain by L-dopa but that this 
reserve is rapidly metabolized or displaced by increased levels of 
dopamine, maintaining constant levels of neuronal 
noradrenaline and contributing little if at all to functionally 
significant releasable stores of noradrenaline (see Commissiong, 
1985; Ehrenstrom and Johansson,1984). It is therefore assumed in 
the present study that the dopamine levels but not noradrenaline 
levels may be affected by the interval between death and the last 
dose of L-dopa and that this may disguise the effect of Parkinson's 
disease on the level of dopamine in the spinal cord. In addition, 
the results of the dopamine levels in the lumbar cord may be 
somewhat misleading for technical reasons as discussed above 
(page 109 ). 
A conclusion arising from the differential effect of 
Parkinson's disease on spinal cord noradrenaline and dopamine 
levels is that this supports the evidence out-lined in the General 
Introduction that the dopaminergic and noradrenergic 
innervation of the spinal cord are independent of each other. 
Effects of age, PMI and sex on neuroamine and peptide levels 
There were a number of factors which directly affected the 
levels of neurochemicals measured in the spinal cord. The 
following factors are discussed here: sex of the subject; age of 
subject; and PM!. 
Effects of age 
The factor which demonstrated the greatest effect on 
neurotransmitter levels was the age of the subject. 5HT levels 
declined with age in thoracic dorsal and ventral regions but not in 
lumbar spinal cord and, in contrast, TRH levels increased with 
age in the thoracic ventral cord but not the dorsal hom nor in 
lumbar regions. The failure for the increase in age in the lumbar 
ventral region to reach a significant level was again probably due 
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to the low numbers in the study. However, noradrenaline, 
dopamine and substance P levels were unaffected by age. The 
literature is in agreement that substance P levels in human CSF or 
post-mortem brain tissue are generally reported to be unaffected by 
age (Helme and White, 1983; Buck et. a1.,1981). 5HT levels in 
selected brain regions are reported to be stable with age (Stanley et. 
al.,1986; Morgan 1987; Allen et a1., 1983; Severson et.a1.,1985) 
whereas serotonergic receptors are reported to be reduced with age 
(Mann et.al 1986; Marcusson et.a1., 1984; Allen et.a1., 1983). The 
literature concerning the catecholamine levels in the human eNS 
is contradictory. Indicators of catecholamine turnover and / or 
catecholamine levels are reported to be reduced or unaffected by 
age (Morgan 1987; see Allen et. a1.,1983 for references). 
Effects of PMI 
The literature covering the effect of PM! on neuroamine and 
peptide levels is similarly confusing. In this study the only 
significant effects were of increases in TRH levels in selected 
spinal cord regions with PM!. Substance P, noradrenaline, 5HT 
and dopamine levels were unaffected by PM!. With respect to 
substance P, however, there is a high degree of compatibility with 
published data as a number of authors report stability in 
immunoreactivity of substance P and other peptides including 
neurotensin and somatostatin in post-mortem rat and human 
brain tissue (Helme and White,1983; see Buck et.a1.,1981 for 
references; Bennett et.a1., 1986) and it has been proposed (Buck 
et.a1.,1981) that the important factor affecting post-mortem 
substance P levels is not the PM! but the time until the body is stored 
at 40c. Surprisingly, this stability is not apparent for all peptides 
as TRH levels are reported to decline (Bennett. et.a1.,1986), 
increase (Ems on et. a1.,1981a; Bird and Iverson, 1982) and remain 
stable (Yates et.a1., 1983; Mitsuma et.a1., 1984) with increasing 
PM!. Some sense can be made of these conflicting proposals when 
the actual post-mortem time intervals are taken into account. 
There is evidence that in the human spinal cord tissue TRH levels 
initially decrease over the first 24 hours post-mortem and then 
begin to rise again (Bennett et.a1., 1986) which would account for 
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variations in results depending on the mean and range of the PMI 
of the sample. However, reports which draw conclusions about the 
effects of PM! on human eNS transmitter levels from plots of PMI 
against levels can be misleading. Such a plot from the results of 
the present study is illustrated in Fig.3.7 and might be taken to 
indicate that there was no correlation between TRH levels and 
PM!. The strong correlation is only revealed using ANCOV A 
statistical analysis by accounting for the effect of the parallel 
correlation between age and TRH levels. It is important then that 
proposals of correlations with any variable are substantiated by 
suitable statistical analysis. 
Variation in transmitter levels with PMI may be dependent 
on enzyme activity occurring after death. Geola and co-workers 
(1981) demonstrated that synthesis of another peptide, 
somatostatin, from its precursor continued for some time post-
mortem. Presumably, post-mortem enzymatic peptide 
degradation also occurs. Therefore, in a similar manner, the 
levels of TRH at different intervals after death may depend on the 
relative balance between the rates of synthesis and degradation. 
Furthermore, that the precursor ofTRH is processed to produce 5 
molecules of TRH CLechan et.al.,1986) may account for the 
significant post-mortem increases in the levels of this 
neuropeptide. It has been proposed that stability of post-mortem 
peptide levels is due to their location within synaptic vesicles 
which protects them from degradative enzymes (Emson et.al 
1981a). Therefore instability of TRH may reflect a different 
storage mechanism to that of other peptides. 
Effects of sex 
In this study there were no differences in the levels of 
noradrenaline, dopamine, 5HT, substance P or TRH between 
male and female subjects. Differences could have been expected 
considering that there are a number of gender related variations 
which might affect neurotransmitter state including expected life-
span, hormonal balance and diet. Furthermore, TRH levels have 
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Fig. 3.7 TRH-LI levels in thoracic ventral spinal cord samples 
from control subjects plotted against the interval between death 
and post-mortem (PMI). Each point represents one subject. Note 
that the positive correlation between the two factors revealed 
statistically using analysis of variance (see text) is not obvious 
when the data is plotted in this way. 
been reported to be higher in men than women in a number of 
discrete brain regions (Edwardson and McDermott, 1982). 
However, in the majority of evidence, sex is reported to have no 
effect on post-mortem neurotransmitter measurements in the 
human. There have been reported to be no gender differences in 
the levels of noradrenaline, 5HT, 5HIAA and dopamine 
(Gottfries,1980; Scatton et. al.,1986; Severson et.al.,1985) or in 
adrenergic or serotonergic binding (Mann et.al.,1986) in the 
human brain. 
Evidence discussed in the General Introduction (pp. 34-35) 
indicates that the effects of both PMI and age on eNS transmitter 
levels vary depending on the eNS region studied and this is 
supported by the results of this study in which age and PMI affected 
very selective regions of the spinal cord. In addition the evidence 
(pp.34-35) indicates that the effects on transmitter levels depends 
on the exact ranges of age or PMI investigated. The corollary of 
this evidence in the light of the present results is that every study of 
amine and peptide levels in the human eNS should be 
accompanied by an analysis of the relationship between these 
transmitters and age and PMI as it is unlikely that this 
relationship has been previously investigated within identical 
limitations of age, PMI and eNS region, factors which may have 
very specific effects on neurochemical levels. 
Whether the differences in spinal cord levels of amines and 
peptides in both aged and Parkinsonian subjects are due to effects 
specific to the spinal cord or secondary to changes in the cell nuclei 
in the brain is undetermined. In Parkinson's disease there is loss 
of noradrenaline and 5HT content from their brainstem nuclei, 
the locus coeruleus and raphe nuclei respectively (Farley and 
Hornykiewicz,1976; Greenfield and Bosanquet,1953). Evidence 
from rats demonstrates that electro-thermic destruction of the 
pontine noradrenergic nuclei, the locus coeruleus, results in 
approximately 60% loss of both thoracic and lumbar ventral cord 
and 35% loss of thoracic and lumbar dorsal noradrenaline content 
(Commissiong and Neff, 1979). However, this study has shown 
that in Parkinson's disease the amine losses are not the same in 
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equivalent regions of the thoracic and lumbar cord which may 
indicate that they are not solely dependant on brain-stem cell 
nuclei destruction. Although, the complication of the effects of age 
on these levels must also be considered. Furthermore the 
proportional deficiency of noradrenaline and 5HT is much 
greater in the lumbar spinal cord than in the respective brain stem 
nuclei. 
In summary, the levels of 5HT and 5HlAA in the thoracic 
ventral hom and of noradrenaline in thoracic and lumbar 
ventral horns of Parkinsonian spinal cords were significantly 
lower than in equivalent control cords with no apparent changes in 
the 5HIAAl5HT ratio. The reduction in 5HT levels in the thoracic 
ventral cord was however dependent on the difference in age 
between the Parkinsonian and control subjects and not on 
Parkinson's disease. Reductions in noradrenaline and 5HT 
levels were found in lumbar dorsal horn regions in Parkinson's 
disease but here the 5HlAAl5HT ratio was increased compared 
with controls. Dopamine levels were significantly higher in 
thoracic ventral and dorsal Parkinsonian cord compared with 
controls. This finding was discussed with reference to L-dopa 
therapy. In contrast to these findings, there were no differences in 
the levels of either substance P, TRH, adrenaline or DOPAC in 
any of the spinal cord regions. The lack of changes in the peptide 
levels was discussed with respect to co-existence of these peptides 
with 5HT in the human spinal cord. 
The results indicate that Parkinson's disease may be 
associated with reduced levels of two amine neurotransmitters 
(noradrenaline and 5HT) known to be involved in spinal 
regulation of motoneurone, and possibly nocioceptive functions. 
The results also demonstrate that spinal levels of substance P and 
TRH are unchanged in Parkinson's disease. This may indicate 
that either (i) these neuropeptides do not co-exist to a great extent 
with 5HT in the human spinal cord, (ii) that serotonergic-
peptidergic neurones are spared in Parkinson's disease or (iii) 
that compensatory processes maintain the spinal cord peptide 
levels when 5HT levels are depleted. 
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Chapter 4 Serotonergic and adrenergic 
binding in the human spinal cord: ligand 
binding and autoradiograpbic evidence 
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Introduction 
In the previous chapter the levels of indoleamines and 
catecholamines in human spinal cord tissues from Parkinsonian 
patients were compared with those from control subjects. Some of 
the possible reasons for the lower levels of neuro-amines observed 
in the Parkinsonian cord, including neuronal loss and 
degeneration, were also discussed. It was decided that a study of 
the effect of Parkinson's disease on the aminergic receptors may 
clarify the nature of the changes occurring in this condition at the 
neuronal level assuming that changes in the numbers of receptors 
and their affinities for certain ligands may occur as a result of 
effects such as neuronal loss or variations in transmitter release. 
In this chapter radio-ligand binding and autoradiography were 
used to investigate serotonergic and adrenergic binding in human 
spinal cord tissue. The evaluation of these two methods for use 
with human spinal cord material is described as there have been 
very few quantitative reports of serotonergic or adrenergic ligand 
binding in this tissue and furthermore a number of modifications 
of the protocols had to be made to adapt them for use with human 
spinal cord material. The results of ligand binding studies using 
rat brain tissue (and in some cases human cortical tissue), a 
comparison of the results with previously published data, the 
subsequent attempt to use these same methods with control human 
spinal cord material and the problems arising are detailed here. 
D e t e r m i n a t ~ ~ of the number and affinity of 01.. 2-adrenoceptors in 
Parkinson's disease is found in the following chapter. 
To comprehend the results of the ligand binding studies and 
understand how receptor affinities and number may be related to 
the levels of endogenous neurochemicals it is important to know 
the location of the receptor sites under investigation. The binding 
studies were therefore performed with ligands for which the 
affinities for specific subtypes of serotonergic and noradrenergic 
sites were well documented. Ligands were chosen on the basis of 
their specificity and on the location of the sites to which they are 
purported to bind. 
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Radio-ligand Binding Studies 
Serotonergic receptors 
Radio-ligand binding is a well established technique for 
investigating the characteristics of the binding of 5HT and 5HT 
analogues to eNS tissue membrane preparations (Peroutka and 
Snyder 1979; Pedigo et. al., 1981;Pazos et.al., 1984a,b; Peroutka 
and Hamik, 1988). Multiple 5HT binding sites have been 
demonstrated using radio-ligand binding with selective ligands 
for these sites. [3H] 5HT binding in rat brain has been divided into 
5HTI and 5HT2 types on the basis of the different affinities of 5HT 
and spiroperidol for the sites (Peroutka and Snyder,1979). More 
recently evidence for a 5HT3 receptor in the eNS and specifically 
in rat cortical membranes has been reported (Kilpatrick et. al., 
1987; Hoyer and Neijt, 1987; Peroutka and Hamik, 1988). The 
5HT1 site has high affinity for 5HT whereas the 5HT2 site has a 
low affinity for 5HT and high affinity for a number of classical 
5HT antagonists such as ketanserin (Leysen et.al., 1982; Peroutka 
and Snyder, 1981; Engel et. al.,1984b). However the binding of 
[3H] 5HT to 5HT1 sites has also been shown to be heterogeneous 
(Pedigo et. al., 1981) and with the development of selective 
agonists, the 5HT binding site in eNS tissue from various species 
has been further classified into 5HT1A, 5HT1B, 5HT1C and more 
recently 5HT1D subtypes (Middlemiss and Fozard, 1983; Gozlan 
et. al., 1983; Doods et. al., 1985; Peroutka, 1986; Heuring et. al., 
1986; Heuring and Peroutka, 1987). 
The functional correlates of these receptor subtypes are as yet 
unclear however there is evidence that the 5HT1 receptor may be 
associated with the 5HT autoreceptor mediating prejunctional 
inhibition of neuronal transmitter release (Engel et. al., 1986; 
Schlicker and Gothert, 1981). The evidence indicates that in rats 
analogues with selectivity for the 5HT1B receptor act at an 
autoreceptor on nerve terminals (Middlemiss,1985) and in vivo 
voltammetry studies support this proposal (Martin and Marsden, 
1986; Marsden et.al.,1987). Furthermore, the 5HT1A receptor in 
the rat appears to be an autoreceptor located on pre-synaptic 5HT 
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cell bodies and dendrites involved in regulation of neuronal 
firing and 5HT release (Sprouse and Aghajanian, 1986; Garrett 
et.al.,1988). There is also evidence of a post-synaptic 5HTIB 
receptor mediating inhibition of adenylate cyclase stimulation 
(De Vivo and Maayani, 1986; Sleight et.al.,1988) and of post-
synaptic 5HT1B and 5HT1C receptors mediating hypophagia 
(Kennett and Curzon,1988). In addition, there is species specificity 
in receptor subtypes, for instance, the 5HT1B autoreceptor is present 
in rat but not human brain membranes and the autoreceptor in the 
human cortex may be the 5HT1D receptor (Heuring et. al.,1986; 
Heuring and Peroutka, 1987; Galzin et.al., 1988). In contrast the 
5HT2 receptor in the rat eNS is located post-synaptically (Hoyer 
et.al.,1985b) and has been implicated in mediation of behavioural 
effects including head twitches, fore-paw treading and wet-dog 
shakes (Leysen, 1989; Fone, 1989a). 
On the basis of published data it was proposed to investigate 
the binding to both 5HT1 and 5HT2 receptors using ligands which 
have been well documented as showing specificity for these sites. 
Firstly, 5HT from the above evidence is known to label all 5HT1 
receptors whereas 8-hydroxy-2-(di-n-propylamino) tetralin 
(DPAT) is now well established as a 5HT agonist with high 
affinity for the 5HT1A receptor specifically (Middlemiss and 
Fozard 1983; Peroutka et. al., 1986). Secondly, [3H] ketanserin 
was used to label 5HT2 receptors. Ketanserin has been established 
as a 5HT antagonist with high affinity for the 5HT2 receptor and 
importantly with negligible affinity for the 5HT1 receptor or for the 
0(. -adrenoceptor when used up to a concentration of 2 nM [3H] 
Ketanserin (Leysen et. al., 1982). 
Adrenoceptors 
In vitro binding studies have identified adrenergic receptor 
sites in the eNS of humans and rats (Greenberg et. al.,1976; Miach 
et. al., 1978; Sumners et al., 1983) which were pharmacologically 
identical to peripheral oL 1, 0/... 2, B1 and B2-adrenoceptors. The 
cellular localisation of these receptors has not however been 
clarified. Alpha1-adrenoceptors seem to be post-synaptic since 
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their numbers increase after treatment with 6 hydroxy dopamine, 
a neurotoxin causing lesions in catecholaminergic neurones 
specifically (Dausse et. aI., 1982; Reader and Briere, 1983) 
whereas the localisation of C>t2-adrenoceptors is controversial and 
there is evidence for both pre- and post-synaptic sites (Langer, 
1974; Levin, 1984; U'Prichard et. a1.,1980) 
[3R] Idazoxan (RX 781094) was selected as the ligand to 
distinguish ()('2-adrenoceptor binding sites as its specificity for 
this receptor is well documented (Doxey et. aI., 1982 ;Langer et. a1., 
1983; Hamilton et. aI., 1988; Howlett et. aI., 1982). 
[1251] AmiK (7-amino-8-iodo-ketanserin) was also 
employed in preliminary ligand binding studies to identify both 
0( 1 _adrenoceptors and 5HT2 receptors for which it is reported to have 
high affinities (Wouter, 1986; Schotte and Leysen, 1988). 
Autoradiographic localisation of serotonergic and 
adrenergic receptors 
In this chapter autoradiographic studies were performed to 
determine the distribution of serotonergic and adrenergic 
receptors in the human spinal cord. The binding kinetics and 
pharmacological profiles of the ligands used had been established 
previously either in ligand binding studies, in autoradiographic 
investigations or in both. Briefly, (i) the use of AmiK in 
autoradiographic studies has provided data on the density and 
localisation of 5HT2 receptors and o(.l-adrenoceptors in the rat 
brain which supports published results from ligand binding 
studies (Schotte and Leysen,1988; Wouters et.a!., 1986) (ii) DPAT 
has been reported to be an appropriate ligand for labelling 5HTIA 
receptors in both ligand binding studies (see above) and 
autoradiography (Pazos and Palacios, 1985) whereas (iii) the 
specificity of Idazoxan for ()(.2-adrenoceptors has been confirmed 
in binding studies (see above) but its use in autoradiography has 
not been reported. 
The results using these ligands either in autoradiographic 
studies or for binding to sections of tissue on glass slides are 
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compared with results from ligand binding to homogenates of 
human cord and rat brain. 
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Methods 
Autoradiography 
Autoradiography studies were made in rat brain and 
human spinal cord samples using the radio-ligands [1251] 7-
amino-B-iodo-ketanserin (AmiK), [3H] DPAT and [3H] Idazoxan. 
The various concentrations of the radio-active ligands used were 
.....d t> ~ ' t \ \ \ o . ~ ~
checked by gamma"counting (LKB, Riagamma) the diluted 
solutions before incubation of the sections. 
Tissue preparation 
Whole rat brains were dissected from male Wistar rats 
(250-300g) cut into 5 horizontal or sagittal slices of equal width and 
stored at -20oc for 4-5 hours before transferal to -BOoc to match the 
storage conditions of the human tissue. Spinal cord tissue was also 
taken from two human control subjects without histories of 
neurological illness. The subjects were both females aged 62 and 
73 years who had died of respiratory failure. The intervals 
between death and post-mortem were 11.5 and 19 hours 
respectively. The spinal cord was dissected into thoracic and 
lumbar regions and segments from the first subject were stored at 
-200 c for 4-5 hours before transferal to -BOoc. The tissue from the 
second subject was 'fast frozen' by holding sections, wrapped in tin 
foil to maintain their shape, in a beaker of liquid nitrogen within a 
trough of dry ice for 5 - 10 seconds. The segments were then stored 
at -Sooc. 
Rat brain tissue was transferred from the freezer on dry ice 
for cryostat sectioning. On a metal sheet, cooled over a mixture of 
ice and dry ice, horizontal and sagittal sections were cut into slices 
of 2-3mm width manually using a razor blade. Cryostat blocks 
were covered with a layer of tissue paper and the slices were then 
adhered to the block with Tissue Tek OCT compound (Miles 
Scientific), a tissue embedding medium. The tissue and block 
adhered in this manner were then slowly lowered into a glass 
beaker of isopentane cooled to sub-zero temperature in liquid 
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nitrogen. The blocks were placed in the cryostat for 2 hours prior to 
sectioning to equilibrate with the temperature of -15 to -20oc. 
Samples of human thoracic and lumbar spinal cord were 
transferred from storage to the microbiological hood on dry ice 
within sealed containers. Slices of 2 - 3mm width were cut and 
mounted on cryostat blocks and precooled as described for the rat 
brain samples. From experience it was found that to cut the human 
spinal cord tissue successfully the slices must be completely 
embedded in the Tissue Tek whereas for the rat brain only enough 
Tissue Tek to cover the base of the tissue sample was required. 
Sectioning 
Horizontal and sagittal slices of rat brain and GOI ollal ~ ~
slices of human spinal cord were cut into 20J.Ul\sections in a 
microtome cryostat (Brighton Instrument Company) at -15 to -200 c. 
The sections were made manually by rotating a handle to sweep 
the block mounted sample across the cryostat knife blade which 
was static. Sections were thaw mounted onto glass slides i.e. the 
section was melted onto the slide by pressing a finger onto the back 
of the slide. Glass microslides (Chance Propper Ltd) had been 
prepared either with acid washing and/or gelatin subbing (see 
below). Sections were collected on separate labelled slides and 
stored in the same sequence as they were cut. They were left in the 
cryostat for 1 - 2 hours after which time they were stored at -Sooc 
within sealed plastic bags. Sections were used within 3 weeks of 
storage and generally within 1 week. Autoradiographic images of 
the rat brain in horizontal and sagittal section are given in FigA.2 
demonstrating the regions of the brain revealed. 
Experience in cryostat sectioning improved the uniformity 
of the sections. However under the light microscope small tears 
could be sometimes be seen in the sections. As this may have been 
the result of the formation of ice crystals during storage the effect of 
slow and fast freezing on the condition of the tissue was observed. 
There was no apparent difference with respect to the Occurrence of 
small tears using either method but great care had to be taken when 
fast freezing the tissue that it did not fracture and that its shape was 
preserved. In the studies described below only sections in a good 
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Frontal cortex 
cortex 
-r---Cerebellum 
Fig.4.1 The dorsal aspect of the rat brain showing the regions 
dissected for ligand binding experiments. Frontal cortex was used 
in studies of 5HTl receptor binding and the remainder of the cortex 
was taken for studies of <x2-adrenoceptor binding. Whole cortex 
was used in 5HT2 binding studies. 
Frontal cortex was dissected 4 mm from the optic lobe. 
Lateral septal nuclei 
Thalamus Caudate Putamen 
Cerebellum Cortex Caudate putamen 
~ o r t e x x
\ Thalamus _ ~ ~Periaqueductal I " gray - - - - - - - - - - - - - - ~ 4 4
Cerebellum -----__ 
A B 
Fig. 4.2 Autoradiographs of (A) sagittal and (B) horizontal section through the rat brain showing the thalamic nuclei, 
periaqueductal gray-matter, cerebellum, lateral septal nuclei, caudate putamen and cortex. Areas were identified using a 
rat brain atlas (Paxinos and Watson, 1982). Autoradiography employed 0.5 nM [125I] AmiK. (f\) s ~ ~ ~ - ~ 6 t \ t , , ~ ~
condition were used and there was no difference between the 
results obtained using slow or fast frozen tissue. 
Slide preparation: acid wash 
Chromic acid was made by careful addition of 125 mls of 
sulphuric acid to 5g K2Cr207 dissolved in 200mls DDD. This 
procedure was performed within a bucket of ice in a fume 
cupboard. Glass slides were left in chromic acid over night, 
washed in continuously flowing water for for 2 hours and finally 
rinsed in distilled water and allowed to dry in a heated cabinet. 
Gelatin subbing: Gelatin (2.5g) was dissolved in boiling 
water and allowed to cool to 550c. At this temperature chromic 
potassium sulphate (0.25g) was dissolved into the solution. The 
solution was filtered into a large staining jar and the acid washed 
slides were dipped into the solution and coated in one movement. 
Slides were left to drain in a warm dry dust-free atmosphere. 
Staining slides 
Sections were stained and examined under the light 
microscope and on a light box to determine the physical condition 
of the sections and to ensure the uniformity of the sections. After 
testing a number of different fixing and staining techniques the 
following simple method was found to be suitable for staining 
sections quickly to a standard adequate for making the required 
observations. 
Solutions 10% Buffered formalin: Add NaH2P04. 
2H20 (5.2g) and Na2HP04. 12H20 (5.75g) to 40% formaldehyde 
solution (55m1s) and make up to 500mls with DDD. 
40% Formaldehyde solution: Stir 40g 
paraformaldehyde into lOOmIs DDD over heat in a fume cupboard. 
When the temperature of the mixture reaches GOOc add sodium 
hydroxide pellets until it clears. Allow the solution to cool and 
filter. 
Method Fix and defat the tissue by placing the sections 
in 10% formalin for 10 minutes, rinsing sections in DDD, dipping 
in 70% alcohol (2 seconds) and rinsing again in DDD. Stain 
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sections with Toluene Blue for 30 seconds. Wash the slides in 
running water until the water runs clear, dehydrate in Xylene and 
mount the sections with DPX (80% Xylene, BDH Ltd.). Cover the 
sections with a coverslip. 
Autoradiography using [1251] AmiK 
Rat brain and human spinal cord sections were incubated 
with [1251] 7-amino-8-iodo-ketanserin (AmiK) and a number of 
displacing drugs specific for different receptor types. AmiK has 
been reported to bind specifically to four different sites, eX 1 
adrenoceptors, 5HT2 and histamine H 1 receptors and 
tetrabenazine displaceable sites (Schotte and Leysen, 1987). By 
using a combination of displacing drugs the specific binding to 
each receptor type was investigated as described by these authors. 
The displacing drugs, the concentrations at which they were used 
and the receptors which they were used to identify are given in 
Table 4.1. The buffer used was Tris-HCI (50mM, pH 7.4, see page 
135 for further details). 
Sections were removed from the freezer and allowed to dry 
in a stream of cold air for 1 hour. The effect of pre-incubating the 
sections in buffer on the levels of specific and non-specific binding 
of AmiK to the samples was investigated by comparing (i) pre-
incubation of the sections with Tris-HCI containing 0.1% bovine 
serum albumin (BSA) and (ii) pre-incubation with Tris-HCI 
containing 1% BSA. During pre-incubation the sections were 
placed in racks in staining jars of the respective buffers for 10 
minutes. Slides were dried again in cold air. Gelatin solution 
(5%) was then melted in a water bath (370c) and used to paint a 
circle around the tissue section on the glass slide to confine the 
incubation solution. Slides were laid out flat on racks and the 
Tris-HCI containing [1251] AmiK pipetted carefully onto the tissue 
section. 
Total binding was measured by incubating sections with 
300J.11 (rat brain) or 150J.11 (human spinal cord) ofO.5nM [1251] 
AmiK (2000 Cilmmol) in Tris-HCl. Binding inhibition was 
measured by adding 0.1J.1M Prazosin or 1J.1M ofBW 501 ( N-[2-(3-
chloro-phenyl)propyl]-2-(phenylamino) ethanimidamide Bul pha te 
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Table 4.1 Drugs used to displace [1251] AmiK binding in 
the human spinal cord. 
A. Concentrations of drugs used to displace [1251] AmiK and the 
binding sites identified by them. 
Displacing drug 
Prazosin (PRZ) 
BW 501 (BW) 
Pyrilamine (PYR) 
Tetrabenazine (TBZ) 
Incubation 
coneen tra tion 
0 . 1 ~ ~
1 ~ ~
1 ~ ~
1 ~ ~
Binding site 
0( 1 adrenoceptor 
5HT2 
Histamine HI 
tetrabenazine 
displaceable site 
B. Displacing drug combinations used to identify specific sites 
Drug combination 
PYR+ TBZ + BW 
PYR + TBZ + PRZ 
TBZ+BW+PRZ 
PYR+BW+PRZ 
PYR + TBZ + BW + PRZ 
Binding site identified 
0<.1 
5HT2 
HI 
tetrabenazine 
displaeeable site 
NSB 
(The Wellcome Res. Lab. Beckenham) or the other displacing 
drugs given in Table 4.1. Binding to specific receptor sites and 
non-specific binding was determined using displacing drugs in 
different combinations. A combination of all the displacing drugs 
was used to distinguish binding which was not specific to 0< 1-
adrenoceptors, 5HT2, H1 or tetrabenazine displaceable sites 
(NSB). At least three replicates of each of the 6 combinations 
(Table 4.1B+ total binding) were used. These were incubated with 
adjacent tissue sections in such a way that the binding to each 
receptor site could be compared with NSB and total binding in a 
section that was no more than 1 0 0 ~ m d i s t a n t t in the original tissue. 
An incubation period of either 60 or 30 minutes was used. More 
Tris-Hel containing the correct drugs was added to the sections if 
the buffer appeared to be evaporating during this time. After the 
incubation period the slides were placed in racks and rinsed in 
ice-cold Tris-HCL and finally rinsed in DDD. The duration of the 
rinse periods was varied to find the optimal combination for use 
with human spinal cord tissue samples. Rinse protocols tested are 
shown in Table 4.2. The sections were allowed to dry. Dry 
sections were then opposed to photographic [125I] sensitive 
Hyperfilm (Amersham) within light-tight X-ray cassettes for a 
range of exposure times between 17 and 65 hours. Each cassette 
contained at least one replicate of each drug combination used for 
both rat and human tissue samples. Each film was also exposed to 
[1251] microscales (Amersham). The microscales are [1251] 
standards covering a radio-activity range of 0.185 - 23.68 kBq / mg 
against which the activity in the sections was determined. 
Developing the autoradiograph 
The ~ a y y cassette was opened in safelight condition (using 
light filter 6B) and the film removed. The film was placed in 
developer (Kodak D19) for 5 minutes then washed for 2-3 minutes 
in running water. The film was placed in fixer (nford Hypam 
fixer diluted 1 in 5 with distilled water) until the image had 
cleared and the excess emulsion washed away. This was followed 
by rinsing the film thoroughly in running water for 20 minutes or 
more before leaving it to dry. 
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Table 4.2 Autoradiography protocol modifications for use with human spinal cord sections 
Pre-incubation! 
incubation periods 
minutes 
10/60 
1130 
-/30 
-/ro 
1/30 
10 or 30 / 30 
Rinse time (minutes) 
lit 2nd 3rd 
15 15 
10 10 
6 6 6 
3 3 3 
5 5 5 
10 10 
glass slides tissue condition 
acid washed -50% loss of sections 
acid washed poor 
acid washed poor 
acid washed poor 
gelatin subbed improved 
gelatin subbed >90% of sections 
completely intact 
Analysis of the autoradiographic image 
A qualitative estimation of the degree of binding of [1251] 
AmiK to the different receptor sites was made by comparing by eye 
the density of the images produced. Ligand binding to a specific 
site was estimated by comparing the binding in sections incubated 
with the displacing drugs (Table 4.1) to total and non-specific 
binding. Binding to one specific site was distinguished as the 
binding remaining in the presence of drugs which displaced the 
other specific sites minus NSB. As no specific binding to 0(.1-
adrenoceptors or 5HT2 receptors was discernible in the human 
spinal cord sections quantitative analysis was not performed. 
Tissue homogenate binding using [1251] AmiK 
Ligand binding assays of [1251] AmiK binding to human 
spinal cord homogenate (prepared as described below) were 
performed. The protocol was a modification of that described below 
for [3H] ligands. The total incubation volume used was 5 0 0 ~ 1 1
comprising 4 0 0 ~ 1 1 of tissue suspension (10mg/ml), 5 0 ~ 1 1 [1251] AmiK 
(0.12 nM) and 5 0 ~ 1 1 buffer or drug. Displacing drugs used and 
their concentrations were the same as those given in Table 4.1. 
Combinations of these drugs were used so as to identify 5HT2 
receptors, cx1-adrenoceptors, tetrabenazine displaceable sites and 
NSB. 
[3H] DPAT binding to tissue sections 
Preliminary studies were undertaken to measure [3H] 
DPAT binding in human spinal cord using the autoradiographic 
methods reported by Pazos and Palacios (1985). Sections on gelatin 
subbed slides were pre-incubated for 30 minutes in 0.2 M Tris-HCL 
assay buffer, containing 10J.1M pargyline, 0.1% ascorbic acid and 
4mM CaCl. The incubation was performed using 2 nM [3H] DPAT 
in Tris assay buffer at room temperature for 60 minutes. After 
incubation the sections were washed (2 x 5 minutes) in ice-cold 
buffer. NSB was determined in sections incubated with [3H] 
DPAT and 100 JlM 5HT. The slides were then wiped with filters 
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(Whatman GFIB) which ·were subsequently placed in 10 mls of 
scintillant. Background activity was measured by wiping the 
back of a slide with a filter. Activity was counted on the liquid 
scintillation counter. This protocol was carried out both on tissue 
which had been sectioned the same day and on stored tissue. 
[3H] Idazoxan binding to tissue sections 
Similar preliminary studies of [3H] idazoxan binding were 
also made using a modification of the method employed by Young 
and Kuhar (1979) to measure ot2-adrenoceptors. Briefly, tissue 
sections were incubated with 2.5 nM [3m idazoxan in 50 mrnol 
Tris-HCL buffer pH 7.7 for 60 minutes at room temperature. They 
were washed twice (10 and 5 minutes) and then wiped with filters 
which were treated as above. Inhibition of [3H] idazoxan binding 
was determined using eleven clonidine concentrations within the 
range 10mM to 1 nM and comparisons were made between sections 
of human spinal cord and rat cortex treated in the same way. 
Calculations 
As the half-life of 1251 is relatively short (60 days) there can 
be substantial loss of activity between the dates of supply and use of 
the label. As ligand concentration is determined from its radio-
activity (cpm) and specific activity (Cilmmol) the actual activity 
on the day of assay was calculated before ligand concentration 
could be accurately determined. The activity at the time of assay 
was determined with computer assistance from the specific 
activity on the day of supply, the number of days between supply 
and use and the half-life of 125r AmiK. 
Radio ligand binding studies 
Ligands 
The ligands used and their specific activities were: 
r3H] 5HT in the form of 5 hydroxytryptamine creatine sulphate 
(0.74 - 1.48 TBqlmmol); [3H] Ketanserin (60 Cilmmol); [3H] DPAT 
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[8-hydroxy-2-(di-n-propylamino) tetralin, 2.6 - 4.1 TBq/mmol]; 
and [3H] Idazoxan (manufacturers name: RX 781094, 1.5 - 2.2 
TBq/mmol). Ligand binding assays were performed to determine 
(i) that the ligands were binding to a finite number of sites and that 
the binding was therefore saturable (ii) that binding was 
reversible and could be displaced (iii) the affinities of the ligands 
for the binding site and (iv) the number of receptor sites per unit 
tissue. 
Preparation for studies using tissue homogenate 
Rat brain dissection 
Male wistar rats (250g) were killed by decapitation after 
stunning. The skull was cut open and the whole brain removed 
onto a cooled metal surface. The olfactory bulb was discarded and 
the frontal cortex dissected as shown in Figure 4.1. The 
remaining cortex comprising the parietal and striate regions was 
also removed. The tissue was weighed and stored at -20oc in 
sealed eppendorf tubes. 
Human brain and spinal cord dissection 
Brain and spinal cord tissue was obtained from the 
Cambridge Brain Bank, the Parkinson's Disease Society Brain 
Bank and Nottingham University Hospital. Tissue was taken 
from 4 female and 6 male control subjects with no history of 
neurological illness who had died from either respiratory or 
cardiac failure with one exception who died after a road traffic 
accident. The mean age and interval between death and post-
mortem were 68.9 ± 4.4 years and 31.5 ± 5.7 hours respectively 
(mean ± SEM, n=10). Brains from control subjects were removed 
from the skull at autopsy, transfered to a -200c freezer for 4 - 5 hours 
and then stored long term at -80oc. Samples of the frontal cortex 
were dissected from the brain on a cooled tray, weighed and used 
in binding studies the same day. The spinal cord was removed, 
dissected into thoracic and lumbar regions and stored frozen as 
described in chapter 3 (pp. 94-95). On the day of the binding assay 
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spinal cord tissue was dissected into 5mm slices and in some cases 
into dorsal and ventral regions comprising 2mm punches of the 
gray matter as illustrated in Fig 3.1b in the previous chapter. 
Tissue was weighed and combined from adjacent sections so that 
samples of -lg were used in binding assays. 
Membrane Preparation 
The methods used for tissue membrane preparation were 
modifications of that described by Hamon et. al. (1984). Tissue 
was homogenized in 50 volumes of ice cold buffer using a Polytron 
(setting 5, 20 seconds), followed by centrifugation at 4,POOg for 15 
minutes at 40 c. Supernatant was removed and the pellet was 
resuspended in buffer, homogenized and centrifuged twice more 
as above. Samples were kept on ice as far as possible. For [3R] 
5HT, Ketanserin and DPAT binding the tissue suspension was 
incubated at 370c for 15 minutes in buffer before the final spin to 
remove endogenous 5HT. After the third spin supernatant was 
discarded and the pellet was resuspended in 70 (5HT binding) or 
100 (adrenoceptor binding) volumes of assay buffer of specific 
composition depending on the ligand binding assay. For human 
tissue biohazard precautions were taken (Appendix 2), in 
particular centrifugation was carried out in sealed tubes and 
supernatant was aspirated into chloros solution in the 
microbiological hood. 
Assay protocols 
The assays were based on the general ligand binding 
protocol described by Peroutka and Snyder (1979). 
(1) [3H] 5HT and [3H] ketanserin 
Briefly, this assay was initiated by addition of 8 5 0 ~ 1 1 of tissue 
suspension to tubes containing 5 0 ~ 1 1 [3H] ligand and 1 0 0 ~ 1 1 of drugs 
or assay buffer. Tubes were vortex mixed and incubated for 15 
minutes at 370c. For the ketanserin binding assay incubation 
time was 10 minutes. 
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Buffers: Membrane preparation: Tris-HCL buffer - 50mM Tris 
(tris [hydroxymethyl] amino methane) hydrochloride made with 
DDD, pH 7.5. Assay buffer: lOOmIs 50mM Tris-HCL buffer, 1 0 ~ M M
pargyline (mono amine oxidaze inhibitor), 0.1% (wt/vol) ascorbic 
acid (antioxidant) and 4mM CaCl2 adjusted to pH 8.0. The pH of 
Tris buffer is temperature dependent and a pH of 8.0 obtained at 
room temperature will give pH 7.5 at 370 c. 
(2) [3H] DPAT binding 
In this assay the volumes of tissue suspension and drugs 
were taken from a paper by Middlemiss and Fozard (1983). Tissue 
homogenate (0.7 ml), [3H] DPAT (0.1 mn and the competing drug 
(0.1 ml) made up to a final volume of lml with assay buffer were 
incubated at 370 c for 15 minutes. 
Buffers: Membrane preparation: 50 mM Tris-HCL, pH. 7.7. 
Assay buffer: Binding was compared using two buffers (i) 50mM 
Tris-HCL pH. 7.7 and (ii) Tris-SALT - 50mM Tris-HCL pH. 7.7 
containing 1 0 ~ M M pargyline, 0.1% ascorbic acid and 4mM CaC12. 
(3) [3H] Idazoxan binding 
Modifications were taken from a report by Giron and co-
workers (1985). A total assay volume of L1ml was used 
comprising 1m! of resuspended tissue, 5 0 ~ 1 1 of [3H] ligand and 5 0 ~ 1 1
of drug or assay buffer. After addition of the tissue the tubes were 
vortex mixed and incubated for 30 minutes at 250c. 
Membrane preparation and assay buffer: 50mM Tris-HCL, pH 
7.7. 
The tissue concentration for all assays was approximately 
10mg/ml. 
After the incubation period bound and free ligand were 
separated by filtering the suspension under vacuum through 
Whatman GBIF filters. The filtration block had 10 wells, in each 
of which a filter was supported by a metal mesh. Filters were 
washed with 3 x 3mls ice-cold Tris-HCL buffer. Filters were 
transferred to scintillation vials containing 10mls of scintillant 
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(LKB Optiphase 'X') and allowed to soak for at least 5 hours. The 
amount of bound ligand was measured by scintillation counting 
on a liquid scintillation counter (LKB 1214 Rackbeta) at -40% 
counting efficiency. Radio-activity in standards containing 
ligand only in the absence of tissue suspension was measured to 
determine the exact concentrations of ligand used in each assay. 
In competition studies one concentration of [3H] ligand was 
incubated with a range of concentrations of an unlabelled drug 
which competed for the same binding site. Displacing drug and 
[3H] ligand concentrations used are given in Table 4.3A. Non-
specific binding (NSB) of the ligands was determined in the 
presence of drugs at the concentrations given in Table 4.3A. Total 
binding was determined from tubes containing ligand and buffer 
in the absence of the competing drug. 
In saturation studies a range of [3H] ligand concentrations 
was used. Total and non-specific binding at each ligand 
concentration were determined using respectively either buffer or 
the drug used to define non-specific binding at the concentration 
described above. The concentrations of [3H] ligand and 
displacing drugs used in saturation studies are given in Table 
4.3B. For competition and saturation studies there were 3 
replicates of each tube per assay and each assay was performed in 
triplicate. 
Protein content of the tissue was determined by the method of 
Lowry et. a1.,1951 (Appendix 1). 
Studies undertaken 
Using the protocols outlined above a number of studies of 
ligand binding to serotonergic sites and ct2-adrenergic sites in rat 
and human cortex and human spinal cord tissues were made. 
(i) Ketanserin binding in fresh and frozen rat cortical 
tissues. Specific [3H] ketanserin binding was compared in rat 
brain tissue which had been freshly dissected without storage and 
in tissue dissected and stored for 24 hours at -20oc. 
(ii) Ligand binding to a heterogeneous population of 5HT1 
receptors was demonstrated by displacing [3H] 5HT binding in rat 
cortex with DPAT. 
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Table 4.3 Details of [3H] ligands and displacing drugs used in binding assays. 
A. Competition assays 
[3H] Ligand 
Assay [ ] (nM) 
Displacing drug (1) 
Drug [ ] range (M) 
Displacing drug (2) 
Drug [ ] range (M) 
NSB: Displacing drug 
Drug[]M 
B. Saturation assays 
[3H]Ligand 
[ ] range (nM) 
NSB: Displacing drug 
Drug[]M 
[ ] = concentration 
5HT 
2 
DPAT 
10-4 -10-10 
5HT 
10-6 
DPAT 
0.2 -10 
5HT 
10-5 
DPAT 
1 
5HT 
10-4 -10-10 
5HT 
10-5 
Idazoxan 
0.3 -20 
clonidine 
10--5 
Idazoxan 
4 
clonidine 
10-4 -10-10 
idazoxan 
10-4 - 10-9 
clonidine 
10-0 
Ketanserin 
1 
methysergide 
10-5 -10-8 
methysergide 
lo-t> 
(iii) The number of receptor sites for [3H] DPAT and [3H] 
idazoxan and the affinities of the ligands to their receptor sites in 
rat cortex were determined from competition and saturation 
studies and the values obtained were compared with previously 
published data. 
(iv) [3R] Ketanserin, [3R] 5HT, [3R] DPAT and [3R] 
idazoxan binding were performed in human thoracic spinal cord 
tissue. 
(v) Synaptosomal Preparation: An attempt was made to 
reduce the level of N8B observed in crude homogenate by using a 
synaptosomal preparation of the tissue: 
Rat cortex (500mg or 19) and human spinal cord (lg) were 
homogenized in 3.2M sucrose (10 mIs) and centrifuged for 10 
minutes (lOOOg, 40 c). The first supernatant (Sl) was collected and 
the pellet (PI) discarded. Sl was centrifuged at 20,000g for 20 
minutes (40 c), 82 was discarded and 10mls of cold DDD added to 
P2. The pellet was homogenized for 30 seconds (Polytron, setting 
6) to disrupt the synaptosomes. The volume was made up to 15 mls 
with cold double distilled deionised water (DDD) and the 
suspension spun at 8,000 g for 20 minutes (40 c). Centrifuge tubes 
were shaken to disperse the buffy coat surrounding P3 and then S3 
and the buffy coat were collected and centrifuged at 48,000g (10 
minutes, 40 c). After discarding P3 and 84 10mls DDD were added 
to P4 which was homogenized further (Polytron, 30 seconds). To 
break the pellets down the volume was made up to 20 mls and they 
were centrifuged at 48,000g for 10 minutes (40 c). Finally the 
supernatant (85) was disposed of and the pellet retained and stored 
overnight at - 200c. 
(vi) To see whether the N8B of[3H] idazoxan to human 
spinal cord tissue was dependent on the concentration of 
displacing drug a saturation binding assay was performed using 
boiled tissue. Tissue homogenate prepared in the usual way was 
boiled for 5 minutes, allowed to cool and assayed according to the 
method generally used. 
(vii) To maximize the use of the human spinal cord tissue 
an investigation was made into the effect on [3H] idazoxan 
binding of reducing the amount of tissue per assay tube. [3H] 
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displacement was performed using 5 mg/ml and the standard 
concentration of 10 mg/ml of rat cortical membranes. 
Data analysis 
In order to analyse the results of the competition and 
saturation studies a number of assumptions were made regarding 
the kinetics of the interactions between the ligands and the 
receptors sites at which they bind. Reversible ligand receptor 
interactions were assumed to follow kinetics similar to the well 
established interactions between enzymes and their substrates as 
described here: 
For reversible ligand-receptor interactions where [R] = 
concentration of unoccupied receptor sites, [L] = concentration of 
free ligand and [RL] = concentration of receptor-ligand complex 
k1 
----=:::::. 
-=:::-a[R] + b[L] c[RL] [1] 
k.1 
is a description of binding phenomena with a, band c representing 
the stoichiometry of the reaction. At equilibrium the rate of the 
forward reaction equals the rate of the reverse reaction 
and the equilibrium binding constant can be defined as a 
dissociation binding constant (Kn) 
k.1 [R]a [L]b 
Kn= -----
k1 [RL]C 
[3] 
or as the association constant (KA) which is the inverse of Kn' 
[2] 
It was also assumed that there were a finite number of 
specific sites per unit of tissue for ligand binding and therefore 
that the binding was saturable. This maximum number of specific 
receptor sites is generally described as Bmax. 
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Bmax = [RL] + [R] 
From equation [3] and [4] and assuming a = b = c = 1 
Bmax[L] 
[RL]= ---
[L]+Kn 
which is the law of mass action adapted to receptor-ligand 
interactions. 
[4] 
[5] 
By defining RL as bound ligand = B, and L as free ligand = 
F and after rearrangement of equation [5] 
Bmax- B 
BIF = 
Kn 
which is the Scatchard (Scatchard, 1949) equation. From this 
equation and knowing the concentration of ligand bound and free 
at equilibrium both the equilibrium binding constant (Kn) and the 
maximum number of binding sites (Bmax) can be detennined (see 
below). 
Inhibition curves were constructed from the data obtained 
from competition studies as follows. Binding at each drug 
concentration was determined as the ratio of binding in the 
presence of drug to total binding (in the absence of drug) and 
expressed as % total binding. These ~ a l u e s s were plotted against 
-log. drug concentration as illustrated in Fig 4.3B. Non-specific 
binding (NSB) was determined as the proportion of total binding 
remaining at maximum binding inhibition. Specific binding 
was defined as binding minus NSB (FigA.3A) and Bmax was 
calculated as total binding minus non-specific binding. Where 
the cold (displacing) and labelled ligand are the same their Kn is 
defined as the 1C50 (the concentration of unlabelled ligand at 
which the maximum binding of labelled ligand is displaced by 
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50%). Estimations of the affinity of the displacing drug for the site 
labelled by the radio-active ligand were obtained in the form of the 
inhibition constant (Ki) from 
IC50 
Ki= (Cheng and Prusoff, 1973) 
1 + [L]/Kn 
Saturation curves were produced using data obtained in 
saturation kinetic studies. Specific binding was plotted against 
ligand concentration as illustrated in Fig.4.4A. 
The equilibrium binding constants of the ligand-receptor 
interactions and the maximum number of binding sites for each 
ligand were determined using Scatchard and Hill analysis of the 
data. The analyses were performed using LIGAND which is a 
computer package developed by Munson and Rodbard (1980) for 
characterizing the results of ligand binding studies. (This 
program, its approach, uses and versatility are discussed in the 
chapter 5, pp.165-166 & 176). 
Scatchard analysis 
Scatchard plots were constructed by plotting bound ligand 
(B) against the ratio of bound / free ligand (BIF). Bound ligand 
was measured directly as described above and free ligand was 
calculated as the difference between the amount of ligand added 
(determined from standards) and the amount of ligand bound. A 
straight line indicates binding to one receptor site. Using 
LIGAND a weighted least squares estimate of the line of best fit 
was fitted to the the data and a correlation coefficient for the fit of 
the data to the line was obtained. A typical Scatchard plot is 
illustrated in Fig. 4.4B using data obtaining from idazoxan 
binding in rat cortical membranes. Kn was estimated as the 
negative reciprocal of the slope of the line. Bmax was estimated by 
the abscissa intercept of the line. 
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Hill Plots 
From Scatchard plots values for KD and Bmax were 
estimated assuming that the ligand-receptor interaction followed 
the law of mass action i.e that the ligand was specifically binding 
to one receptor site. Hill plots were then used to evaluate the 
validity of this assumption. 
The Hill equation is 
B [L]n 
-- = 
Bmax K'D+ [L]n 
where K'n is a composite constant composed of the dissociation 
constant and interaction factors that determine the degree to which 
KD is altered at each binding step and n is the theoretical number 
of ligand binding sites per receptor molecule. When n = 1 the 
ligand binding obeys the law of mass action and the Hill plot is a 
straight line with a slope of unity. Ligand binding data was fitted 
to the Hill equation using LIGAND by plotting 10g.B / Bmax - B 
against 10g.[L] where B is specific binding. A plot with a slope of 
approximately 1 was considered to be representative of a system in 
which the ligand was specifically bound to one receptor site. 
Precautions for the use of biohazard material 
Precautions as set out in Appendix 2 were taken while 
applying the methods described above to human spinal cord tissue. 
Collaboration 
The autoradiography using [1251] AmiK was carried out in 
collaboration with Jose Leysen and Alain Schotte at Janssen, 
Belgium. 
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Drugs 
[1251] 7 -amino-8-iodo-ketanserin (AmiK), ketanserin, 
prazosin, BW 501, pyrilamine and tetrabenazine were obtained 
from and used at Janssen Pharmaceutical, Belgium. [3H] 5 
hydroxytryptamine creatine sulphate, [3H] DPAT [8-hydroxy-2-
(di-n-propylamino)tetralin and [3H] 1dazoxan (RX 781094) were 
obtained from Amersham. 
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Results 
Autoradiography 
[1251] AmiK studies 
Protocol modifications for use with human spinal cord material 
Applying the assay conditions used to measure [1251] AmiK 
binding in rat brain sections (Schotte and Leysen, 1988) to human 
spinal cord tissue resulted in gross deterioration of the tissue 
sections. The incubation and pre-incubation periods were 
therefore reduced from 60 to 30 minutes and from 10 minutes to 1 
minute respectively. Even after these adaptations and after 
cutting the rinse protocol to a minimum, part or all of the the tissue 
sections were washed off the slides in contrast to the rat brain 
sections which were 100% intact under the same conditions. 
However a great improvement in maintaining the condition of the 
tissue was made by mounting the sections on gelatin subbed slides. 
U sing subbed slides the tissue sections were completely preserved 
in over 90% of the samples after 30 and 10 minute incubation and 
pre-incubation periods followed by two rinse intervals of ten 
minutes each as described in Table 4.2. 
Binding in rat brain and spinal cord 
In horizontal slices of the rat brain [1251] AmiK binding 
could be seen in the cortex, caudate putamen, lateral septal nuclei, 
periaquaductal gray-matter and various thalamic nuclei (Fig. 
4.6A). Non-specific binding visualised using JlM tetrabenazine 
(TBZ), JlM pyrilamine (PYR) , IlM BW501 (BW) and O.lJlM 
prazosine (PRZ) produced a uniform grey coloration with a 
slightly darker pigmentation in the caudate putamen (Fig.4.6B). 
Inhibition by TBZ, PYR and PRZ revealed 5HT2 binding sites in 
the cortex and in the caudate putamen and not in the thalamic 
nuclei when compared with NSB as shown in figure 4.6F. 5HT2 
binding in the cortex is shown clearly in sagittal section of the 
brain (Fig.4. 7 A). Inhibition by the other combinations of these 
drugs (out-lined in Table 4.1B) revealed (a) dense ~ l - a d r e n o c e p t o r r
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binding in the thalamic nuclei and cortex (Fig. 4.6C and 4.7B) and 
(b) very dense labelling of tetrabenazine displaceable sites in the 
caudate putamen and periaqueductal gray and distinct but less 
dense labelling in the lateral septal nuclei (Fig.4.6E). 
The distribution and intensity of binding to these sites was 
unaffected by substituting the pre-incubation protocol by 1 hour 
incubation in Tris-HCI buffer containing 1% BSA. 
[125\] AmiK Binding in human spinal cord 
The images of the autoradiographs developed after 24 hour 
exposure to human spinal cord sections labelled with [1251] AmiK 
were very weak. The images were a little darker but no clearer 
after 28 (not shown) or 65 hour (Fig. 4.8A-F) exposure periods. 
Total [1251] AmiK binding demonstrated the highest density of 
binding in the gray matter, especially in the ventral horns. There 
was little or no inhibition of binding in the gray matter by PRZ, 
PYR or BW (not shown). Using combinations of these drugs the 
only binding site indicated in the human cord was for a small 
degree of [1251] AmiK binding to tetrabenazine displaceable sites 
in the gray matter (Fig. 4.8E). These results were unchanged by 
using a 1 hour pre-incubation period in Tris-HCI buffer 
containing 1% BSA. 
[3H] DPAT and [3H] idazoxan binding to human spinal cord sections 
There was no 5HT displaceable [3H] DPAT binding in 
sections of human spinal cord incubated with 2nM [3H] DPAT 
which was detectable by scintillation counting of filters used to 
wipe the slides. Similarly, there was no consistent displacement 
of [3H] idazoxan binding by clonidine both for sections incubated 
with [3H] ligand on the day the sections were cut Or after storage of 
sections at -80oc for a period of less than 3 weeks. On occasions 
saturable idazoxan binding and NSB of 50% of total binding was 
demonstrable. However, this was not reproducible and on other 
occasions under the same conditions there was no measurable 
specific binding. In contrast, there was a concentration dependent 
inhibition of [3H] idazoxan binding by clonidine in rat brain 
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sections processed simultaneously in the same manner as shown 
in Fig. 4.9. 
In summary, autoradiography was performed to determine 
oI...1-adrenoceptor and 5HT2 binding in the human spinal cord using 
[125I] AmiK Autoradiography of [125I] AmiK binding in the rat 
brain was performed simultaneously to validate the protocol. 
However, <X 1-adrenoceptor and 5HT2 binding was demonstrated 
in the rat brain but not in the human spinal cord. In addition, 
preliminary studies were made to determine the optimal 
conditions for autoradiography of [3H] DPAT and [3H] idazoxan 
in the human spinal cord. As no consistent specific [3H] DPAT or 
[3H] idazoxan binding could be measured it was decided to 
continue the investigation of adrenergic and serotonergic binding 
in the human spinal cord using radio-ligand binding studies. 
Radio-ligand binding studies 
[3H] Ketanserin: 5HT 2 binding 
Specific [3H] ketanserin binding displaceable by 
methysergide was demonstrated in the rat cortex (Table 4.4 ). 
There was 16.5% less specific binding measurable in frozen 
compared with freshly dissected rat frontal cortex although there 
was no significant difference in %NSB (p < 0.5, n = 3) as shown in 
Table 4.4. 
There was also measurable specific [3m ketanserin 
binding in frontal cortex tissue from 2 human subjects. 
Maximum specific binding and NSB were at a similar level to that 
in the rat (Table 4.4). However there was no measurable 
methysergide displaceable [3H] ketanserin binding in either 
ventral or dorsal hom tissue from the thoracic spinal cord of 4 
human subjects. 
[3H] 5HT: 5HT 1 binding in rat cortex 
Displacement of [3m 5HT binding by DPAT in rat frontal 
cortical tissue was shallow occurring over the range 1nM to 10mM 
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Table 4.4 [3H] Ketanserin binding in tissue homogenate 
preparations 
Tissue Prep. n Bmax %NSB 
(fmols/mg ww) 
Rat frontal cortex 3 5.56:tO.04 53±5 
(Fresh) 
Rat frontal cortex 3 4.64±o.21 55....+2 
(Frozen) 
Human frontal cortex 2 4.40±o.30 51f"4 
Human spinal cord 
dorsal horn 4 >90 
ventral horn 4 >90 
NSB was defined by [3H] Ketanserin binding in the presence of 
~ M M methysergide. Specific binding (Bmax) was determined as the 
difference between total binding in the absence of methysergide 
and non-specific binding and is expressed as wet weight (ww) of 
tissue. 
(Fig. 4.5). DPAT at a concentration of 100nM, reported to produce 
displacement of the 5HT1A binding site CGozlan et. a1.,1983; 
Middlemiss and Fozard, 1983; Petrouka et. al 1986; Heuring et. 
al., 1986) displaced 21.7± 3% of binding. Micromolar 5HT 
produced 59.5±3% inhibition indicating a level of non-specific 
binding of 40%. Values are expressed as mean ± SEM from three 
experiments. 
[3H] 5HT binding in human cortical and spinal cord tissue 
In human frontal cortical tissue DPAT displacement of [3H] 
SRT binding closely resembled that seen in tissue from the same 
region of the rat eNS. Displacement of [3H] 5HT was shallow over 
the range 1 to 10,000 nM. Binding inhibition with 100nM DPAT 
was 16±3% and NSB measured in the presence of J.lM 5HT was 
43.5±2% (mean±SEM, n = 2). However, in contrast, in human 
spinal cord tissue 100nM DPAT produced no inhibition of [3R] SRT 
binding and NSB was very high (BB.S± 2%, mean±SEM, n = 4). 
[3H] DPAT binding in rat cortex: effects of different buffers 
There were marked differences in the characteristics of [3H] 
DPAT binding to membranes of the rat frontal cortex determined 
using Tris-HCL buffer and Tris-SALT buffer (containing 5.7mM 
CaC12, 0.1% ascorbic acid and 10J.1M pargyline). Using Tris-HCL 
[3R] DPAT binding was inhibited by 1nM through to 10J.1M 5HT 
whereas with Tris-SALT the displacement curve was steeper with 
90% displacement of total binding at O.lJ.lM 5HT. Specific binding 
was saturable in both cases but in the presence of pargyline, 
ascorbic acid and CaCl2 both the affinity of the ligand and the total 
number of binding sites obtained from Scatchard analysis of the 
data were lower than in Tris-HCL (Table 4.SA). However, the Hill 
plots of the data obtained in the presence of the added compounds 
were closer to unity than they were using Tris-HCL alone. KD , 
Bmax and the gradients of the Hill plots obtained using the two 
buffers are given in Table 4.5A 
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Table 4.5 [3H] DPAT binding in rat cortex 
A. Effects of different buffers 
[3H] DPAT binding to membranes of the rat frontal cortex 
determined using Tris-HCL buffer and Tris-SALT buffer 
(containing 5.7mM CaCI2, 0.1% ascorbic acid and 10J.1M 
pargyline). 
Buffer KD (nM) Bmax (fmols/mg ww) Hill slope 
Tris-HCL 0.96 + 0.06 
Tris-SALT 2.24 + 0.06 
B. Comparison of results 
75i"5 
4Of4.0 
1.15 ± 0.02 
0.97 ± 0.02 
The KD (nM) and Bmax (finols fmg tissue) values for [3H] DPAT 
binding in rat cortical tissue obtained in this study are compared 
with previously published data. Specific binding was defined in 
the presence of 5HT except for * where it was defined in the 
presence of DPAT. In all cases binding was performed in Tris-
HCL containing 4-6 mM CaC12, 0.1% ascorbic acid with or without 
0.1 J,lM pargyline. 
Author Rat tissue KD pKD Bmax 
This study frontal cortex 2.24±o.06 8.52 4O:t4 
Hoyer et a1. cortex 8.77±o.05 132±18 
1935 
Peroutka, frontal cortex 2.2±0.5 *3.3 
~ ~
[3H] DPAT binding in human spinal cord 
There were only a very low levels of [3H] DP AT binding in 
human spinal cord determined using Tris-SAL T buffer and this 
was not inhibited by 11M 5HT and was therefore considered to be 
non-specific binding. 
[1251] AmiK binding to tissue homogenate preparation 
In a study of [1251] AmiK binding to a homogenate 
preparation of human spinal cord samples there was no 
displacement of binding by PRZ, BW or by TBZ or by these drugs 
used in various combinations to define 0'-1. SHT2 or tetrabenazine 
displaceable sites. 
[3H] Idazoxan binding in rat cortex 
Unlabelled idazoxan produced approximately 90% 
inhibition of [3H] idazoxan binding to rat cortical membranes 
(Fig.4.3B). The KD of Idazoxan binding in this tissue calculated 
from the IC50 as described in the methods was 4.5 ± 0.7 nM (n = 4) 
compared with previously published values of 3.1 ± 0.4 and 4.0 + 0.8 
( Doxey, 1982; Howlett,1982). Specific binding as determined by 
10llM clonidine (Fig.4.3A) was 70-75% of total binding which is in 
agreement with reported data (McLaughlin and Collins, 1986). 
However the 1C50 and Ki values for clonidine inhibition were 18.0 
± 2, and 11.6 ± 2nM respectively which is rather lower than 
reported. Langer and co-workers (1983) and McLaughlin and 
Collins (1986) found IC50 and Ki values for clonidine inhibition of 
[3H] idazoxan binding in rat cortex of 80nM and 5S.9 nM 
respectively. Typical competition curves for c10nidine and 
idazoxan displacement of [3H] idazoxan binding in rat cortex are 
given in Fig.s 4.3A &4.3B. [3H] Idazoxan binding was found to be 
saturable (Fig.4.4A) and of high affinity. The KD and Bmax 
determined from Scatchard analysis of the saturation study 
(Fig.4.4B) are given in Table 4.6 with data from other comparable 
studies using [3H] idazoxan to label 0( 2-adrenoceptor sites. The 
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Fig. 4.3 [3H] Idazoxan inhibition curves 
100 
-
80 ~ ~0 
......... 
C> 
c: 60 
:0 
c: 
:c 
(.) 40 
:;::::: 
'(3 
Q) 
c. 20 CJ) 
0 
10 9 B 7 6 5 
-log. [clonidine] M 
A. Inhibition of specific [3H] Idazoxan binding in rat cortical 
membranes by clonidine. The data is from a typical experiment. Various 
concentrations of clonidine were incubated in triplicate with 2.2 nM [3H] 
Idazoxan. Non-specific binding defined by 10 J,.LM clonidine was 28% of total 
binding and has been subtracted to determine specific binding. Binding is 
expressed as a % of maximum binding in the absence of clonidine. The Ki 
calculated from the IC50 as described by Cheng and Prusoff (1973) was 16.7 nM. 
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B. Inhibition of total [3H] Idazoxan binding in rat cortical 
membranes by unlabelled idazoxan. The data is from a typical 
experiment. Various concentrations of idazoxan were incubated in triplicate 
with 2nM [3H]idazoxan. Binding is expressed as a % of maximum binding in 
the absence of Idazoxan and non-specific binding defined by 10 ~ ~ Idazoxan 
was 14% of total binding. 
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Fig. 4.4 Specific binding of [3H] Idazoxan binding to rat cortical 
membranes. 
The data is from a typical experiment and each point is the mean of 
a triplicate measurement. NSB was defined by 10 ~ ~ clonidine 
(A) Saturation binding curve. (B) Scatchard plot of the data. The 
line of the plot is a linear regression determined by a least squares 
fit (r= -0.999). Kn and Bmax calculated from the plot were 2.1 nM 
and 483 fmols/mg protein. 
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Fig. 4.4 Specific binding of [3H] Idazoxan binding to rat cortical 
membranes. 
(C) A Hill plot of the same data. Log. B / Bmax - B is plotted 
against log. of Idazoxan concentration where B is the specific 
binding. The gradient of the line is near unity (+0.98) which is 
indicative of binding to a single site. 
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Fig.4.5 [3H] 5HT inhibition curve 
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Inhibition of total [3H] 5HT binding in membrane homogenate of 
rat frontal cortex. The data is from a typical experiment. Various 
concentrations of DP AT were incubated in triplicate with 2nM [3H] 
5HT. The shallowness of the displacement is indicative of binding 
to more than one site. 5HTlA binding defined by lOOnM DPAT 
was 25% of total binding. 
Table 4.6 [3H] Idazoxan binding in the rat cortex 
[3H] Idazoxan binding in the rat cortex determined in ligand 
binding studies: a comparison between the results of this and 
earlier studies. In this study NSB was determined by lOIlM 
clonidine and n=4. KD is expressed in nM and Bmax in fmols / 
mg protein. 
Author Rat tissue KD Bmax 
This study cortex 2.79±O.29 361 ±42 
Mclaughlin and olfactory cortex 5.71:tO.42 25l±8 
Collins, 1986 
Langer et.al 1983 cortex 3.9±O.4 19O±13 
Howlett et. al brain minus 2.8±0.2 230±14 
1982 cerebellum 
Table 4.7 Effect of reduced tissue concentration on [3H] 
Idazoxan binding 
Specific [3H] idazoxan binding measured in rat cortex using two 
concentrations (10 and 5 mglml) of tissue homogenate. There was 
a significant difference in both Bmax and non-specific binding 
(*p<0.05). 
Tissue concentration Bmax (fmols/mg ww) 
10 mglml 5.Q t 0.3 
5 mglml *3.6 ± 0.2 
%NSB 
29±4 
*52±3 
Hill plot of the data was linear (Fig.4.4C) with a gradient near 
unity (0.97+0.02). 
Effect of reduced tissue concentration on [3H] idazoxan binding 
Specific [3H] idazoxan binding was measured in rat cortex 
using two tissue concentrations. Bmax was significantly lower 
(p <0.05, n=3) when the assay tissue concentration was reduced 
from 10 to 5 mg/ml (Table 4.7). Moreover, NSB defined by 1 0 ~ ~
clonidine was significantly greater (p<0.5, n=3) with the lower 
tissue concentration (Table 4.7). 
[3H] Idazoxan binding in human spinal cord 
In initial competition studies of [3H] idazoxan binding to 
human thoracic spinal cord membranes cold idazoxan produced 
80-85% inhibition at 11M concentrations comparable with 
displacement in rat cortex. However, the inhibition by clonidine 
was markedly less and NSB defined by 10JlM clonidine was 
approximately 60% of total binding. Binding to boiled tissue was 
independent of the concentration of clonidine which indicated that 
although the level ofNSB was high it was consistent. The KD 
determined from inhibition curves using unlabelled idazoxan 
was 5.0±0.3 nM (n = 3). The Ki values for clonidine measured in 
two human spinal cords were 523 and 230 nM. On the basis of these 
preliminary results further [3H] idazoxan binding was performed 
in human spinal cord which is described fully in chapter 5. 
Synaptosomal preparation. 
Initially the same wet weight of tissue as generally used for 
the tissue homogenate preparation was used in the protocol for the 
synaptosomal preparation. The final membrane pellet produced 
was smaller than the pellet produced after tissue homogenate 
preparation. M o r e ~ o v e r , , total [3H] idazoxan binding was lower in 
synaptosomal preparations of both rat cortex and the human spinal 
cord. In [3H] idazoxan competition binding studies total [3H] 
idazoxan binding to the synaptosomal preparation was 0.2 - 0.3 
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fold that to homogenate preparations of equivalent initial weight of 
tissue. Furthermore, there was very little or no inhibition of [3H] 
idazoxan binding by c1onidine. The inhibition of total binding by 
unlabelled idazoxan (100 ~ M ) ) was also reduced from 
approximately 85% to 60%. By increasing the initial mass of tissue 
used by approximately 2 fold some inhibition of [3H] idazoxan 
binding by clonidine was seen (30 - 40%) but this did not attain the 
level normally reached using the homogenate preparation for 
either rat or human tissue. 
In summary, 5HTIA and 5HT2 receptors have been 
demonstrated in the rat and human cortex in ligand binding 
studies using [3H] DPAT and [3H] ketanserin. Furthermore, 0(2-
adrenoceptors have been demonstrated in the rat brain using [3H] 
idazoxan. Although attempts to measure 5HTIA, 5HT2 and ex 2-
adrenoceptor binding in the human spinal cord with [3H] DPAT, 
[3H] ketanserin and [125n AmiK were unsuccessful, displaceable, 
high affinity [3H] idazoxan binding was identified in this tissue. 
Additionally, the effects of a number of modifications to the ligand 
binding protocol were investigated. 
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FIG. 4.6 [1 251] AmiK binding to rat horizontal brain sections 
These autoradiographs show: total binding (A), NSB (B) and binding to tx-ladrenoceptors (C), histamine-HI receptors (D), 
tetrabenazine displaceable sites (E) and 5HT2 receptors (F). 
These sites were distinguished using the following combinations of displacing drugs: l ~ ~ tetrabenazine, O.lIlM 
prazosine, 111M BW 501 and 1J1.M pyrilamine (B), 
1 ~ ~ tetrabenazine, 1 ~ ~ BW 501 and 1 ~ ~ pyrilamine (C), 
IJ.LM tetrabenazine, 0 . 1 ~ ~ prazosine and 1 ~ ~ BW 501 CD), 
0.1J.1M prazosine, 1 ~ ~ BW 501 and 111M pyrilamine (E) 
111M tetrabenazine, 0.1J1.M prazosine, and 1J1.M pyrilamine (F). 
A 
B 
FIG. 4.7 [12SI]AmiK binding to rat sagittal brain sections 
[1251] AmiK binding to (A) 5HT2 receptor sites and (B) eX 1-
adrenoceptor sites in the cortex is more easily visualised using 
sagittal sections of the rat brain; 5HT2 receptor sites were 
demonstrated in the presence of l ~ M M tetrabenazine, o. ~ M M
prazosine, and l ~ M M pyrilamine; 0( l-adrenoceptor sites w r 
demonstrated in the presence of l ~ M M tetrabenazine, l ~ M M BW 501 
and l ~ M M pyrilamine 
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Fig. 4.8 [1251]AmiK binding to sections of human thoracic spinal cord. 
[125l]AmiK binding was performed in the presence of the same combinations of displacing drugs as described in the legend 
of FigA.6 to distinguish total binding (A); NSB (B); and binding to 5HT2 receptors (C); histamine HI receptors CD); 
tetrabenazine displaceable sites (E) and Q(.ladrenoceptors (F). In this autoradiograph the sections had been exposed to [125I] 
sensitive film for 65 hours. 
Fig. 4.9 [3H] Idazoxan inhibition in sections of rat brain and human 
spinal cord. 
Competition between [3H] Idazoxan and clonidine for receptor sites 
in sections of human spinal cord (+) and rat brain (El) on glass 
slides. Each point is the mean of triplicate measurements. 
Sections were incubated with 4 nM [3H] Idazoxan and a range of 
clonidine concentrations. Bound [3H] Idazoxan was determined 
by wiping the slides with filter paper and measuring the activity by 
scintillation counting. The results found using human cord 
sections were not consistent and in this case there was no 
measurable specific binding 
Discussion 
This chapter describes in vitro studies of adrenergic and 
serotonergic binding in post-mortem control human spinal cord 
tissue. Because of the limited supply of human cord tissue available 
and in order to prove the reliability of the methods all protocols were 
initially or simultaneously performed using rat brain tissue. The 
binding characteristics of the ligands used in these methods have 
previously been documented by other authors as described in the 
introduction. In general the results obtained in the rat and human 
brain with respect to receptor numbers and distribution and binding 
affinities were in close accordance with earlier reports. However, 
there were a number of major difficulties in determining the same 
parameters in the human spinal cord and these will be discussed 
here. 
Autoradiography 
Consideration of the protocol 
Autoradiography is a useful technique for receptor location. It 
is very appropriate for investigating the distribution of receptors 
throughout a number of different regions, for example through the 
whole of one section of the rat brain. The area of tissue which can be 
investigated is limited mainly by the practical problems of cutting 
large sections on the cryostat (of human brain, for instance) and 
mounting them in one piece on glass slides. It is important not to 
have holes or tears in the tissue section where ligand may collect as 
these will form pockets of apparently high density binding. No 
difference in the quality of the tissue condition was found in this 
study after freezing the tissue slowly or rapidly and it was found that 
the condition of each tissue section could be determined easily by 
holding the slide up to the light. There is controversy over the use of 
autoradiography for quantitative determination of KD and Bmax 
values. The primary criticism is that the values are related to the 
density of binding which is determined from the intensity of the 
colour of the autoradiographic image. The radio-activity bound is 
quantified by comparing the images produced by tissue sections with 
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those produced by standards of known activity. However, the 
autoradiographic image formed after exposure to standards may not 
be representative of that produced by tissue sections as the activity is 
quenched by passage through the tissue. Moretover, the degree of 
quenching may vary throughout different tissue regions and 
especially between white and gray matter. The accuracy of the 
correlation between image density and activity bound in the sample 
is therefore arguable. However, this problem was not encountered 
here as the technique was used qualitatively only, to determine the 
distribution of 5HT2 and o<..l-adrenergic receptor sites in rat brain and 
human spinal cord. 
Performing autoradiography it was discovered that the assay 
conditions used to measure [1251] AmiK binding in rat brain sections 
(Schotte and Leysen, 1988) were not entirely appropriate for use with 
human spinal cord tissue. Initial attempts to incubate the sections 
under these conditions resulted in the sections breaking up or being 
washed off the slides. This problem was solved mainly by mounting 
the sections on gelatin subbed slides which helped to maintain the 
integrity of the tissue sections throughout the incubation, pre-
incubation and rinse cycles. 
The variation between the levels of non-specific binding in 
spinal cord and brain tissue may depend on differences in the 
composition of these tissues. The myelin sheath around the spinal 
cord probably accounts for much of it. Differences in the composition 
of the brain and spinal cord are especially noticeable when preparing 
the tissue for autoradiography. In order to successfully cut sections of 
the spinal cord the tissue blocks must be completely supported in 
embedding medium. Otherwise the tissue sections produced are 
wrinkled. This appears to be because the outer layer of the spinal cord 
is tougher and less penetrable than the core and therefore the force 
required to cut through the cord will damage the section unless it is 
firmly supported. In contrast the composition of rat brain tissue 
appears to be more homogeneous and Tissue Tek is necessary only 
for adhering the tissue to the block. Furthermore whilst cutting the rat 
brain sections the knife became greasy much more quickly compared 
to sectioning human spinal cord and had to be cleaned more 
regularly. It may be that this fatty characteristic of the brain tissue 
explains the ready adherence of brain sections to glass slides. The 
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differences seen were distinct and may account for the high levels of 
NSB to human spinal cord tissues in the binding studies. High NSB 
however, is not necessarily a problem. 1dazoxan binding to boiled 
tissue using a constant concentration of idazoxan was found to be 
unaltered by varying clonidine concentration in ligand binding 
studies and displacement of 40-50% of total binding is a feasible level 
to work with. 
Lack of 5HT 1, 5HT2 receptors and 0l-1-adrenoceptors in human spinal 
cord 
[1251] AmiK studies 
In studies made in parallel to those using human spinal cord 
[1251] AmiK binding in the rat brain had the characteristics of 5HT2 
and o<.l-adrenoceptor binding found in other binding studies with 
homogenates (Leysen et. aI., 1982; Cash et. a11986) and in 
autoradiography (Schotte and Leysen, 1988; Palacios et. al.,1987; 
Jones et. a1.,1985). The greatest concentration of specific binding to 
5HT2 receptors and to o/..l-adrenoceptors was in the cortex and in the 
cortex and the thalamus respectively. To identify these sites 1 ~ ~
pyrilamine was used to inhibit AmiK binding to histamine-HI 
receptors which has been reported (8chotte and Leysen, 1988) though 
histamine-HI binding in the rat brain is very low relative to 5HT2 
and ol.l-adrenoceptor binding as seen here and as described 
previously (Taylor and Snyder, 1971). In this study specific [1251] 
AmiK binding to 5RT2 receptors, to 0<{ -adrenoceptors and to the 
densely labelled tetrabenazine displaceable binding in the caudate 
putamen have been distinguished in accordance with the findings of 
8chotte and Leysen (1988). Furthermore, the total labelling with [1251] 
AmiK in horizontal sections of rat brain is similar to [3R] Ketanserin 
binding in rat cortex and caudate putamen (Pazos et al., 1985) but as 
reported by 8chotte and Leysen [1251] Ami!{ also labels the lateral 
septal nuclei and various thalamic nuclei. 
In contrast, in human spinal cord there was no 
distinguishable labelling of either histamine-HI, 5HT2 000(1-
adrenoceptor sites with [1251] AmiK. Pre-incubating the sections in 
1 % B8A, reported to reduce N8B (Joshi, personnel communication) 
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had no perceivable effect on binding. There was however some 
indication of the presence of tetrabenazine displace able sites in the 
gray matter, particularly in the ventral cord. The labelling of non-
serotonergic sites by AmiK which is displaced by tetrabenazine is an 
interesting phenomenon. Early in vitro binding experiments of 
AmiK with tissue homogenates showed binding to 5HT2 receptors at 
subnanomolar concentrations and to histamine-HI and 0(1-
adrenoceptors at nanomolar concentrations (Wouters et. aI., 1986). 
Leysen and co-workers (1987) described a further AmiK binding site 
which was displaceable by tetrabenazine. They characterized the 
tetrabenazine displaceable [3H] ketanserin binding in rat striatum 
and proposed that these sites are associated with a DOPAC release 
system on dopamine and serotonergic nerve endings (amine 
releasing sites). Schotte and Leysen (1988) subsequently identified 
tetrabenazine displaceable AmiK binding sites in the rat brain. 
Reported here is the first description of tetrabenazine displaceable 
AmiK binding sites in the human spinal cord. 
In tissue homogenate studies using [1251] AmiK there were no 
distinguishable 5HT2 receptors or o(l-adrenoceptors in human spinal 
cord in accordance with the autoradiography results. However, there 
was also no evidence of tetrabenazine displaceable sites. Lack of 
discernible tetrabenazine displaceable sites in the homogenate 
preparation is understandable considering that the binding seen in 
the sections was low and limited to the gray matter. The binding 
could therefore have been masked by NSB to the rest of the tissue. 
The evidence obtained using [1251] AmiK in autoradiography 
and homogenate binding studies indicates that there are negligible or 
very low levels of 5HT2 receptors in the human spinal cord. It also 
indicates negligible levels of histamine -H 1 and <X.l-adrenoceptor 
sites. However, there is evidence of amine releasing sites in the 
human spinal cord comparable to those described in the rat brain 
(Schotte and Leysen, 1988). 
[3H] DPAT binding to tissue sections 
Experiments were performed in which sections of human cord 
were incubated with [3H] DPAT and the ligand binding measured by 
wiping the sections with filters and determining the activity by 
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scintillation counting. This was done as a preliminary step to set up 
the optimal conditions with respect to incubation and wash times for 
autoradiography of [3H] DPAT binding in sections of human cord. 
However due to the results of these preliminary tests no 
autoradiographs were prepared using the tritiated ligands. No 
specific [3H] DP AT binding could be measured. This indicated that 
there are very few or no 5HT1 and in particular 5HTlA receptors in 
human spinal cord. The method used was that described by Pazos and 
Palacios (1985) for autoradiography of 5HT1 receptors in the rat eNS. 
Consideration of o(.2-adrenoceptors in the human spinal cord 
The results obtained after incubating [3H] idazoxan with 
spinal cord sections in numerous preliminary experiments designed 
to obtain optimal conditions for autoradiography were neither 
consistent nor conclusive. On all occasions the NSB was high, 
exceeding 60%, but in some cases specific, saturable binding was 
apparently measurable and in a similar number of other cases there 
was no specific binding. Factors which may have been affecting the 
binding were investigated including (i) the effect of refreezing; 
sections were incubated on the day of sectioning without refreezing 
and up to 3 weeks after sectioning with frozen storage (ii) preventing 
the solutions evaporating during incubation by performing the 
experiment in humid boxes (iii) ensuring that the binding had come 
to equilibrium by varying the incubation period from 5 to 60 minutes 
and (iv) attempting to obtain the lowest possible ratio of specific to non-
specific binding by testing a large range of wash protocols of 1-3 
rinses for 1 - 15 minutes each. None of these manipulations resulted 
in satisfactory reproducible results. It was decided therefore not to set 
up autoradiographs which would take 2-3 months to develop but to 
continue the line of research using ligand binding with which 
reproducible results could be rapidly obtained. 
The reasons for the failure to obtain satisfactory conditions are 
not clear but it is likely that the protocol used was not suitable. As no 
autoradiography using [3H] idazoxan has been reported the method 
was developed on the basis of reports of general protocols for 
autoradiography and those used with other o<..2-adrenoceptor 
antagonists (Edwards and Hendrickson, 1982; Young and Kuhar 
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1979; Stephenson and Summers, 1985). The buffer was taken from the 
ligand binding protocol for [3H] idazoxan (Giron et. al., 1985). It may 
have been better to pre-incubate the tissue with Krebs-phosphate buffer 
containing Na+-GTP which is reported to increase o(2-antagonist 
binding possibly by removing endogenous noradrenaline and 
adrenaline which compete for the sites (Unnerstall et. al., 1984). 
Furthermore McLaughlin and Collins (1986) report that in studies of 
[3H] idazoxan binding to rat cortex specific binding was considerably 
less when the experiments were performed in Tris-HCL compared 
with physiological salt solution though KD and the Hill coefficients 
were unaltered. Other authors measuring cx2-adrenoceptor binding 
with idazoxan or other cX2-adrenoceptor specific ligands report using a 
number of different buffers including Tris-HCL buffer alone or in 
conjunction with chloride salts, phosphate buffers, physiological salt 
solutions and glycylglycine buffer (Doxey et. al., 1982; Giron et. al., 
1985; Petrash and Bylund, 1986; Simmons and Jones, 1988). In the 
light of the differences reported by Mclaughlin and Collins and those 
discussed below concerning serotonergic binding studies it would be 
useful to compare cX2-adrenoceptor binding with autoradiography 
using different buffers. From such a study it may be possible to select 
a more appropriate buffer for autoradiography with idazoxan. In the 
small number of investigations made using rat brain sections 
idazoxan binding appeared to be reproducibly displaceable which 
would indicate that the problems arose due to the tissue rather than the 
methodology. It is however possible that in a larger study similar 
variability would have occurred. On the other hand this may be 
further evidence of the idiosyncratic nature of the spinal cord tissue 
which may require tailored conditions. 
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Radio-ligand binding studies 
Evidence of little or no serotonergic binding in the human spinal cord 
Consideration of the protocol 
There is controversy over the use of additives to Tris-HCL 
buffer in the binding assays for serotonergic receptors. The 
compounds commonly added to the buffer are CaCI2, pargyline, a 
mono-amine oxidase inhibitor to prevent the breakdown of 5HT by 
endogenous enzymes and ascorbic acid an anti-oxidant which 
protects 5HT from air oxidization. However the presence of 
ascorbic acid in the buffer has been reported to be deleterious for 
several neurotransmitter receptors including those for serotonin 
due to its proposed destruction of receptor sites (Leslie et. al., 1980; 
Weiner et. aI., 1982; Hall et. aI., 1985). Furthermore, the 
inclusion of physiological concentrations of electrolytes and / or 
0.1% ascorbic acid and 1 ~ ~ pargyline was reported to reduce the 
Bmax value of [3H] ketanserin binding to 5HT2 sites by 30% and 
its binding affinity by up to 3 fold (Ley sen et. aI., 1982). It was 
proposed by these authors that this was due to the effect of the 
additives on the surface phenomena inherent in interaction 
between ligands in solution and membrane micelles. However, 
more recently, there has been evidence indicating that inclusion of 
ascorbic acid in serotonergic ligand binding assays is 
imperative. Firstly, Hamblin and co-workers (1987) reported that 
in the absence of ascorbic acid [3m 5HT decomposes and that the 
breakdown products mimic specific ligand/receptor binding 
though the binding is irreversible. Secondly, Demopoulus and 
Peroutka (1987) provided thorough evidence of [3H] DP AT binding 
to glass fibre filter paper which appeared to saturate and could 
therefore be misinterpreted as specific binding. This binding was 
prevented in the presence of 0.1 % ascorbic acid. In the present 
study the affinity of [3H] DPAT binding to rat cortical tissues and 
the Bmax value were approximately 50% lower when determined 
in the presence of 0.1% ascorbic acid, 0.1J,LM pargyline and 5.7mM 
CaCI2. However although the Scatchard plots of the data using both 
buffers were straight lines the displacement curves and Hill plots 
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indicated that binding in the absence of these additives may not be 
to one specific site only. With the inclusion of additives all 
specific binding was inhibited with O.lIlM 5HT whereas in their 
absence NSB was defined by a 100 fold greater 5HT concentration. 
More-over, the slope of the Hill plot in the absence of additives was 
less close to one (Table 4.5). [This final point indicates the 
importance of the Hill plot which can indicate that the ligand is 
binding to more than one specific site even when binding is 
apparently saturable and the Scatchard plot may be linear with a 
good correlation coefficient.] These results therefore support the 
proposal that in the absence of CaCl2, pargyline and ascorbic acid 
there is a component of [3H] DPAT binding which may be 
misinterpreted as specific binding. In view of the previously 
published reports this component may be partly or wholly due to 
saturable binding to glass fibre filters. Studies of [3H] DPAT, [3H] 
5HT and [3H] ketanserin binding in rat brain and human spinal 
cord were therefore performed in Tris-HCL containing 0.1% 
ascorbic acid, O.lIlM pargyline and 5.7mM CaCI2. 
5HT 2 receptors 
[3H] Ketanserin binding to 5HT2 receptors in the rat 
frontal cortex was comparable with that reported by Leysen. and co-
workers in 1983. The relatively low level in this study (5.56±.04 
compared with 11.5±1 fmols/mg tissue) can be accounted for by the 
differences in protocol. In particular Leysen reports that inclusion of 
salts in the buffer (as used in this study) can reduce specific binding 
by as much as 90% (Leysen et. aI., 1982). Furthermore the level of 
specific binding and the %NSB to 5HT2 receptors measured in human 
frontal cortex using [3H] k ~ t a n s e r i n n were in accordance with earlier 
reports of 5HT2 binding in human frontal cortex using [3H] 
ketanserin (Reynolds et. al., 1984) and other 5HT analogues 
(Stanleyet. al. , 1986; Marcusson et. aI., 1984). 
In contrast, there was negligible specific binding of [3H] 
ketanserin in the human spinal cord indicating that the numbers of 
5HT2 receptors in the human spinal cord are below levels detectable 
by these methods. This supported the evidence from autoradiography 
and homogenate binding studies using [1251] AmiK. 
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5HT 1 receptors 
Binding studies using [3H] 5HT indicated that this ligand 
reveals more than one binding site in rat brain as reported previously 
(Peroutka, 1986; Hamon et. aI., 1984) and the % of total binding 
accounted for by 5HT1A receptors as defined by inhibition by 100 nM 
DPAT was also close to the value reported by Peroutka (1986). 
Similarly, inhibition of [3H] 5HT binding by DPAT in human 
frontal cortex indicated the presence of multiple 5HT receptor sites in 
this tissue which has also recently been reported in a study using [3H] 
5HT with DPAT and a number of other 5HT analogues (Todd and 
Ciaranello, 1987). 
[3H] DPAT binding in the rat frontal cortex was shown to 
reveal a single binding site which, from previous evidence, was the 
5HTIA receptor. The binding was saturable, reversible and the KD 
value corresponded closely to that reported by other authors using a 
similar buffer composition (Table 4.5B). 
However, in contrast, when the above studies were performed 
using human spinal cord negligible specific binding of [3H] 5HT or 
[3H] DPAT was measurable. Where there was substantial total 
ligand binding 85-100% of this was accounted for by non-specific 
binding. These results probably indicate that the 5HT1 receptors in 
the human spinal cord in the lumbar region are present in numbers 
that are difficult to measure with the methods used. The evidence 
obtained in ligand binding studies supports the results obtained using 
[3H] DPAT binding to sections on slides indicating that there are 
negligible or very low levels of 5HT1, and in particular, 5HTIA 
receptors in the human spinal cord. 
The few reports of the number or distribution of serotonergic 
receptors in spinal cord tissue which have been published confirm 
these findings. Low levels of 5HT2 receptors are reported in the rat, 
guinea-pig and rabbit spinal cord compared with concentrations in a 
number of cortical regions, the striatum and nucleus accumbens 
(Leysen et. aI., 1982). Levels of 5HT2 binding in the rat spinal cord 
revealed by autoradiography by Pazos and Palacios (1985) were 
described as 'very low' (0 and 6.2 - 6.4 fmols fmg protein using [3H] 
mesulergine and [3H] ketanserin respectively). In a similar study 
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they described low levels of [3H] 5HT binding in the rat cervical cord 
which they attributed to 5HT1A and 5HT1B sites. There are 
apparently no data published concerning serotonergic receptor sites 
in the human spinal cord. In future attempts it may be possible to 
measure lower levels of receptors using the membrane preparation 
employed by Leysen and co-workers (1982) from which nuclei and 
cell debris were removed by homogenising and spinning the tissue in 
0.25 M sucrose. However this would require more tissue (original wet 
weight) for each assay as discussed below. 
Although there are apparently no reports of serotonergic 
receptors in the human spinal cord Pazos and Palacios (1985) reported 
finding low or very low concentrations of 5HT1 receptors in the rat 
spinal cord and low (1-2 fmols/mg protein) but distinct levels of 5HT2 
binding have been described in the rat spinal cord in in vitro binding 
studies (Leysen et al., 1983). The lack of evidence for serotonergic 
receptors in this study may result from inappropriate methodology 
and the assays may not be sensitive enough to measure the level of 
receptors present in the spinal cord. Although the methods described 
in this chapter have been used to provide reproducible results in rat 
brain tissue a better preparation of the spinal cord tissue may be 
necessary if serotonergic receptor binding in the human spinal cord 
is to be determined. Also, considering the effect of freezing on 
receptor number (below), where receptor numbers are low it is 
important to use fresh tissue. Bearing in mind the differences 
between brain and spinal cord tissue a greater effort to attain the 
optimal conditions of incubation and rinse protocol, the incubation 
temperature and the ligand concentration may maximize the ratio of 
specific to non-specific binding and facilitate the measurement of low 
levels of binding. 
[3H] Idazoxan binding 
The results of [3H] idazoxan binding in rat cortex revealed 
high affinity of the ligand for a single receptor site with saturable, 
displaceable binding. From the data KD and Bmax values were 
calculated which were very close to the published results of a number 
of other authors (Table 4.6). Displaceable, high affinity [3H] 
idazoxan binding was also demonstrated in human spinal cord. It 
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was therefore assumed that the D<.2-adrenoceptor binding method was 
satisfactory. However, a number of possible refinements were 
explored as adaptations to factors which were relevant to using 
human spinal cord tissue. 
Modifications of the binding protocol 
Initially, as the availability of human tissue was limited the 
possibility of reducing the tissue concentration per incubation tube 
used was investigated. [3H] Idazoxan binding was performed using 
half the tissue concentration stated in the methods. This modification 
was found to significantly reduce specific binding and increase NSB 
and so was not incorporated into the protocol. Published data supports 
this finding, Leysen and co-workers (1982) reported that in rat 
cortical membranes specific [3H] ketanserin binding per mg tissue 
decreased marginally and % NSB increased with decreasing tissue 
concentration. 
The effect of freezing tissue on specific binding and % NSB was 
also investigated as all human tissue was stored at -BOoc before 
analysis. Freezing was found to produce a significant reduction of 
approximately 16% in specific [3H] ketanserin binding with no effect 
on % NSB. It was decided that frozen storage of the tissue would be 
continued despite the loss in receptor number for a number of reasons. 
Firstly as the tissue could arrive at any time of day performing the 
binding assay immediately on its delivery would be practically 
inconvenient. Secondly, as the methods were developed for a 
comparative study between Parkinsonian and control subjects it was 
less essential to obtain absolute values whereas the facility to store the 
tissue and assay paired samples concomitantly was important. 
Thirdly the majority of studies on human tissue are performed with 
frozen samples and therefore the results would be directly comparable 
with published data. For completion the effect of freezing on binding 
in the human spinal cord tissue with each ligand used should be 
investigated as there may be differences due to variation in species, 
eNS region and the ligand used. 
As NSB binding in the human spinal cord was high 
(approximately 60% of total binding) relative to that in rat brain an 
attempt to increase the ratio of specific to non-specific binding was 
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made by producing a synaptosomal preparation rather than the crude 
membrane homogenate. However, as a result, specific binding was 
in fact reduced using the synaptosomal preparation probably because 
of the loss of tissue mass which occurs with this method. In the light of 
this evidence binding experiments were continued with the 
homogenate preparation and the human spinal cord was treated in the 
same way as the rat brain except for application of the biohazard 
procedures laid out in Appendix 2. 
In conclusion, ligand binding and autoradiography were used 
to determine levels and / or distributions of 5HTIA and 5HT2 
receptors and oll- and ~ 2 - a d r e n o c e p t o r s s in the rat brain which 
corresponded to previously published results. However, using the 
same techniques, no 5HTIA or 5HT2 receptors or o(.l-adrenoceptors 
were identified in the human spinal cord. Nevertheless it was 
possible to determine high affinity, reversible binding of [3H] 
idazoxan, a selective 0<.2-adrenoceptor antagonist, in the human 
thoracic spinal cord and a number of modifications of the protocol 
were investigated. It is proposed that success in future attempts to 
determine serotonergic binding in the human spinal cord may be 
obtained using synaptosomal preparations of fresh tissue. 
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Chapter 5 Alpha 2-adrenoceptors in the 
spinal cord in Parkinson's disease 
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Introduction 
Alpha 2-adrenoceptor binding has been determined in the 
rat spinal cord (Simmons and Jones,1988; Giron et.al.,1985; 
Unnerstall et.al.,1984) but although 0I-2-adrenoceptor binding has 
been demonstrated in the human spinal cord (Unnerstall 
et.al.,1984) it has not been defined in terms of number of receptors 
or receptor affinity. In the previous chapter experiments were 
performed to obtain a ligand binding protocol suitable for 
measuring [3H] idazoxan binding in this tissue. The use of this 
method to define ()I. 2-adrenoceptor binding in the human spinal 
cord is described here. Binding is defined in terms of the affinity 
of [3H] idazoxan to o(.2-adrenoceptors and the number of receptor 
sites. 
The eNS location of cx2-adrenoceptors has been investigated 
in the rat using chemical and surgical lesions of noradrenergic 
neurones (U'Pritchard et.al.,1980; Dausse et.al., 1982). The 
Parkinsonian spinal cord was shown in chapter 3 to have up to 80% 
depletion of noradrenaline in selected regions. It is therefore used 
in this study as a model of noradrenergic depletion to investigate 
O(2-adrenoceptor binding in the human. There is evidence that 
sensory (Howe et.al.,1983; Fleetwood-Walker et.al.,1985; 
Sawynok and Reid, 1986) and motor (Anden et.al.,1970; Kitazawa 
et.al., 1985) function is mediated by spinal cord o(-adrenoceptors in 
the rat. In addition, there is evidence for interaction between 
spinal cord serotonergic and noradrenergic systems (Archer 
et.al.,1985; Clatworthy et.al.,1988; Gorea and Adrien, 1988). In the 
human these functions may be important in the symptoms of 
Parkinson's disease which include motor dysfunction and pain. 
This study was therefore performed to determine o<.2-adrenoceptor 
binding in the post-mortem spinal cord from Parkinsonian 
subjects. 
In the light of earlier results which demonstrated 
significant effects of age and PMI on transmitter levels serious 
consideration was given to the problems associated with the use of 
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human tissue and ligand binding data was analysed for 
correlation with subject age, sex and the PMI using ANCOV A. 
The analysis of ligand binding data has been made easier 
and less time consuming with the advent of computer packages 
which are capable of performing multiple data transformations 
very rapidly. Use of a computer package also enables a more 
accurate determination of KD and Bmax values from lines fitted to 
the data by least squares non-linear regression analysis instead 
of by guesswork. The ligand binding data described in this 
chapter and the previous one has been analysed by the computer 
package LIGAND (Munson and Rodbard, 1980) the use of which 
will be reported here. 
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Methods 
Spinal cord samples 
Spinal cord tissue was obtained from the Cambridge Brain 
Bank, the Parkinson's Disease Society Brain Bank and 
Nottingham University Hospital. Thoracic and/or lumbar tissue 
was taken from 2 female and 6 male control subjects with no 
history of neurological disorder who had died from cardiac 
failure, bronchopneumonia or septicaemia. Thoracic and / or 
lumbar spinal cord tissue was taken from 4 female and 2 male 
subjects who were confirmed as Parkinsonian by post-mortem 
neurochemical analysis. The details of subject age, sex and the 
PMI are given in Table 5.1. Tissue was dissected and stored as 
described in chapter 3, pp.94-95. 
[3H] Idazoxan binding 
Adjacent 5mm slices of spinal cord segments were 
combined so that samples of -1g were used in binding assays. 
Membrane homogenate preparation and [3H] idazoxan binding 
were performed using the methods and buffers described in the 
previous chapter (pp.134-136). An assay tissue concentration of 
-10mg/ml was used. Eight [3H] idazoxan concentrations within 
the range 0.2-16 nM were employed and NSB was determined with 
10llM clonidine. 
Analysis of data binding using LIGAND 
Results from the ligand binding studies were analysed to 
define the binding in terms of the affinity (lIKD) of [3H] idazoxan 
for its binding sites and the number of binding sites (Bmax). 
Initially, data obtained using thoracic spinal cord tissue from 
control subjects were plotted as saturation curves to ensure that 
binding site saturation was attained within the [3H] idazoxan 
concentration range used. The computer program LIGAND 
produced by Munson and Rodbard (1980) and adapted for use on 
microcomputers (McPherson, 1985) was used for analysis of the 
165 
Table 5. 1 Age, sex, and interval between death and autopsy 
(PMI) of control and Parkinsonian subjects. 
Control Parkinsonian 
Age mean 64.4 80.5 
(years) range 39-81 73-89 
PMI mean 36.6 35.8 
(hours) range 6-53 9.5-78 
n total 8 6 
females 2 4 
males 6 2 
ligand binding data. The program employs non-linear least 
squares curve fitting to estimate values for the KD, Bmax and 
NSB. The program was used to obtain Scatchard transformation of 
the data using linear regression in the first instance to find 
estimates of KD and Bmax. Hill plot transformations were also 
produced using linear regression. These initial estimates were 
then applied to a one site binding model and iteration continued 
until the lowest residual variance for the fit of the line to the data 
was achieved. If the iteration failed then the initial estimates were 
adjusted and the iteration begun again. In the event of a successful 
fit the sum of squares (of variance from the line) and mean square 
were displayed. Also displayed were the results of the runs test 
which indicated whether the points were randomly distributed 
about the line. A graphic display of the data and the fitted line was 
then viewed. Whether the fit was considered to be appropriate was 
dependent on there being a small residual variance (i.e.-IOOO or 
less) and a random distribution of points about the line. The latter 
was determined from the runs test and the graphic display. The 
final estimates of KD, Bmax and NSB were given with the 
approximate SEM of each parameter. The SEM were also used to 
estimate the goodness of fit of the line to the data. A number of 
successful fits were obtained for the data from each spinal cord 
using different initial parameter estimates. The F- ratio test (page 
98) was used to determine whether there was any statistically 
significant difference between the various fits. The final 
estimates ofKD and Bmax were then taken from the best fit. 
Saturation curves for selected samples which did not fit to a 
one site model using all the data points were plotted manually to 
determine whether the binding sites were saturated 
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Statistics 
Two distinct groups of subjects were identified. The data 
from one group represented specific, saturable [3H] idazoxan 
binding and the data from the other group did not. Analysis of 
covariance (ANCOVA, pp.97-98) was used to investigate whether 
differences in age or PM! were associated with the two groups. In 
addi tion, the Chi square Exact test was used to determine whether 
either group was associated with Parkinson's disease. 
Specific [3H] idazoxan binding 
The data corresponding to specific, saturable binding was 
analysed further. ANCOVA was employed to determine whether 
there were any differences in KD and Bmax values of the thoracic 
and lumbar segments. Results obtained from thoracic and lumbar 
spinal cord were combined and analysed to determined whether 
there were any correlations between the KD and Bmax values and 
the age, sex or PM! of the Parkinsonian and control subjects. Data 
from Parkinsonian and control subjects were identified as being 
from different groups for purposes of analysis although there were 
only 2 Parkinsonian subjects from whom the data represented 
specific binding. 
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Results 
[3H] Idazoxan binding in the human spinal cord 
Specific, saturable [3H] idazoxan binding was demonstrated 
in the spinal cord from 5 out of 8 control subjects and 2 out of 6 
Parkinsonian subjects (illustrated in Fig. 5.1). The binding data 
from these subjects were fitted to a one site model in which the data 
points were randomly distributed about the Scatchard plot 
regression lines (with residual variances less than 1000) and the 
Hill coefficients were close to unity An example of the results for 
two different fits generated by LIGAND for the data from one 
spinal cord sample is given in Table 5.3. In addition, typical 
graphical displays of Scatchard plots generated from the different 
fits are shown in Fig. 5.3. The following results relate to data 
representing specific [3H] idazoxan binding. 
KD and Bmax values of [3H] idazoxan binding in the 
human thoracic and lumbar spinal cord from control subjects were 
6.62±2 nM, 342±189 fmols/mg protein (thoracic cord, n=3) and 
7.89±3 nM, 315±166 fmols! mg protein (lumbar cord, n=3). 
Statistical analysis using ANCOV A revealed that there was no 
significant difference in the values of KD and Bmax between 
thoracic and lumbar spinal segments (Table 5.2). Values from the 
different segments were therefore combined as the numbers of 
each were small. Where samples from both segments were taken 
from one subject the mean value of each was used (and for this 
reason total number of samples is not simply the sum of the 
numbers of lumbar and thoracic segments). 
The KD of [3H] idazoxan in the control spinal cord was 
7.1 ± 2.1 nM and number of binding sites (Bmax) was 341± 134 
fmol/mg protein (n=5 in each case) (Table 5.4 and Figs. 5.6 & 5.7). 
NSB was 30 -60% of total [3H] idazoxan binding. 
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Fig. 5.1 Total, specific and non-specific binding (dpm) of [3H] 
idazoxan binding (0.2 - 15 nM) to homogenate of thoracic spinal 
cord from a control subject. Each point is the mean of 3 replicates. 
Scatchard transformation of this data was fitted to a single 
binding model. This plot is typical of a number of other control 
and Parkinsonian subjects for which the data represented binding 
to a single specific receptor site. 
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Fig. 5.2 Total, specific and non-specific binding (dpm) of [3H] 
idazoxan binding (0.2 - 15 nM) to homogenate of lumbar spinal 
cord from a Parkinsonian patient. Each point is the mean of 3 
replicates. From this data specific [3H] idazoxan binding could 
not be determined. Scatchard transformation of this data could not 
be fitted to a binding model of either one or more sites using 
LIGAND. 
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Fig 5;3 Graphic display of Scat chard plots of the same data 
fitted to two different lines by the computer package LIGAND. 
Data was generated from saturation studies of [3H] Idazoxan 
binding in the thoracic spinal cord from a control subject. 
Scatchard plots were used in conjl,lIltion with data such as that 
shown in Table 5.3 to determine the best fit of the data. 
Table 5.2 ANCOVA details for analysis of O<2-adrenoceptor binding in the human spinal cord. 
Correlations between (A) KD and (B) Bmax and age, PMI, Parkinson's disease (Pd), sex and segment (SEG: lumbar or thoracic). (C) 
Correlation between age and PMI and specific, saturable binding. MS=mean square ; d.f=degrees of freedom ; res.var=residual variance . 
The results indicate that KD and Bmax are correlated with age, PMI and Pd and that specific saturable binding depended on subject age. 
Factor MS d.f Res.var d.f F value p<O.05*/p<0.01 ** 
A. N3E 50.8 1 .115 1 442 * 
PMI 22.8 1 .115 1 198 * 
Pd 71.0 1 .115 1 617 * 
SEX 0.26 1 .115 1 2.26 
SEG 0.88 1 .115 1 7.65 
B. N3E 256260 1 7750 2 66.1 • 
PMI 124280 1 7750 2 32.1 • 
Pd 212660 1 7750 2 54.9 • 
SEX 1080 1 7750 2 0.14 
SEG 372 1 7750 2 0.05 
C. ICE 723 1 847 12 10.2 * * 
PMI 37.6 1 6571 10 0.06 
FIT 1/KD SEM KD 
1 3.8E+8 1.4E+8 2.6nM 
2 2.SE+8 3.8E+7 4.0nM 
Bmax SBv1 
2.7E-11 8.6E-12 
4.2E-11 3.4E-12 
MS 
91 
98 
RESIDUALS 
+ 
4 3 
4 3 
Table 5.3 Typical output from LIGAND used to obtain values of KD and Bmax. 
RUNS 
p<O.05* 
6 
5 
F 
p<O.05* 
1.4 
This table shows the results generated for two different fits of ligand binding data. The results were obtained from [3H] 
idazoxan binding in the spinal cord of a control subject. Values are given for 1IKD and Bmax with their approximate 
standard errors. These values have not been adjusted for assay volume or protein content. The residuals are the 
number of points above and below the fitted line and these are expressed as the number of runs of points either above or 
below the line. The runs test does not reach a significant level indicating that the points are randomly distributed about 
the line. MS is the mean square of the residual variance from which the F ratio is calculated. There is no significant 
difference between the two fits and the second fit was selected as the best because the SEM values were smaller and a 
better fit was indicated by the graphic display (Fig.5.3). 
KD Bmax Hill 
Parkinson's 1.03 56.1 0.99 
disease 2.47 140 0.99 
n 2 2 
Control 7.1t2.1 341±134 0.98 
±0.01 
n 5 5 
Table 5.4 
Alpha 2-adrenoceptor binding in the human spinal cord of 
Parkinsonian and control subjects. Binding determined by [3H] 
idazoxan is expressed in terms of KD (nM), Bmax (fmols/mg 
protein) and the Hill coefficient. Control values are expressed as 
mean± SEM. 
Effects of age, sex, PMI and Parkinson's disease on [3H] idazoxan 
binding 
KD and Bmax values were found to increase significantly 
with both age and PMI (p<O.05 in each case) as shown in Table 5.2 
and Fig.5.B. For each subject KD was significantly correlated 
with Bmax (r=O.96, p<O.001, Fig.5.5). 
KD and Bmax values were determined for only two 
Parkinsonian subjects. These values given in Table 5.4 and 
Figs. 5.6 & 5.7 were significantly lower than in the control 
subjects (Table 5.2). 
In addition, there were no differences in either KD or Bmax 
between females and males (Table 5.2). 
The percentages of the total intra-subject variation 
accounted for by differences in age and PMI, determined from the 
residual variance of ANCOV A analysis, was; 16% and 45% (age) 
and 17% and 26% (PM!) for KD and Bmax values respectively. 
Non-saturable binding 
The data from the remaining 7 subjects were not 
representative of specific saturable binding and did not fit to a one 
or two site binding model using LIGAND. An example of total, 
specific and non-specific binding data which could not be fitted to 
any binding model is given in Fig.5.2. It appears that the 'specific 
binding' (determined from the difference between total and non-
specific binding) did not saturate and this was typical of the results 
for which the data did not fit a binding model. Whether the data 
represented saturable binding or not was dependent on the age of 
the subject (p<O.01, Table 5.2 and Fig.5A) i.e. the non-saturable 
data was from older subjects and was not correlated with either 
PMI (Table 5.2) or Parkinson's disease. 
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Fig 5.4 Age and specific [3H] idazoxan binding 
Ages of the subjects from whom tissue was taken to determine [3H] 
idazoxan binding in the spinal cord. Subjects are 
Parkinsonian x or control + and are divided into those for 
whom the binding data did and did not exhibit specific binding. 
This figure illustrates that data obtained from many of the older 
subjects did not correspond to [3H] idazoxan binding to a 
single.specific site 
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Fig 5.6 The affinity of [3H] Idazoxan for binding sites in 
human spinal cord. The affinity for sites in spinal cords from 
Parkinsonian and control subjects determined using ligand 
concentrations of 0.2-15 nM are shown. Each point represents 
the result from one subject. 
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Fig 5.7 [3H] Idazoxan binding in the human spinal 
cord. The number of binding sites (Bmax) in spinal cords from 
Parkinsonian and control subjects determined using [3H] 
Idazoxan concentrations of (0.2 -15 nM) are shown. Each point 
represents the result from one subject. 
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Fig. 5.8 Correlation of KD and Bmax with age and PM I 
These scatter diagrams give some indication of the correlation 
between the KD and Bmax values of [3H] idazoxan binding in the 
human spinal cord and age and PM!. The significant correlation 
ofKD and Bmax with each factor (age or PM!) is obscured due to the 
dependency on the other factor (PMI or age). Note that Bmax and 
KD values from the Parkinsonian subjects (. ) are lower than 
those from control subjects (EJ ) but are similarly correlated with 
age and PM!. Individual subjects are numbered for cross-
reference. 
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Discussion 
Alpha 2-adrenoceptor binding sites in the human spinal cord 
There were problems in defining [3H] idazoxan binding in 
the human spinal cord as the data from a number of subjects did 
not appear to represent binding to a specific saturable site. 
However, data from half of the subjects represented saturable, 
displaceable [3H] idazoxan binding and this data will be 
considered first. 
There is growing evidence for heterogeneity of the ol-.2-
adrenoceptor (Cheung et.al.,1982; Lanier et.al.,1988) and Petrash 
and Bylund (1986) have proposed that there are subtypes of D(2-
adrenoceptor in specific areas of the human brain. However, in 
this study [3H] idazoxan binding appeared to be binding to a 
specific site. Specific [3H] idazoxan binding to cx.2-adrenoceptors 
was demonstrated in the human spinal cord with an affinity of 
approximately 7nM. In addition, the number of binding sites has 
been determined as approximately 360 fmols/mg protein. Due to 
the wide variation in the results these values are considered to be 
initial estimates in preliminary experiments and suggestions for 
more accurate determinations are discussed below. The results of 
this study are comparable with previously published work. 
Autoradiography employing [3H] para-aminoclonidine (PAC) has 
been used to locate o<.2-adrenoceptors in the human thoracic spinal 
cord (Unnerstall et.al., 1984). High levels of £x2-adrenoceptors 
were described in the dorsal horn substantia gelatinosa and in the 
intermediolateral cell column whilst lower levels were distributed 
in the ventral hom in association with motor nuclei. The 
distribution in the human cord paralleled that in the rat spinal 
cord. However, binding in the rat tissue was quantified in terms of 
KD and Bmax whereas binding in the human cord was not. 
Reasons for this were not given but it is possible that difficulty in 
distinguishing specific binding in the human cord may have been 
due to high levels of non-specific binding. High and variable 
levels of non-specific binding in rat spinal cord have reported 
(Howe and Yaksh, 1984; Janns et.al.,1987; Simmons and Jones 
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1988) which is consistent with findings in human cord in the 
present study. Moreover, no other reports of quantitative analysis 
of cx2-adrenoceptors in the human spinal have been published. 
However, o<.2_adrenoceptors have been located in the rat spinal cord 
(Jones and McEnna, 1980) and the cX2-adrenoceptor is described as 
a homogeneous binding site distinct fromcx1-adrenoceptors present 
in ventral and dorsal regions of cervical, thoracic and lumbar 
segments (Giron et.al.,1985; Simmons and Jones, 1988). 
Furthermore, <X2-adrenoceptor binding to a single site is reported 
in the cat spinal cord (Howe and Yaksh,1984). Bmax and KD 
values for oZ2-adrenoceptors in the human cord described here 
using [3H] idazoxan are greater than those in the whole spinal cord 
of the rat (21 and 70 fmols/mg protein, 1.7 and 1.39 nM) using [3H] 
PAC (Giron et.al.,1985; Simmons and Jones, 1988). Alpha2-
adrenoceptor binding in the human brain however, is similar to 
that in the spinal cord. Bmax values of 375-940 fmols/mg protein 
and KD values of 4.6 -18.4 nM are described for various regions of 
the brain (Shimohama et.al.,1986). This study therefore indicates 
that in the human consistent with other species CX2-adrenoceptor 
binding in the spinal cord is homogeneous and is of a similar 
order of affinity and number to that in the human brain. 
Non-saturable binding data 
There were difficulties in fitting to either a one or two site 
binding model certain ligand binding data obtained using spinal 
cord both from patients who had died with Parkinson's disease and 
control subjects. This binding data was assumed to represent non-
specific, non-saturable binding and lack of specific sites or 
specific sites which could not be distinguished from relatively high 
and variable levels of non-specific binding. The non-saturable 
binding was dependent on age of the subjects at death and not 
Parkinson's disease. Data from those subjects older than 74 years 
of age did not represent specific binding to a single site in all but 
one subject whereas specific [3H] idazoxan binding sites were 
identified in all 5 subjects below the age of 70. However, the 
Parkinsonian subjects were on average older than the control 
subjects. In addition, in the Parkinsonian patients duration and 
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degree of illness is also likely to increase with age. There may, 
therefore, be parallels between severity of Parkinson's disease 
and loss of Q(..2-adrenoceptors 
Effect of Parkinson's disease, age, sex and PMI on adrenoceptors 
The results may indicate higher affinity and lower 
numbers of 0l2-adrenoceptor binding sites in the Parkinsonian 
spinal cord compared with controls. This can only be considered 
as a possible indication because of the low numbers and wide 
variation in both values. The variation in KD and Bmax was 
partly accounted for by their significant correlation with age and 
PMI (see below). Considering the intra-group variation and the 
low sample number it is concluded that a much larger sample size 
is required to determine the effects of Parkinson's disease on the 
O(2-adrenoceptors in the human spinal cord. Whether the changes 
in ~ - a d r e n o c e p t o r s s seen in the older subjects are dependent to any 
degree on Parkinson's disease could be investigated further in age 
matched subjects. 
This study has demonstrated that there was an increase in 
number and decrease in affinity of CX2-adrenoceptors with PM!. 
This may be explained by structural alterations occurring in the 
synaptic membranes after death resulting in hidden receptors 
being revealed. 
Similarly there was a decrease in the affinity of [3H] 
idazoxan for the <X2-adrenoceptor and an increase in the number of 
binding sites in the human spinal cord with age. For each 
individual subject low binding affinity was correlated with high 
Bmax. [It must be noted that the Parkinsonian subjects were 
considered in this analysis to be from a different population from 
the control subjects (with a lower KD and Bmax) in which the KD 
and Bmax values similarly increased with age.] A 
conformational change in the adrenoceptor with age resulting in a 
lower affinity for endogenous noradrenaline and a compensatory 
increase in receptor number is concordant with these results. 
Progression of this alteration in binding site confonnation to the 
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extent that the site is no longer capable of binding [3H] idazoxan 
may account for the lack of specific receptors in the older subjects. 
Alternatively, it is possible that the lack of measurable receptors is 
due to particular susceptibility in the older subjects to the reduced 
affinity to [3H] idazoxan with increasing PM!. 
The increase in adrenoceptor number with age may be 
dependent to some degree on alterations in the spinal serotonergic 
system. In chapter 3 (page 115) a reduction in 5HT content of the 
spinal cord with age was described and there is evidence for the 
interaction of noradrenergic and serotonergic systems both at the 
level of the brain stem (Gorea and Adrien, 1988) and the spinal 
cord, especially regarding the modulation of nocioception (Jensen 
and Smith, 1983; Clatworthy et. a1., 1988; Archer et.al.,1985). 
Moreover, spinal depletion of 5HT has been shown to induce a 
drastic potentiation of noradrenaline-induced analgesia (Archer 
et.al.,1986) and the authors concluded that the spinal 
noradrenergic system has an important role in modulation of 
descending serotonergic function. It may be that spinal 
noradrenergic and serotonergic systems interact in the 
modulation of spinal cord function and that depletion of the 
serotonergic system results in adaptation in the noradrenergic 
system. This proposal is concordant with the results of the present 
study. 
It is interesting that, in accordance with factors affecting the 
levels of neuroamine levels in post-mortem spinal cord, the 
characteristics of 0'.2-adrenoceptor binding are dependent 
primarily on subject age and the PM!, and are independent of the 
sex of the subject. 
Location of the ~ - a d r e n o c e p t o r r
The exact location o f ~ - a d r e n o c e p t o r s s in the eNS is unclear. 
There is evidence of a heterogeneous distribution on both pre- and 
post-synaptic membranes though the number of pre-synaptic sites 
is probably minor compared with post-synaptic sites 
(U'Pritchard et.al.,1980; Dausse et.a1., 1982; Levin, 1984). As 
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the loss of noradrenaline in the spinal cord of Parkinsonian 
patients was up to 80% of control values (pp.109-110) the 
Parkinsonian spinal cord was used as a potential model of 
adrenergic neuronal depletion in humans to investigate 
adrenoceptor location. Unfortunately, the results of this study do 
not help to resolve this question due to the low numbers of 
Parkinsonian subjects for which specific binding was 
demonstrated. However, the general indications for higher 
affinity and lower numbers of o(.2-adrenoceptors in Parkinson's 
disease is not in accordance with comparable studies. It has been 
reported previously that neurotoxin induced lesion of the locus 
coeruleus did not significantly modify o(2-adrenoceptor number in 
several brain regions (Cash et.a1.,1986). Similarly, neurotoxic 
depletion of spinal cord noradrenaline did not affect 0<.2-
adrenoceptor binding in the cat lumbar spinal cord (Howe, Yaksh 
and Tyce, 1987). The authors concluded that ""2-adrenoceptors may 
be situated on neuronal elements unrelated to noradrenergic 
input. However, consideration must be given to factors which 
complicate the interpretation of the results from human models of 
neurological denervation. Firstly the results of this study 
illustrate that limitations on subject age and the PMI are 
imperative as there are significant changes in ol2-adrenoceptor 
binding due to these factors. In addition, the time scale of the 
illness compared to neurotoxically induced onset of neuronal 
degeneration in experimental animals poses problems. For 
instance, it has been reported recently that in the brain of patients 
with Parkinson's disease loss of nigro-striatal dopaminergic 
neurones is accompanied by atrophy in length and number of the 
dendritic arbor of post-synaptic striatal neurones (McNeill 
et.al,.1988). This may result from the reduced innervation of these 
neurones and means that receptor loss accompanying long term 
pre-synaptic neuronal degeneration can not necessarily be located 
to the pre-synaptic terminal. Furthermore, slowly progressing 
pre-synaptic denervation occurring over a number of years may 
result in both pre- and post-synaptic compensation in receptor 
affinity and number. In conclusion, any possible changes in KD 
and Bmax indicated in the Parkinsonian cord are likely to be a 
result of both degeneration of pre-synaptic noradrenergic 
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pathways and the processes associated with long-term deficit in 
noradrenergic transmission and would not be expected to be 
exactly similar to changes induced by neurotoxic or surgical 
lesions. 
Future studies 
1. [3H] Idazoxan was selected as the ligand to determine 0(2-
adrenoceptor binding for a number of reasons including (i) its 
specificity for this receptor which is well documented (Doxey et. 
aI., 1982 ; Langer et. aI., 1983 ; Hamilton et. a1., 1988; Howlett et. 
aI., 1982) (ii) the classic ot2-adrenoceptor specific agonists 
clonidine and p-amino clonidine are imidazoline structures 
which may have actions unrelated to noradrenaline-mediated 
effects (Diamant et.al.,1987; Bousquet et.al.,1986; Hicks 
et.a1.,1985) and (iii) it was considered that the hydrophilic nature 
of idazoxan may reduce the non-specific ligand binding to the 
spinal cord which tends to be high. However, the variability in the 
KD and Bmax values observed in this study may result from rapid 
dissociation of [3H] idazoxan from its binding sites. If during 
rinsing the bound [3R] idazoxan dissociates then the binding 
affinity determined would be lower and receptor numbers higher 
than the true values. In addition, both values would be very 
dependent on variations in rinse time. The rate of dissociation 
may be reduced by conducting the ligand binding at OOc and this 
could be performed to investigate the effect on the KD and Bmax 
values so determined. 
2. In addition, the maximum ligand concentration used in 
the ligand binding studies was only 2 fold greater than the mean 
KD of [3H] idazoxan binding in the human spinal cord. These 
studies should therefore ideally be repeated with a maximum 
ligand concentration of 5 fold the III value to ensure that 
saturation of the binding sites is achieved and to determine the KD 
more accurately. 
3. To fully characterize o(2-adrenoceptor binding in the 
human cord ligand binding studies performed using a number of 
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different specific <X2-adrenoceptor ligands should produce 
comparable results. 
4. More data points per saturation curve would enable more 
accurate determination of KD and Bmax values. 
5. Furthermore, in light of the results, future studies of 0<.2-
adrenoceptor binding in the human cord should utilize high 
numbers of subjects to overcome intra-subject variation and 
subjects should be carefully matched for age and PMI in 
comparisons between control and disease states. 
Rationalization for the use of the computer package LIGAND 
Analysis of ligand binding data using the computer 
package LIGAND was easier and quicker than performing the 
multiple transformations of the data manually. Using the package 
also enabled a more accurate estimation of the values of KD and 
Bmax. Firstly, manual determination of Scatchard plots relies on 
guess-work whereas using LIGAND the line is determined by 
least squares estimate. Secondly, the best of a number of fits 
generated from different initial parameter estimates can be 
obtained and the goodness of fit is tested statistically. LIGAND 
also calculates standard errors for each parameter which are an 
indication of the precision of the estimates. In addition, in 
LIGAND there is the facility to restrict analysis to certain data 
points which means that in event of binding to more than one site 
estimates can be obtained for KD and Bmax values for potential 
high and low affinity sites. These estimates can then be used in 
non-linear curve fitting to an exact mathematical model to 
calculate KD and Bmax values for one or more binding sites. 
Furthermore, non-linear least squares analysis is a better method 
than using linear regression because in the Scatchard plot there 
are non-uniform errors in both of the co-ordinates. In LIGAND the 
total ligand concentration is used as this variable is precisely 
known. In this study LIGAND was useful for differentiating 
between data which did and did not correspond to a specific, 
saturable binding site. 
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In summary, the computer package LIGAND was used to 
determine that [3H] idazoxan binds to a homogeneous population of 
cJ.. 2-adrenoceptors in the human spinal cord. Further investigation 
is required to determine whether there is any difference between 
of.-2-adrenoceptor affinity and number in spinal cords from 
Parkinsonian and control subjects as the variation in these values 
was large and dependent on the age of the subject and PM!. 
Furthermore, in a nwnber of cords there was no distinguishable 
specific [3R] idazoxan binding and further studies are needed to 
determine whether this was due to age, Parkinson's disease or to 
other factors such as freezing or storage of the tissue. 
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Chapter 6 General discussion 
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Summary of the thesis 
This study has addressed the projected aims which were (i) 
to investigate of the levels of indoleamines, catecholamines, 
substance P and TRH in the human spinal cord (ii) to compare 
these levels in the spinal cord of Parkinsonian and control 
subjects (iii) to use the Parkinsonian spinal cord, in the light of co-
existence of amines and peptides in the rat, to investigate whether 
depletion of spinal cord 5HT is paralleled by depletion of substance 
P and TRH in the human and (iv) to study serotonergic and 
noradrenergic binding in the spinal cord in Parkinson's disease. 
In order to carry out these aims a number of existing methods were 
validated in rat spinal cord or brain tissue or human cortical 
tissue producing closely comparable results to previously 
published work. These and other established methods were 
developed and adapted for use with human spinal cord material 
including (i) development of a sensitive reproducible and specific 
RIA for the detection of substance P which does not detect other 
tachykinins reported to be present in the spinal cord (ii) 
development of a method for the concomitant extraction of 
indoleamines, catecholamines and neuropeptides from eNS tissue 
which enables maximum use of a limited amount of tissue (iii) the 
concentration of catecholamines on alumina as these were found 
to be present in low levels in the human spinal cord and (iv) 
adaptation of autoradiography and ligand binding methods for 
detection of adrenergic and serotonergic ligand binding in the 
spinal cord. 
The work described here compliments the post-mortem 
investigations of other authors into the distribution of 
neurotransmitters and neuropeptides in the human eNS which 
has been mainly restricted to the brain. The spinal cord has 
previously been largely neglected possibly because of the greater 
difficulty incurred in the dissection of the spinal cord from the 
body. The study also incorporates the novel use of some of these 
methods, in particular [1251] AmiK and [3H] idazoxan binding, to 
human spinal cord. 
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The use of human post-mortem tissue 
A recurring phenomenon throughout this study was the 
greater difficulty incurred in making measurements in the 
human cord compared with the rat brain. This was dependent both 
on the tissue being from humans and apparent differences between 
the spinal cord and the brain. It is important to note that 
measurement of transmitter and neuropeptide levels and receptor 
binding made using the rat brain were reproducible and consistent 
with previously published work indicating that difficulties which 
arose were specifically associated with human post-mortem spinal 
cord tissue. Some considerations arising from the use of post-
mortem human tissue are discussed here. 
There were difficulties due to low levels of both 
catecholamines and serotonergic receptors in the spinal cord. 
There were also problems arising from the nature of the cord 
including maintaining tissue sections on slides for 
autoradiography and difficulties arising from high non-specific 
binding in ligand binding studies. 
A large influence on the protocol throughout the study was the 
limited availability of the spinal cord material. The standard 
problems of obtaining post-mortem tissue, such as waiting for 
suitable subjects and relying on the good will of the pathologist to 
dissect the tissue, were further compounded by the difficul ty of 
dissecting the cord from the vertebrae. In the experience of this 
author, direct contact with the morticians who carry out the 
dissections increases the likelihood of difficult requests being 
serviced. However, where all the requests are channelled through 
a Brain Bank it appears that tissue which is more problematic to 
dissect receives a lower priority and more.,9ver that requests are 
ranked according to the professional status of the researcher. This 
would be an important consideration in future work using post-
mortem human tissue. Furthermore, the limit on the supply of 
spinal cord tissue restricted the matching of Parkinsonian and 
control subjects with respect to post-mortem interval (PMI), age 
and sex. The statistical evaluation of the effects of these factors on 
transmitter and receptor levels was therefore very important and 
revealed significant effects on both measurements. This 
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indicates that all studies of post-mortem human tissue should 
include appropriate statistical analysis of these factors. 
The cause of death and terminal factors such as coma may 
affect the concentrations of neurochemicals and receptor levels in 
the eNS. For example, glutamate decarboxylase, an enzyme 
marker for GABA-containing neurones is reported to be reduced 
in the brains of patients dying in coma or prolonged terminal 
illness (McGeer et.al.,1971; Spokes et a1.,1979). In contrast, 
neither a violent death nor death by hypoxia affects serotonergic or 
B-adrenergic receptors in the post-mortem human brain (Mann et. 
al.,1986). In this study the causes of death reported apart from 
Parkinson's disease itself were similar for Parkinsonian and 
control patients and were generally cardiac or respiratory failure 
and pneumonia. However, the different causes of death and 
duration and degree of confinement amongst the subjects may 
have contributed to the intra-group variation. 
Ante-mortem medication is an important factor to account 
for. In this study the effects of ante-mortem L-dopa therapy on post-
mortem catecholamine levels has been considered (page 114). L-
dopa may also affect serotonergic systems through competition for 
transport systems and displacement of 5HT by dopamine 
synthesized in serotonergic neurones (see Reynolds and Reiderer, 
in press) though it is widely accepted that the predominant effects of 
L-dopa are mediated via conversion to dopamine in the CNS 
(Lloyd et.a1.,1975; Bunney et.a1.,1973; Hefti and Melamed, 1980). 
However, recent evidence indicates that the effects of L-dopa may 
be wider than previously believed. L-dopa may directly induce the 
release of endogenous noradrenaline and dopamine by regulatory 
mechanisms via effects on pre-synaptic receptors (Goshima 
et.al.,1986). Further exploration into the effects of L-dopa on CNS 
transmitter levels in animals would be useful in elucidating the 
obviously complex nature of the action of L-dopa therapy and 
deciphering the post-mortem transmitter and receptor changes in 
Parkinson's disease which are not related to medication. 
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In this study comparison between Parkinsonian and control 
subjects was made assuming that effects of PM! and age are the 
same in this pathological condition as they are in the control 
subjects, however this may not be so. For example, there are 
differences in post-mortem stability of ChAT activity and 
cholecystokinin levels in cerebral cortex from subjects with 
Alzheimer's disease compared with controls (Davies and 
Terry,1981; Perry et.al.,1981). This and other evidence discussed 
in this work indicates that generalizations should not be made 
about the post-mortem effects on neurotransmitter levels and if 
post-mortem levels are to be used as an indication of changes 
found in pathology a clear understanding of these effects, and 
therefore further investigation, is necessary. 
These various factors arising from the use of human tissue 
have been taken into account where possible. It is these factors and 
numerous others such as differences in diet, environment and 
level of fitness during the subjects life that result in the intra-group 
variation in transmitter and receptor levels which was generally 
larger in the human studies than in the corresponding studies 
using laboratory bred rats. It may be that this variation masks 
some of the effects of Parkinson's disease on transmitter and 
receptor levels but this problem has been overcome as far as 
possible by using larger numbers of subjects than in the rat. 
Furthermore, more than 30% of the variation in transmitter levels 
and the number and affinity of cx2-adrenoceptor binding sites was 
accounted for statistically by differences in PMI and age. 
It is interesting that although the levels of the indoleamines 
measured were high compared to the levels of the catecholamines, 
adrenergic but not serotonergic receptor binding could be determined 
in the spinal cord. It should be noted that the phenomenon of low levels 
of receptors in areas of high levels of the corresponding 
neurotransmitter is widely reported and is the rule rather than the 
exception. Some reasons given to explain this mismatch include (i) 
expression of transmitter or receptor molecules not only at their 
contact site but throughout the neurone (ii) occupied receptors and 
unrecognized low affinity receptors and (iii) sites of action of 
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transmitters released from a distance (See Herkenham, 1987). 
Mismatch between levels of receptors and transmitters may also be 
dependent on the different effects of PM! on transmitter and receptor 
levels as this study revealed a significant reduction in affinity and 
an increase in number of ~ 2 - a d r e n o c e p t o r s s with PMI but no 
significant effect of PMI on noradrenaline levels. In addition, in 
post-mortem tissue down regulation of receptors may occur due to 
spontaneous release of transmitters and peptides at death. 
The symptoms of Parkinson's disease 
Noradrenaline and 5HT in the spinal cord have previously 
been shown to be involved in central generation of locomotion 
(Grillner et al., 1975) and evidence for their roles in spinal motor 
function has been described (pp.14-16 and 24-25). It is therefore 
possible that human spinal deficiency of noradrenaline and 5HT 
in Parkinson's disease contributes to the symptoms of motor 
dysfunction associated with this disease .. Furthermore, the 
changes in the indoleamine levels and adrenergic receptor state 
with age may be related to symptoms of motor dysfunction 
developed in aging which resemble those in Parkinson's disease. 
It has also been demonstrated that antagonism of certain types 
of pain is mediated through spinal cord serotonergic and 
noradrenergic systems and through ()(2-adrenoceptors in particular 
(Howe et.a1.,1983; Yaksh et.al.,1981; Kuraishi et al.,1985; Tasker and 
Melzack,1989). Furthermore, it is now generally accepted that 
sensory symptoms including numbness, tingling and pain are 
common in Parkinson's disease (Snider et.al,1976; Yahr,1982; 
Koller,1984; Quinn et.al.,1986). The eNS is a likely candidate for the 
origin of painful symptoms as peripheral nerve disease is uncommon 
in Parkinson's disease and evidence indicates that the peripheral 
nerves are intact (Koller,1984). It has been proposed that pain may 
result from an imbalance between noradrenergic, serotonergic and 
dopaminergic systems in Parkinson's disease and, moreover, that 
truncal and limb pain which is predominant may result from altered 
spinal cord function (Quinn et.al.,1986). The loss of spinal cord 5HT 
and NA and the interaction between serotonergic and adrenergic 
systems described in this study may therefore be important to the 
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symptoms of sensory deficit present in Parkinson's disease. In 
addition, the results are in accordance with an imbalance between 
spinal cord noradrenergic, serotonergic and dopaminergic systems 
in Parkinson's disease. 
Future studies 
It was hoped that this report of transmitter levels in the eNS 
would be accompanied by a report of transmitter levels in the 
brains of the same Parkinsonian and control subjects. This would 
have enabled comparisons to be drawn between the effects of 
Parkinson's disease on amine and peptide levels in the brainstem 
nuclei and spinal cord of the same patients. Such evidence would 
provide an indication of the degree of dependency of spinal cord 
changes on changes in the brain stem nuclei. For instance, if 
neurotransmitter depletion were greater in the spinal cord than in 
the nuclei from which the spinal projections originate in each 
individual subject this may indicate effects specific to the spinal 
cord. Unfortunately, this information could not be obtained and it 
is therefore difficult to ascertain the importance of the changes in 
the spinal cord to the symptoms of Parkinson's disease. Such a 
comparison would be worth considering for future study and 
supplies of tissue from the appropriate regions could be collected 
from the beginning. 
In studies performed in this thesis using human spinal cord 
tissue the variation in transmitter and receptor levels determined 
was relatively large for reasons discussed above and it would be 
worthwhile extending these studies using a larger number of 
subjects especially regarding results of transmitter levels in the 
lumbar spinal cord anax2-adrenoceptor binding to back-up the 
current findings. In addition, interpretation of data with large 
intra-group variation may be improved using t-test analysis of log 
transformed data. 
There is a total lack of evidence concerning the effect of long 
term frozen storage of tissue at -80oc on its neurochemical content 
or receptor stability and authors generally do not mention this 
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parameter. This probably arises from the assumption that at -800c 
physiological processes including enzymatic degradation and 
chemical transport systems are inactivated. There is nevertheless 
value in investigating the effects of this factor in future studies. 
Recent developments in dialysis techniques enable in vivo 
determination of transmitter levels. Such techniques have been 
used to measure the endogenous levels of 5HT and TRH released 
in the lumbar spinal cord of the rat (Fone et.al.,1988c). Practical 
problems arising from the size of the rat spinal cord have inhibited 
the use of stimulated release of 5HT in the investigation of co-
release of TRH and 5HT (Fone, personal communication). 
However, in larger animals such as the cat, rabbit or primate in 
vivo dialysis of stimulation-released amines and peptides could be 
exploited to elucidate the interactions between 5HT, substance P 
and TRH. 
Co-existence in the spinal cord has been based mainly on 
evidence of 5HT and peptide distribution in the rat spinal cord in 
control and lesion studies (described fully in the General 
Introduction). There is evidence however that there may be 
distinct species variation in the descending bulbospinal system. 
In the rat 40-50 % of serotonergic descending pathways are reported 
to contain substance P (Johansson et.al.,1981; Marsden et.al.,1982; 
Bowker et.al.,1983) whereas in the primate virtually all the spinal 
cord substance P was found within serotonergic fibres (Bowker, 
1986) and in addition there is a descending serotonergic pathway 
from the locus coeruleus in the cat which has not been identified in 
the rat (Leger et.al,1979; Wiklund et.al.,1981; Lai and Barnes, 
1985). Therefore, in pursuit of understanding of human CNS 
function more information concerning the pathways and 
mechanisms of transmitter systems in this species itself is 
required. Certain measurements in the living human subject 
such the levels of transmitters and their metabolites in plasma 
samples and CSF are not necessarily representative of CNS levels. 
However, investigation of CNS systems in freshly dissected 
(biopsy) tissue from living subjects is possible and has been used to 
investigate receptor-mediated second messenger activity 
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(Kendall and Firth, 1988) and K+ stimulated histamine release 
(Arrang et.al.,1988) in slices of human cerebral cortex. Such 
studies have their difficulties. The co-operation of clinicians 
performing surgical procedures is essential and the researcher 
must organize the experiment in advance and await the arrival of 
the tissue. Nevertheless, the success of these methods indicates that 
they could be used to study indoleamine and peptide release in 
human CNS tissue to gain an understanding of the mechanisms 
involved. 
Conclusive evidence of co-existence of neurotransmitters 
and peptides in the human is dependent on immunohistochemical 
visualization of amines and peptides within the same neurones. 
Obtaining high quality sections would be difficult as unlike 
animal tissue it is not possible to fix human tissue at death. 
However, the use of fresh post-mortem tissue sectioned after fixing 
and embedding in wax would avoid damage caused to tissue 
sections by freezing and may be suitable for double labelling 
immuno-histochemical staining techniques. By this method it 
may be possible to visualize co-existent neuro-amines and peptides 
in the human spinal cord. 
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Appendix 1 Protein Detennination with Folin Phenol 
Reagent (Lowry et. al.,195I) 
Solutions 
Stock solution A 
Solution B- make fresh 
Sol ution C - make fresh 
Solution D 
Standard albumin 
Standard curve 
Method 
2% Na2C03 in O.lM NaOH 
0.5% CuS04:5H20 in 1% 
potassium sodium tartrate solution 
Mix 50mls. solution A with 1ml. 
solution B 
Folin phenol reagent diluted 1:1 
5mg BSA in 10mls double 
distilled water 
Range of BSA concentrations from 
0-0.25mg 
Resuspend tissue samples in 1ml distilled water. 
Take 0.5ml tissue suspension diluted to a concentration within the 
standard range. 
To 0.5ml of each sample and each standard add 0.5ml Solution C. 
Wait 10 minutes. Add 0.5ml Solution D. Leave 20 minutes in 
dark. 
Measure the optical density of samples and standards at 500nm 
wavelength using a spectrophotometer. 
Calculate protein content of the standards by extrapolation of the 
standard curve. 
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Appendix 2 
Protocol for: 
Conditions for work with human tissue 
(a) Dissection of frozen human tissue 
(b) Incubation of sections of tissue with [3H] 
ligand on glass slides 
(c) Homogenate ligand binding assay of tissue 
All human tissue to be transported in and out of Human Tissue 
Laboratory (E62) in sealed packaging on dry ice or in capped tubes 
within a closed container. 
1) Dissection of sections of frozen spinal cord to be carried out 
in a microbiological safety hood with extractor fan on in E62. 
Tissue will be dissected on a piece of metal cooled on a trough of 
ice. Disposable apron. gloves and mask to be worn during this 
procedure. Single edged razor blades used for dissection will be 
disposed of in "sharps safe" after immersion in phenolic 
disinfectant (eg 2% stericol). Trough of ice will be sterilised 
overnight by immersion in hypochlorite (>2.5% chloros). 
2) The tissue will be transferred to a sealable bag and placed in 
an insulated closed container with dry ice for transport to the 
department of Human Morphology for cryostat sectioning. 
3) After sectioning the brain sections will be returned to E62 
within a sealed container and incubated with a tritiated ligand 
inside a second microbiological hood by pipetting the ligand onto 
the slides. The sections will be dried using a fan which will 
remain in the hood. The slides will then be either a) wiped with 
filters (2.5 cm) wetted with buffer solution which will be placed into 
vials containing 10% perchloric acid within the hood or b) removed 
from the hood in a dry condition and taken out of E62 for exposure 
to a [3H] sensitive film in a dark room. 
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4) Waste sections on glass slides and slides from procedure 3a 
will be disinfected and decontaminated by overnight immersion 
in hypochlorite (>2.5% chloros), and then disposed of through the 
normal glass disposal route. 
After development of the film the slides of 3b will be either disposed 
of in the same way or stored in a sealed, well labelled box in E62. 
5) For homogenate binding tissue will be dissected as in (1) 
and homogenized in buffer using a homogenizer permanently 
housed within the hood. Homogenate will be transferred to a clean 
tube, capped and centrifuged. Supernatant will be as.pirated from 
the pellet within the hood by means of a water vacuum pump into a 
trap containing hypochlorite (>2.5% chloros). 
6} The pellet will be resuspended in buffer and procedures in 5) 
repeated twice. All procedures to be carried out within the hood 
except for centrifugation which will take place in capped tubes. 
7) The final supernatant will be transferred to a second 
microbiological hood and added (1 ml approx) to radio-active 
substrates using a pipette with disposable tips. Supernatant and 
radioactive substrate will be incubated together in capped tubes 
within a water bath adjacent to the hood. 
8) The incubation medium will be passed through filters (2.5 
em) under vacuum in a filter block and the filters washed with 
buffer dispensed from a glass container within the hood. Filters 
then will be transferred to vials containing 1 ml of perchloric acid 
(10%). All procedures in 7 and 8 (excluding incubation) to occur 
within the hood. 
9) All glassware and instruments including the filter block 
used in E62 will be sterlised by immersion in hypochlorite (>2.5% 
chloros) or phenolic disinfectant (2% sterico}). 
10) All procedures involving open tubes will take place within 
the microbiological hood. Disposable apron and e:loyes to be worn 
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durin" these procedures. The automatic pipette bodies will be 
permanently housed within the hood. Water baths will contain 
centrimide solution (10%). All fluid transfers inside the 
microbiological hood will take place over a plastic tray with a 
disposable plastic insert. This will be sterlised with chloros 
(>2.5%) after each experiment. 
11) Plastic incubation tubes and all other disposables including 
small amounts of solid human tissue and protective clothing will 
be placed in a plastic bag for incineration. 
12) All chloros solutions containing radioisotopes will be 
disposed of via a designated radioactive sink in E62. The 
microbiological safety cabinet will be monitored for radioactivity 
at monthly intervals by swabbing area with a filter paper (2.5 cm) 
soaked in methanol. This will be added to 1 m1 of 10% perchloric 
acid in a plastic scintillation vial. 
13) An appropriate scintillant will be added to filters from 
monitoring procedures and experiments half-an-hour after 
immersion in perchloric acid. After scintillation counting the 
plastic vials and contents will be disposed of by incineration. 
14) Any spillage will be wiped up with 10% chloros. 
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